antitumorpromot principl angelica keiskei potent antitumor promot activ nonpolar extract root ashitaba angelica keiskei koidz umbellifera eaten veget japan activ fraction angular furanocoumarin archangelicin sr angeloyloxydihydrooroselol linear furanocoumarin psoralen bergapten xanthotoxin chalcon hydroxyderricin xanthoangelol novel chalcon name ashitabachalcon isol compound angular type furanocoumarin chalcon suppress otetradecanoylphorbolacet tpa piincorpor phospholipid cultur cell coumarin less effect addit chalcon prove antitumorpromot activ mous skin carcinogenesi induc dimethylbenz anthracen dmba plus tpa chalcon calmodulininteract properti chalcon reveal antitumorpromot activ via modul calmodulin involv system chalcon effect prevent
effect catechin mous lung carcinoma cell adhes endotheli cell effect kind catechin adhes mous lung carcinoma ll cell monolay bovin lung endotheli cell epicatechin gallat epigallocatechingal activ inhibit ll cell adhes catechin epicatechin inact epigallocatechin consider cytotox specif structur requir exert inhibitori activ catechin search cellular bind protein bound inhibitori catechin clue clarifi mechan interact cell endotheli cell
cyclooxygenas inhibitor potenti properti colon epidemiolog laboratori indic invers risk colon intak nonsteroid antiinflammatori agent aspirin mechan nonsteroid antiinflammatori agent inhibit colon inhibit prostaglandin cyclooxygenas isozym cox cox overexpress cox colon inhibitor cox potenti serv agent properti sc cox inhibitor sulindac control doubleblind azoxymethan induc colon aberr crypt foci acf measur efficaci fiveweekold male fed control modifi aina ppm sc ppm sulindac ppm placebo later anim except vehicl normal salin sc inject azoxymethan bodi onc age sacrif colon acf expect sulindac suppress acf crypt term aberr crypt focus ppm sc inhibit total acf crypt sc suppress colon acf format crypt strengthen hypothesi cox inhibitor possess activ against colon 
phase novel sulfonamid discov slowgrow colon carcinoma cell screen model exhibit broad spectrum antitumor activ against human xenograft mechan action arrest cell phase cell cycl inhibit tubulin polymer object phase maximum allow dose mad pharmacokinet singl repeat dose singledos administ oral patient dose doselimit peripher neuropathi dose hematolog gastrointestin mild repeateddos patient dose per doselimit peripher neuropathi intestin paralysi gastrointestin dosedepend not sever hematolog not dosedepend pharmacokinet singledos rapid plasma level after disappear variat area plasma concentrationtim curv auc patient dosedepend manner total recoveri urin after indic favor absorpt elimin profil chang plasma level repeateddos indic did not accumul singledos spinal cord metastasi exhibit reduct patient uterin sarcoma minor mr pulmonari adenocarcinoma patient repeateddos decreas carcinoembryon antigen cea squamous cell carcinoma antigen scc patient stomach patient recurr uterin cervic carcinoma recommend phase ii dose singledos per repeateddos activ timedepend ie certain requir suppress growth leukemia cell recommend phase ii conduct dose schedul maintain blood level e
retinoid iv design synthesi structureact ditbutylphenyl compound retino analogu play role modul cell growth differenti apoptosi clinic moieti ditbutylhydroxi phenyl ring seri substitut amid ester chalcon design synthes mimic molecular shape size spacial disposit retino general structur formula see text where stand hydrogen atom methyl linkag conh nhco coo coch ch member heterocycl substitu differ sar indic presenc hydrophob end molecul carboxyl end conjug system molecul necessari full prerequisit exhibit activ loss abolish activ obligatori antioxid effect hydroxi not convey biolog activ after methyl hydroxi compound differentiationinduc activ lose antioxid effect indic correl activ stabl conform phenyl ring cisconform nmethyl acyl amid featur bent shape molecul instead extend conform taken nonnmethyl partner alltran retino bent conform account inact paper compound exhibit signific activ ditmethoxyphenyl oxopropenyl benzoic activ compar retino pharmacolog action 
elicit pleiotrop molecular effect head neck cell trihydroxyisoflavon report induc cell cycl arrest apoptosi differ cell line vitro antitumor activ against varieti anim model report induc cell cycl arrest apoptosi upregul pwaf bax downregul cyclin bcl head neck cell line precis molecular mechan elicit effect head neck cell still elucid report induc specif molecular chang head neck cell downregul cerbb express downregul mmp mmp secret inhibit cell invas downregul nuclear factorkappab bind activ addit inhibit level phosphoryl akt express protein moreov induc telomer shorten cell telomeras activ vitro inhibit transloc telomeras catalyt subunit human telomeras revers transcriptas htert nucleus result telomer shorten activ telomeras unaffect inhibit metaphas spread chromosom result togeth publish report conclud elicit pleiotrop molecular chang result inhibit cell growth apoptot cell death head neck cell chemotherapeut agent head neck 
mechanismbas vitro screen potenti agent identif effect agent becom issu public healthrel research identif potenti constitu set up batteri cell enzymebas vitro system relev prevent carcinogenesi vivo system modul inhibit cypa activ nadphquinon reductas qr activ hepacc murin hepatoma cell cultur scaveng dpph scaveng antioxid effect scaveng superoxid anion hydroxyl peroxylrad antiinflammatori mechan inhibit lipopolysaccharid lps mediat nitric generat induc synthas ino raw murin macrophag cyclooxygenas cox inhibit antitumor promot activ inhibit phorbol ester induc ornithin decarboxylas odc activ murin keratinocyt test seri known belong structur compound identif novel agent mechan organosulfur compound phenethylisothiocyan peitc diallylsulfid diallyldisulfid terpen limonen perillyl alcohol oleanol betaglycyrrhetin shortchain fatti sodium butyr indol indolecarbinol quercetin silymarin catechin epigallocatechingal egcg simpl ellag piceatannol curcumin pharmaceut agent piroxicam acetylsalicyl tamoxifen deriv ascorb trolox confirm known mechan compound addit demonstr approach identif hitherto unknown mechan agent exampl detect antiinflammatori properti peitc nfkappabmedi inhibit peitc inhibit phorbol ester induc superoxid anion granulocyt odc cell line mechan contribut potenti peitc
epigallocatechingal inhibit activ her neu downstream signal pathway human head neck breast carcinoma cell overexpress her neu receptor her associ poor prognosi patient breast carcinoma patient head neck squamous cell carcinoma hnscc hnscc cell line epigalocathechingal egcg biolog activ compon green tea inhibit activ epiderm growth receptor egfr therebi inhibit egfrrel downstream signal pathway hnscc cell effect egcg activ her receptor human hnscc breast carcinoma cell line display constitut activ her cell microg egcg dose inhibit growth mark inhibit phosphoryl her cell line associ inhibit stat activ inhibit cfos cyclin promot activ decreas cellular level cyclin bclxl protein egcg microg plasma after administ singl oral dose egcg green tea extract mark enhanc sensit type cell line growth inhibit taxol frequent breast carcinoma hnscc result taken togeth evid egcg inhibit activ egfr carcinoma cell egcg case breast carcinoma hnscc activ egfr her play role surviv growth
xenoestrogen induc erk erk activ via membraneiniti signal pathway xenoestrogen mimic antagon activ physiolog estrogen mechan xenoestrogen action involv bind esr er failur vitro vivo assay strong genom activ xenoestrogen compar estradiol make difficult explain abil abnorm anim human reproduct via pathway steroid action rapid intracellular signal chang level intracellular calcium camp nitric activ varieti kinas via action membran demonstr xenoestrogen rapid activ extracellularregul kinas erk pituitari cell line gh express level membran receptor esr mer test phytoestrogen coumestrol organochlorin pesticid endosulfan dieldrin dde deterg byproduct plastic manufactur pnonylphenol bisphenol xenoestrogen except bisphenola produc rapid min after applic depend erk phosphoryl distinct differ activ pattern signal pathway involv erk activ specif inhibitor er epiderm growth receptor ca signal src phosphoinositid kinas membran structur disrupt agent inhibitor block erk activ simultan pathway complex signal web interact inhibitor differenti xenoestrogen action help explain distinct abil xenoestrogen disrupt reproduct low 
effect empir appl hydrogen peroxid induc inhibit gapjunct intercellular communic antioxid antitumorpromot activ phytochem appl content antioxid empir appl quantifi contribut total antioxid activ appl assay inhibit otetradecanoylphorbolacet induc superoxid generat cell cultur model express equival antioxid capac vceac estim contribut total anitoxid capac fresh empir appl quercetin vceac chlorogen phloretin procyanidin epicatechin superoxid scaveng assay report mechan carcinogen hydrogen peroxid ho associ inhibit gapjunct intercellular communic gjic involv promot appl extract protect effect against inhibit gjic ho dosedepend manner quercetin exert strongest protect effect antioxid appl ho induc inhibit gjic epicatechin procyanidin chlorogen phloretin effect result indic activ appl associ antioxid capac antitumorpromot activ divers antioxid
lowdos phytoestrogen abrog tamoxifenassoci mammari prevent wildtyp erbb neu transgen mice interact tamoxifen phytoestrogen dose vivo mice random formula implant continuousreleas tamoxifen placebo pellet age placebotr mice soy meal not supplement lowdos highdos casein result prolong latenc tamoxifentr mice fed soy meal casein highdos enrich format age mice latenc prolong tamoxifentr mice fed lowdos enrich much rate mammari shorter latenc vitro human mous mammari cell line confirm low dose coadminist tamoxifen promot cell prolifer tamoxifen alon tamoxifen dose growth inhibitori summari lowdos abrog tamoxifenassoci mammari prevent vivo interact support vitro human mous mammari cell line doseassoci interact like relev human tamoxifen prevent breast 
new anticanc agent vitro vivo antitumor antimetastat action compound isol medicin plant review search new anticanc effect compound isol medicin plant growth metastasi mice bear metastat drugresist mous antitumor antimetastat action stilben deriv isol polygonum cassia stilben deriv cassiagrol stilben dimer display antitumor antimetastat action inhibit induc neovascular vitro vivo model chalcon deriv angelica keiskei root inhibit growth metastasi tumorbear mice inhibit induc neovascular inhibit suppress basidiomycet fungi low molecular isol agaricus blazei ganoderma lucidum antitumor antimetastat basidiomycet inhibit growth metastasi lung inhibit induc neovascular inhibit suppress 
celecoxib revers hypoxia induc angiopoietin upregul gastric potenti effect cyclooxygenas cox hypoxia induc angiopoietin ang express gastric cell result reveal hypoxia augment cox ang express hypoxia induc ang mimick cocl genestein partial counteract hypoxia induc ang express celecoxib not cox inhibitor sc revers hypoxia induc ang express effect partial restor addit exogen pge hypoxiaelev ang express gastric cell mediat coxderiv pge hifalpha pathway celecoxib counteract hypoxia induc ang express
third men mortal affluent countri tea green tea demonstr promis prevent green tea compon catechin categori properti evid epidemiolog not comprehens strengthen anim vitro evid consumpt tea associ decreas risk evid potenti biolog mechan role green tea prevent review
inhibitori effect green tea cyclooxygenas inhibitor growth human cell vitro vivo cyclooxygenas cox inhibitor hold promis concern new strategi need approach overcom limit dose cox inhibitor agent complementari mechan effect epigallocatechingal egcg promis agent green tea test alon specif cox inhibitor growth human cell vitro vivo human cell lncap pc cwrrnu egcg ns alon effect growth apoptosi vivo athym nude mice implant androgensensit cwrrnu cell green tea drink water celecoxib ip daili per alon effect growth egcg micromol ns micromol result enhanc cell growth inhibit apoptosi express bax procaspas procaspas polyadpribos polymeras cleavag inhibit pparg inhibit nuclear factorkappab compar addit effect agent alon synerg vivo green tea celecoxib result enhanc growth inhibit prostatespecif antigen level insulinlik growth factori level circul level serum insulinlik growth bind protein compar result singleag synergist addit effect combinatori agent underscor need ration design human clinic trial
combretastatinchalcon hybrid synthesi cytotox seri alltransarylarylarylpentanedieneon hybrid chalcon combretastatin synthes against panel cell line murin hct colon human epidermoid carcinoma human umbil venous endotheli cell huvec structureact seri reveal dihydroxyphenyl pentanedieneon essenti cytotox alltransdihydroxyphenyl methoxyphenyl trimethoxyphenyl pentanedieneon potent compound seri
effect acetylsalicyl celecoxib nnitrosodiethylamin induc carcinogenesi esophagus effect nonsteroid antiinflammatori acetylsalicyl celecoxib nnitrosodiethylamin induc carcinogenesi esophagus inhibitori effect celecoxib carcinogenesi pronounc acetylsalicyl manifest decreas neoplast chang tissu esophagus delay malign esophagus eros ulcer gastric mucosa after celecoxib indic celecoxib inhibit nnitrosodiethylamin induc carcinogenesi esophagus
compar antiprolif antiangiogen apoptosi induc potenti black tea hamster buccal pouch carcinogenesi model efficaci black tea polyphenonb pb btf dimethylbenz anthracen dmba induc hamster buccal pouch hbp carcinogenesi hamster right buccal pouch anim paint dmba hamster receiv anim receiv pb btf dmba paint continu until end anim pb btf alon anim serv untreat control anim sacrif aftesr express cyclin glutathion stransferas pi gstp nuclear kappa nfkappab bcl bax cytochrom caspas caspas polyadpribos polymeras parp cytokeratin vascular endotheli growth vegf analys rtpcr immunohistochem western blot analys dmba anim buccal pouch carcinoma display express cyclin gstp nfkappab cytokeratin vegf bcl decreas express bax cytochrom caspas caspas parp pb btf dmba induc hbp carcinoma modul cell prolifer cell surviv infiltr angiogenesi apoptosi result mechanist potenti black tea greater efficaci btf inhibit hbp carcinogenesi modul molecular target potenti role prevent oral 
abund mortal western world nutrit microbi flora mark influenc risk format butyr shortchain fatti scfas play role microbi ferment colon effect butyr scfas scfa transcinnam deriv intestin degrad constitu fruit veget global histon deacetylas hdac activ nuclear extract colon carcinoma cell cultur tertbutoxycarbonyllysin acetyl aminomethylcoumarin boclysac amc substrat inhibit hdac activ eg butyr suppress malign apoptosi precancer colon cell nuclear extract ht human colon carcinoma cell butyr potent hdac inhibitor ic assay pcoumar ic ohphenyl propion ic caffeic ic potent hdac inhibitor test interest butyr potent hdac inhibitor wholecel hela mad report gene assay butyr play outstand role endogen hdac inhibitor colon
xenoestrogen modul vascular endotheli growth secret breast cell esrdepend mechan environment human health disrupt endocrin role mammari gland breast still unknown demonstr vascular endotheli growth vegf key angiogenesi estrogenregul gene vegf express regul differ xenoestrogen breast cell meln deriv mcf melp deriv mdamb stabli express esr cell line stabli express estrogen element betaglobin luciferas bisphenol bpa tertoctylphenol op dieldrin phthalat benzyl butyl phthalat bbp diethylhexyl phthalat dehp estrogen compound induc dosedepend vegf secret meln mcf cell maxim effect microm noncytotox inhibit antiestrogen ici vegf not esrneg mdamb cell vegf transcript level meln cell gammahexachlorocyclohexan vinclozolin phthalat mononbutyl ester phthalic diisononyl phthalat diisodecyl phthalat ineffect vegf secret estrogen luciferas cell line specif kinas inhibitor pd sb ly suppress xenoestrogen induc vegf activ mek kinas phosphatidylinositolkinas pathway vitro result xenoestrogen bpa op dieldrin bbp dehp upregul vegf express meln cell erdepend mechan vegf capillari permeabl breast angiogenesi vivo physiolog relev discuss
geraniinmedi apoptosi cleavag focal adhes kinas upregul fas ligand express human cell geraniin tannin separ geranium cell death apoptosi cell death characterist geraniin not yet elucid mechan geraniin induc apoptosi human cell demonstr geraniin abl induc cell apoptosi timedepend manner signal pathway geraniin induc apoptosi clarifi focal adhes kinas fak geraniin induc apoptosi human cell geraniin result dose timedepend degrad fak fak cleavag inhibit cell pretreat inhibitor caspas acaspgluvalaspcho demonstr geraniin trigger cell death caspasemedi cleavag fak mechan activ caspas mitochondriamedi receptormedi apoptosi confirm geraniinrelev signal pathway immunoblot geraniin induc apoptosi associ upregul fas ligand express activ caspas cleavag bid cytochrom mitochondria cytosol geraniin caspas activ dose timedepend manner proteolyt cleavag polyadpribos polymeras fragment geraniin induc apoptosi pivot mechan cancerchemoprevent action
epoxyquinol antiangiogen antitumor effect inhibit vegfr egfr fgfr pdgfr angiogenesi new blood vessel nutrient indispens solid growth inhibit angiogenesi modal report antiangiogen mechan antitumor effect epoxyquinol epqb isol fungal shortterm epqb result reduct growth blood vessel direct murin xenograft model furthermor epqb inhibit vascular endotheli growth vegf induc migrat tube format human umbil vein endotheli cell huvec cytotox vegfstimul phosphoryl vegf receptor vegfr phospholipas cgamma plcgamma map kinas erk inhibit epqb dosedepend manner vitro assay kinas domain vegfr epqb coval bound inhibit vegfr kinas bind site vegfr differ su wellknown vegfr kinas inhibitor interest epqb inhibit growth induc activ not vegfr epiderm growth receptor egfr fibroblast growth receptor fgfr plateletderiv growth receptor pdgfr epqb novel kinas inhibitor epqb good lead compound potent antiangiogen antitumor 
pretreat black tea modul xenobioticmetabol enzym oral carcinogenesi model object potenti black tea polyphenonb btf preiniti phase dimethylbenz anthracen dmba induc hamster buccal pouch hbp carcinogenesi hamster six anim receiv polyphenonb btf carcinogen age continu until final exposur carcinogen age anim paint dmba anim polyphenonb btf alon anim serv control anim sacrif after period phase phase ii xenobioticmetabol enzym hydroxydeoxyguanosin ohdg buccal pouch biomark hamster paint dmba express ohdg enhanc activ phase cyp total well cypa isoform cytochrom phase ii gst quinon reductas xenobioticmetabol enzym immunohistochem express cypa cypb isoform buccal pouch accompani phase decreas phase ii enzym activ polyphenonb btf decreas damag phase enzym activ well express cypa cypb isoform enhanc phase ii enzym activ buccal pouch result mechanist potenti black tea furthermor greater efficaci btf hbp carcinoma via inhibit damag modul xenobioticmetabol enzym impact human oral prevent
mitochondria ppar receptorindepend action ppar agonist key discoveri ppar well known certain classic ppar agonist induc hepatocarcinoma peroxisom prolifer rodent deriv fibric clofibr bezafibr fenofibr never human patient hypolipidem thiazolidinedion new ppar activ show greater specif gamma isoform ppar insulin sensit type ii diabet addit induc cell differenti apoptosi model ppar ligand induc cell differenti paradox pparg activ report act carcinogen confus pictur complic seri intrigu effect pharmacolog ppar ligand rhabdomyolysi heart anemia leucopenia effect cannot easili explain simpl interact nuclear receptor effect indic ligand biolog activ independ nuclear receptor role mitochondria potenti connect organell ppar physiolog reciproc influenc fundament not biolog defin pharmacotoxicolog profil modul ppar
anticanc action mechan dihydroartemisinin gene chip action mechan artesun inhibit leukaemia cell line molecular level gene chip detect express panel gene leukaemia cell line dihydroartemisinin cell mol dihydroartemisinin modal chang invert microscop morpholog chang nucleon hoechst pi stain cell cycl flow cytometri fcm total rna sampl trizol revers transcrib cdna cdna sampl hybrid gene chip hybrid signal scan gene pix drift cell densiti cell decreas invert microscop after cell dihydroartemisinin morpholog chang cell apoptosi karyopyknosi conglomer hoechst pi stain flow cytometr cell arrest phase differenti express gene hybrid upregul chk downregul pcna cyclinb cyclind cyclin cdk cdk ef dnapk dnatopo mcl jnk vegf dihydroartemisinintr cell dihydroartemisinin inhibit leukaemia cell line exert anticanc effect alter express gene involv cell cycl dihydroartemisinin act via apoptosi pathway
marin phosphatidylcholin suppress dimethylhydrazin induc colon induc apoptosi vitro anim indic polyunsatur fatti pufa suppress carcinogenesi new insight effect marin phospholipid suppress colon purpos growth inhibit apoptosi induc effect pufa marin phosphatidylcholin pc induc dimethylhydrazin colon growth inhibit caco cell colorimetr sodium iodophenyl nitrophenyl disulfophenyl htetrazolium wst dye reduct assay anim fed differ docosahexaeno dha ethyl ester eicosapentaeno epa ethyl ester squid meal pc rich dha starfish pc rich epa corn oil dimethylhydrazin salin inject hour anesthet apoptot well mitot cell crypt count morpholog criteria isol crypt squid meal starfish pc potent inhibit growth caco cell pufa suppress colon consum dhaethyl ester epaethyl ester squid meal pc starfish pc apoptosi suppress prolifer result marin pccontain effect protect against colon 
transcript tfiii transcript upregul grp synthesi cell receptorrecogn alpha macroglobulin alpham bind cell surfaceassoci grp induc prolif surviv signal cell cellular alpham grp express upregul stimuli transcript tfiii upregul grp bind gene promot role tfiii transcript upregul grp ln human cell alpham threefold tfiii grp synthesi label precursor amino synthesi tfiii grp silenc tfiii gene express pretreat cell actinomycin confoc microscopi employ demonstr reloc tfiii nucleus alphamstimul cell moreov tfiii bound grp promot chip assay demonstr bind tfiii cfos promot consist role upregul cfos gene express nonlymphoid cell phosphoryl csrc activ tfiii ligat grp ln cell alpham tyrosin phosphoryl csrc well tfiii conclud alpham induc grp synthesi transcript upregul tfiii bind grp promot potenti cell surviv antipoptot ln cell
vitisin suppress lps induc inhibit erk nfkappab activ raw cell vitisin tetram isol viti vinifera root exhibit antioxid anticanc antiapoptot antiinflammatori effect inhibit nitric mechan vitisin inhibit lipopolysaccharid lps induc raw macrophag cell vitisin dose depend inhibit lps induc induc synthas ino express proinflammatori cytokin tnf interleukin il not alter vitisin signal pathway inhibit vitisin nuclear factorkappab nfkappab activ mitogenactiv protein kinas mapk pathway inflamm induc signal pathway raw cell vitisin inhibit lps induc erk erk erk phosphoryl suppress lps induc nfkappab activ raw cell vitisin decreas via downregul erk nfkappab signal pathway raw cell
synthes potenti antiprost activ iononebas chalcon report sar iononebas chalcon demonstr vitro antiprolif activ lncap mdapcab rv cb pc cell line compound ic microm lncap cell potent antagon dht induc transactiv wild type clinic relev ta wc hy mutat androgen receptor novel chalcon panantagonist androgen receptor
epigallocatechin gallat suppress azoxymethan induc colon premalign lesion male cbl ksjdb db mice obes diabet mellitus risk colon activ insulinlik growth igf igfir axi play role carcinogenesi epigallocatechingal egcg constitu green tea antiobes antidiabet effect effect egcg azoxymethan induc colon premalign lesion cbl ksjdb db db db mice obes diabet mellitus male db db mice sc inject azoxymethan bodi receiv drink water egcg sacrific drink water egcg signific decreas total aberr crypt foci larg aberr crypt foci betacatenin accumul crypt mice premalign lesion colon colon mucosa db db mice express level igfir phosphoryl igfir pigfir pgskbeta betacatenin cyclooxygenas cyclin protein egcg drink water mark decreas express protein mice egcg serum level igfbp convers decreas serum level igfi insulin triglycerid cholesterol leptin egcg overcom activ igf igfir axi therebi inhibit colon premalign lesion obesityrel colon model associ hyperlipidemia hyperinsulinemia hyperleptinemia egcg obesityrel 
synthesi biolog trimethoxychalcon analogu inhibitor nitric cell prolifer seri trimethoxychalcon analogu synthes inhibitori effect nitric lps ifngammatr macrophag cell prolifer hydroxytetramethoxychalcon dihydroxytrimethoxychalcon hydroxytetramethoxychalcon tetramethoxychalcon potent growth inhibitori agent ic microm cell prolifer assay result reveal compound exhibit potent inhibit activ against differ cell line chalcon potent antiprolif compound seri ic microm hep colon colon cell line pentamethoxychalcon hexamethoxychalcon hexamethoxychalcon hydroxytetramethoxychalcon signific antiprolifer action hep colon cell ic microm test agent compound inhibit ic microm effect cell prolifer ic microm pentamethoxychalcon antiprolifer effect hep cell addit potent inhibit colon cell formyltrimethoxychalcon moder growth inhibit colon cell effect hep cell prolifer result insight correl structur properti trimethoxychalcon vitro antiinflammatori anticanc differenti activ
capsaicin display antiprolif activ against human cell lung cell cultur nude mice model via ef pathway cell lung sclc rapid low surviv rate novel therapeut agent urgent need diseas capsaicin activ ingredi chilli pepper display antiprolif activ epidermoid vitro antiprolif activ capsaicin not human sclcs manuscript fill void knowledg antiprolif effect capsaicin sclc vitro vivo brdu assay pcna elisa capsaicin display robust antiprolif activ human sclc cell line furthermor capsaicin potent suppress growth human sclc vivo ascertain cam assay nude mice model second attempt insight molecular mechan antiprolif activ capsaicin antiprolif activ capsaicin correl decreas express efrespons prolif gene like cyclin thymidyl synthas cdca cdc mrna protein level transcript ef mediat antiprolif activ capsaicin ablat ef level sirna methodolog suppress capsaicin induc arrest chip assay demonstr capsaicin recruit ef efrespons prolif promot therebi inhibit cell prolifer antiprolif effect capsaicin human sclcs
revers multidrug resit natur plant multidrug resist mdr protein belong atpbind cassett superfamili pglycoprotein pgp mrp human constitut therapeut failur inhibitor mdrefflux protein improv effect mechan action believ competit resist modifi bind site pgp work modul mdr cell express pgp mrp carotenoid flavonoid extract medic chines plant capsanthin capsorubin carotenoid isol paprika potent pgp inhibitor lycopen lutein antheraxanthin violaxanthin induc moder effect flavonoid effect modul rotenon chrysin phloretin sakuranetin chloroform extract chines herb inhibit mdr efflux pump effect modul pgp activ measur rhodamin uptak cell human mdr genetransfect mous lymphoma cell human breast cell mdamb express mrp pump htb addit abil alter biophys properti lipid bilay carotenoid differenti scan calorimetri antiprolif effect well mdr revers activ compound appli anticanc discuss
icariin deriv inhibit inflamm suppress mitogenactiv protein kinas nuclear factorkappab pathway antiinflammatori effect icariin deriv dihydroxymethoxydimethydihydropyrano flavon icariin deriv inhibit tnf induc nitric synthas ino cyclooxygenas cox mrna express protein express lipopolysaccharid lps raw macrophag allevi paw edema induc carrageenan mice clarifi molecular mechan antiinflammatori effect effect compound phosphoryl mitogenactiv protein kinas mapk phosphoryl inhibitori kappabalpha ikappabalpha nuclear transloc subunit nuclear nf kappab suppress activ mapk inhibit transloc nfkappab nucleus decreas phosphoryl ikappabalpha result properti icariin deriv potenti diseas
chalcon dihydrochalcon augment trailmedi apoptosi cell chalcon dihydrochalcon exhibit antitumor activ trail tnfrelat apoptosisinduc ligand natur endogen anticanc agent cytotox apoptot effect chalcon dihydrochalcon trailmedi apoptosi lncap cell cytotox mtt ldh assay apoptosi detect annexin vfitc flow cytometri fluoresc microscopi deltapsim depsiph stain fluoresc microscopi test chalcon chalcon dihydroxymethoxychalcon dihydrochalcon dihydroxydimethoxydihydrochalcon dihydroxymethoxydihydro chalcon trihydroxydihydrochalcon call phloretin mark augment trail induc apoptosi cytotox lncap cell confirm signific role chalcon 
methylxanthin human health recogn countri caffein consum coffe confound fact coffe bioactiv addit caffein rich quinid chlorogen lacton diterpen fatti ester potassium niacin magnesium precursor trigonellin paradox consumpt caffein caffein coffe result mark insulin resist yet habitu coffe consumpt repeat report mark risk type diabet strong evid caffein insulin sensit skelet muscl direct antagon receptor indirect adrenerg result sympathet activ caffein induc glucos output except bone miner littl evid caffein impact health issu coffe not risk cardiovascular diseas evid former 
butein tetrahydroxychalcon suppress induc osteoclastogenesi inhibit receptor activ nuclear factorkappab ligand signal osteoclastogenesi associ age agerel chronic diseas receptor activ nuclear factorkappab nfkb ligand rankl member tnf superfamili implic mediat bone resorpt agent suppress rankl signal inhibit osteoclastogenesi close link bone resorpt butein tetrahydroxychalcon inhibit rankl signal suppress osteoclastogenesi induc rankl cell human myeloma cell mms breast cell mdamb cell pc induc differenti macrophag osteoclast indic tartrateresist phosphatas trap cell butein suppress chalcon suppress express rankl cell butein suppress rankl induc nfkb activ suppress correl inhibit ikbalpha kinas suppress phosphoryl degrad ikbalpha inhibitor nfkb final butein suppress rankl induc differenti macrophag osteoclast dosedepend timedepend manner result indic butein suppress osteoclastogenesi induc cell rankl suppress nfkb activ pathway
green tea gt black tea bt differ postharvest gt monomer numer intracellular signal pathway involv cap bt polym hand poor absorb convert colon microflora after consumpt gt circul after bt consumpt level circul vitro cell cultur vivo anim clinic intervent effect extract gt purifi epigallocatechingal egcg carcinogenesi strong evid support effect gt result epidemiolog gt consumpt mix evid effect bt much weaker bodi evid regard gt anim bt intervent demonstr inhibit cap growth articl review detail avail epidemiolog human clinic well anim basic mechanist gt bt support role cap
flavokawain inhibit growth human squamous carcinoma cell involv apoptosi cell cycl dysregul vitro vivo flavokawain natur chalcon isol rhizom alpenia pricei hayata antiprolif apoptot effect flavokawain against human squamous carcinoma kb cell exposur kb cell flavokawain result apoptosi evidenc loss cell viabil profound morpholog chang genom fragment subg phase accumul apoptosi induc flavokawain result activ caspas cleavag poli adp ribos polymeras parp bid kb cell flavokawain downregul bcl concomit bax level result cytochrom taken togeth apoptosi flavokawain involv death receptor mitochondri pathway flavokawain phase arrest mediat reduct level cyclin cyclin cdc cdcc waf wee level moreov flavokawain inhibit matrix metalloproteinas urokinas plasminogen activ express tissu inhibitor matrix metalloproteinas plasminogen activ inhibitor play role metastasi addit flavokawain inhibit vivo growth human kb cellderiv xenograft nude mice evidenc augment apoptot fragment detect situ termin deoxynucleotidyl transferasemedit dutp nick endlabel stain cell cycl arrest apoptosi flavokawain pivot mechan action
gallic induc phase arrest apoptosi human leukemia hl cell inhibit cyclin activ mitochondriadepend pathway gallic ga induc apoptosi differ type cell line apoptot effect induc ga human promyelocyt leukemia hl cell clarifi mechan result ga viabil hl cell dose timedepend manner ga led phase arrest hl cell promot inhibit level cyclin cyclin ga damag fragment hl cell assay dapi stain comet assay flow cytometr reveal ga ca level mitochondri membran potenti Ã³m hl cell apoptot protein express western blot result indic gamedi apoptosi hl cell depend mitochondri pathway promot cytochrom apoptosisinduc aif endonucleas endo upregul protein express bclassoci protein bax caspas caspas caspas addit ga activ death receptordepend pathway enhanc protein express fatti synthas fas fas ligand fasl caspas bcl interact domain bid mrna express gene level protein realtim pcr result gamedi apoptosi hl cell depend upregul mrna caspas caspas caspas aif endo ga induc apoptosi occur death receptor mitochondriamedi pathway ga potenti therapeut agent leukemia warrant
synthet chalcon potent induc glutathion biosynthesi chalcon continu attract consider interest antiinflammatori antiangiogen properti report abil dihydroxychalcon dhc induc breast resist proteinmedi export glutathion gsh cjun ntermin kinasemedi intracellular gsh level report structureact seri synthet chalcon deriv hydroxyl methoxyl halogen cl substitu abil intracellular gsh level effect drastic improv electrowithdraw phenyl ring up methoxyl hydroxyl phenyl ring optim structur chlorodimethoxyhydroxychalcon induc potent nferel mediat transcript format glutam cystein ligas holoenzym human breast cell line stabli express luciferas report gene driven antioxid element
curcumin inhibit prolifer induc neutrophil elastas upregul alphaantitrypsin lung lung carcinogenesi complex unregul environ curcumin extens multitarget antitumor antiinflamm compound paper demonstr novel inflammationrel mechan curcumin induc inhibit lung growth neutrophil elastas regul direct trigger cell prolifer human lung adenocarcinoma cell curcumin complet suppress excess prolifer induc neutrophil elastas alphaantitrypsin synthes cell natur inhibitor neutrophil elastas curcumin counteract decreas alphaantitrypsin induc neutrophil elastas induc promot activ alphaantitrypsin promot express cell inhibit neutrophil elastas induc prolifer curcumin depend pik akt pathway knockdown alphaantitrypsin sirna enhanc cell prolifer induc neutrophil elastas block antiprolifer effect curcumin against neutrophil elastas curcumin remark inhibit primari growth lewi lung carcinoma llc cbl mice curcumin upregul level alphaantitrypsin primari tissu promot local express protein level neutrophil elastas tissu obvious decreas mice curcumin result neutrophil elastas alphaantitrypsin play role modul lung prolifer microenviron curcumin inhibit neutrophil elastas induc prolifer via upregul alphaantitrypsin express vitro vivo
secondari plant inhibit abc transport revers resist cell microb cytotox antimicrobi agent fungal bacteri cell resist against antifung antibacteri anticanc agent mechan resist complex multifactori mechan activ atpbind cassett abc transport pgp pump out lipophil compound enter cell activ cytochrom oxidas lipophil agent hydrophil access conjug glucuron sulfat amino activ glutathion transferas conjug xenobiot review summar evid secondari sm plant alkaloid terpenoid interfer abc transport cell parasit bacteria fungi activ natur lipophil terpenoid monoterpen diterpen triterpen saponin steroid cardiac glycosid tetraterpen alkaloid isoquinolin protoberberin quinolin indol monoterpen indol steroid alkaloid probabl competit inhibitor pgp resistanceassoci protein breast resist protein cell efflux pump bacteria nora fungi polar flavonoid catechin chalcon xanthon stilben anthocyanin tannin anthraquinon naphthoquinon direct inhibit protein hydrogen ionic bond disturb structur transport natur interest medicin agricultur enhanc activ activ chemotherapeut pesticid even revers multidrug resist least partial adapt resist cell sm appli cytotox antimicrobi agent revers resist synergist fashion
epigallocatechingal induc mesothelioma cell death via depend ttype ca channel open malign mesothelioma mme aggress lethal requir effect green tea epigallocathechingal egcg inhibit growth type cell egcg cytotox mme cell normal mesotheli cell mme cell viabil inhibit predomin apoptosi dose necrosi dose egcg elicit cell cultur exogen catalas cat abrog egcg induc cytotox apoptosi necrosi confoc imag fluo load egcgexpos mme cell signific ca rise prevent cat dithiothreitol ttype ca channel blocker mibefradil nicl cell load dihydrorhodamin reveal egcg induc ros prevent cat mibefradil ca chelat baptaam direct exposur cell produc effect ca ros effect prevent inhibitor sensit ren cell egcg correl express cav ttype ca channel cell compar normal mesothelium cav sirna mme cell vitro egcg cytotox abat apoptosi necrosi intrigu cav express malign pleural mesothelioma biopsi patient not normal pleura express ttype ca channel mme tissu role egcg cytotox mme cell channel novel mme pharmacolog target
xanthorrhizol induc apoptosi rosmedi mapk activ human oral squamous cell carcinoma cell inhibit dmba induc oral carcinogenesi hamster xanthorrhizol natur sesquiterpenoid compound isol curcuma xanthorrhiza roxb known inhibit growth human colon breast cervic cell xanthorrhizol decreas cell viabil induc apoptosi decreas level fulllength parp scc oral squamous cell carcinoma oscc cell decreas cell viabil parp degrad not prevent caspas inhibitor zvadfmk xanthorrhizoltr cell xanthorrhizol intracellular ca ros level scc cell ca chelat egta am did not xanthorrhizol induc cytotox cell viabil recov endogen antioxid gsh hydroxi trapper mci furthermor viabil xanthorrhizoltr scc cell restor sb sp not pd xanthorrhizol induc activ mapk jnk block mci final xanthorrhizol suppress buccal pouch surviv rate hamster dimethylbenz anthracen xanthorrhizol induc caspaseindepend apoptosi rosmedi mapk jnk activ scc oscc cell prevent induc oral carcinogenesi xanthorrhizol promis agent
curcumin suppress tpa induc invas inhibit pkcalphadepend mmpexpress mcf human breast cell curcumin diferuloylmethan deriv plant turmer curcuma longa common spice anticarcinogen antioxid antiinflamm antiangiogen properti report effect curcumin breast metastasi unknown matrix metalloproteinas mmp compon cell invas inhibitori effect curcumin otetradecanoylphorbolacet tpa induc mmp express cell invas molecular mechan involv mcf cell result curcumin inhibit tpa induc mmp express cell invas suppress nfkb ap activ curcumin strong repress tpa induc phosphoryl jnk inhibit tpa induc transloc pkcalpha cytosol membran did not transloc pkcdelta result indic curcuminmedi inhibit tpa induc mmp express cell invas involv suppress pkcalpha mapk nfkb ap pathway mcf cell curcumin potenti restrict breast metastasi
novel involv leukotrien receptor erk activ ppa downregul leukotrien induc keratin phosphoryl reorgan pancreat cell perinuclear reorgan via phosphoryl specif serin residu keratin involv deform metastat cell level leukotrien pancreat role ltb cognat receptor keratin reorgan pancreat not known ltb dosedepend induc phosphoryl reorgan keratin revers ly blt antagonist blt agonist comp hete induc phosphoryl serin moreov comp induc phosphoryl reorgan block ly gene silenc blt suppress comp induc phosphoryl reorgan panc cell overexpress blt promot phosphoryl comp promot migrat panc cell dosedepend manner ly block comp induc migrat pd erk inhibitor suppress comp induc phosphoryl serin reorgan gene silenc blt suppress express perk overexpress blt express perk even comp comp induc express activ erk perk blt block pd comp decreas ppa express hinder bind ppa lead activ erk pd suppress comp induc migrat panc cell blt overexpress induc migrat panc cell result blt involv ltb induc phosphoryl reorgan erk activ ppa downregul lead migrat panc cell
effect lphenylalanin pal activ naphthoquinon pigment suspens cultur arnebia euchroma royl johnst effect lphenylalanin phe cell growth shikonin deriv acetylshikonin ac isobutyrylshikonin ib suspens cultur arnebia euchroma supplement media phe success util enhanc shikonin cell cultur boraginacea lphenylalanin key compound phenylpropanoid pathway convert phenylalanin ammonia lyas pal transcinnam precursor phydroxybenzo phb coupl phb geranyl pyrophosph deriv mevalon pathway phydroxybenzoatemgeranyltransferas lead later biosynthesi shikonin addit phe cultur medium cell prolifer where fresh cell biomass measur ratio final eightfold control cultur growth media supplement phe mark rate cell growth twofold precursor feed detriment effect ac ib phesuppl media total content intracellular extracellular red pigment per flask detect control cultur phe ac compon naphthoquinon fraction cell postcultur media shikonin postcultur media cultur supplement phe pal activ correspond well accumul naphthoquinon control cultur peak pal activ did not direct correl maximum shikonin deriv cytotox extract prepar cell cultiv presenc phe control cultur test cell line hl hela mcf extract prepar untreat control cultur prove potent against cell line mean inhibitori hl hela mcf cell 
glycolysi inhibitor screen bisgeranylacylphloroglucinol protonophor moronon moronobea coccinea cell exhibit enhanc glucos consumpt lactat even suppli adequ phenomenon known warburg effect aerob glycolysi pharmacolog inhibit aerob glycolysi potenti tumorselect approach target differ normal malign tissu human breast mdamb cell assay system discov natur productbas glycolysi inhibitor assay employ hypersensit glycolyt inhibit cell mitochondri electron transport inhibitor rotenon condit atp suppli henc cell viabil depend exclus glycolysi assay system plant marin organ extract us nation institut open repositori bioassayguid isol activ moronobea coccinea extract yield new bisgeranylacylphloroglucinol deriv moronon compound exhibit enhanc antiprolif cytotox activ presenc rotenoneimpos cell surpris mechanist reveal did not inhibit glycolysi protonophor dissip mitochondri proton gradient presenc rotenon cell hypersensit protonophor atp util atp synthas
multifunct albumin nanoparticl carrier intratumor challeng weak solubl exhibit nonuniform biodistribut poor bioavail new platform advanc healthcar materi albumin nanoparticl anp engin penetr deliveri vehicl combinatori appli solid materi design overcom sequenti key barrier tissu level transport across solid matrix uptak kinet individu cell therapeut resist singl chemotherapeut anp design penetr deeper solid matric collagenas decor threedimension multicellular spheroid model collagenas modifi anp exhibit magnitud greater penetr unmodifi anp spheroid mass after hour preferenti uptak individu cell smaller size anp nm enhanc efficaci collagenas coat anp modifi therapeut agent curcumin riluzol complementari mechan action cell cycl arrest apoptosi collagenas coat load nanoparticl induc cell death model unmodifi dual load anp particl kinet cytotox influenc anp size multifunct nanoparticl imbu complementari size proteas activ featur allow penetr solid deliv combinatori therapeut payload enhanc cytotox minim collater damag healthi primari cell
anticanc activ flavonol flavanol rich extract croton celtidifolius latex croton celtidifolius baill euphorbiacea tree atlant forest southern brazil where common known sanguededrago red latex tradit ulcer diabet antitumor activ croton celtififolius latex vitro vivo phytochem analys conduct hplcdadm cytotox nucleas proapoptot properti tetrazolium salt assay mtt plasmid damag assay ethidium bromid eb acridin orang antitumor activ ehrlich ascit carcinoma eac mous model phytochem indic content flavonol myricetin quercetin flavanol epicatechin epigallocatechin latex compound mcf eac cell viabil mtt assay ic latex compound signific fragment apoptot cell control nc latex indic differenti stain eb acridin orang assay vivo latex bodi median surviv compar nc addit latex inhibit growth result agre ethnopharmacolog report show cytotox antitumor activ celtidifolius latex mechan antitumor action direct fragment surviv induc apoptosi
shogaol inhibit breast colon cell prolifer activ peroxisom prolifer activ receptor gamma pparg shogaol possess antitumor properti inhibit cell growth inhibit metastasi apoptosi cell cell differenti despit promin antitumor effect direct molecular target shogaol elus direct target shogaol comprehens antitumor profil shogaol nsc test nci cell line vitro screen result shogaol compar via mechan action distinct exist therapeut agent microarray gene profil connect map mcf cell shogaol display gene express signatur characterist pparg pparg agonist shogaol activ pparg signal pathway antitumor effect inde mcf ht cell shogaol induc pparg transcript activ suppress nfkb activ induc apoptosi breast colon cell ppargdepend manner furthermor shogaol capabl bind pparg bind affin compar delta prostaglandin natur ligand pparg togeth antitumor effect shogaol mediat activ pparg impli activ pparg breast colon 
role compound fight against cancera review scourg lead death countri countri mankind tri effort cheaper fewer effect diseas consequ mortal year compound intens antitumor proapoptot antiangiogen effect year usag compound consider manuscript intend structur differ compound flavonoid hydroxycinnam hydroxybenzo coumarin xanthon chalcon stilben lignin lignan pathway well review result compound deriv prevent cell line vitro murin model vivo final result human trial
identif novel bioactiv demethylnobiletin mice biotransform compon vivo biolog activ after oral ingest biotransform demethylnobiletin polymethoxyflavon citrus fruit mice implic inhibit human colon cell urin sampl mice fed demethylnobiletin lcesim hplc coupl electrochem detector didemethylnobiletin didemethylnobiletin tridemethylnobiletin compar esim hplc profil authent standard synthes multistep rout cell viabil assay human colon cell demonstr demethylnobiletin didemethylnobiletin much stronger inhibitori effect cell growth demethylnobiletin exampl ic sw cell demethylnobiletin inhibit after novel mice after oral demethylniobiletin exhibit strong inhibitori effect against human colon cell result report bioactiv warrant molecular mechan action
antioxid proapoptot effect marinederiv multiminer aquamin supplement pine bark extract enzogenol green tea extract sunphenon intak associ decreas risk cardiovascular diseas attribut antioxid activ proapoptot effect aquamin multiminer algal extract enhanc bone miner reliev osteoarthr aid digest aquamin not demonstr antioxid activ aquamin supplement enzogenol pine bark extract content sunphenon green tea extract content produc mix ae antioxid activ ae compar constitu compound catechin epigallocatechin measur total content ferricreduc antioxid potenti diphenylpicrylhydrazyl hydrat cytotox apoptot effect compound measur human monocyt blood cell line ae demonstr antioxid activ equal compound prepar ae cytotox primari mechan cell death apoptosi biolog effect aquamin enhanc supplement enzogenol sunphenon antioxid effect abil induc apoptosi cell
gingerol prevent disassembl cell junction activ mmps invas human pancrea cell erk nf snail signal transduct pathway effect gingerol ginger phytochem tight junction tj molecul tj tighten signal transduct pathway human pancreat duct cellderiv cell line panc util mtt assay cytotox zymographi matrix metalloproteinas mmp activ transepitheli electr resist ter paracellular flux tj measur rtpcr immunoblot protein tj invas emsa nf activ panc cell reveal ter claudin mmp decreas compar control tj protein level zonula occluden zo occludin ecadherin gingeroltr cell correl decreas paracellular flux mmp activ furthermor nf snail nuclear transloc suppress via downregul extracellular signalregul kinas erk pathway gingerol moreov erk inhibitor complet block nf activ demonstr gingerol regul tjrelat protein suppress invas metastasi nf snail inhibit via inhibit erk pathway gingerol suppress invas activ panc cell
role adipokin cytokin obesityassoci breast therapeut target obes larg proport breast mortal postmenopaus women obes peopl level growth insulin insulinlik growth igf insulin level lead secret estrogen bind circul sex hormon bind globulin shbg estrogenmedi downstream signal favor breast carcinogenesi obes lead alter express profil adipokin cytokin leptin adiponectin il tnf ilbeta level leptin decreas adiponectin secret direct associ breast level proinflammatori cytokin microenviron promot efficaci avail breast against obesityassoci breast yet confirm review discuss differ adipokin cytokinemedi molecular signal pathway involv obesityassoci breast avail therapeut strategi potenti therapeut target obesityassoci breast 
scientif valid medicin efficaci tinospora cordifolia communic report scientif tinospora cordifolia medicin efficaci phytochem screen antimicrobi antioxid anticanc activ plant secondari anthraquinon terpenoid saponin extract addit total content extract catechol equival per gram ce disc diffus assay polar extract exhibit consider inhibit against klebsiella pneumonia extract antibacteri activ against pathogen strain coli pseudomona spp proteus spp minimum bactericid mbc potenti extract lowest mbc record aceton ethyl acet extract against pneumonia pseudomona spp antioxid activ extract compar standard antioxid concentrationdepend power assay aqueous extract demonstr metal ion chelat activ extract exhibit consider metal chelat extract reveal consider inhibit mcf cell line remark antibacteri antioxid anticanc potenti cordifolia stem extract
inhibit ikb kinasebeta ikb kinasealpha heterocycl adamantyl arotinoid report seri retinoidrel molecul adamantyl aka adamantyl arotinoid adar signific cell growth inhibitori activ activ rxralpha nrb transient transfect assay devoid rar transactiv capac now adar bind inhibit ikkbeta known target mediat apoptosi cell growth inhibit adar chalcon addit prepar novel adar incorpor central heterocycl ring connect adamantylphenol carboxyl polar termini result indic rxralpha activ compound lack ikkbeta inhibitori activ novel heterocycl adar thiazol pyrazin ring link benzoic motif potent inhibitor ikkalpha ikkbeta case parallel signific growth inhibitori apoptosi induc activ
licochalcon suppress migrat invas human hepatocellular carcinoma cell downregul mkk jnk via nfkb mediat urokinas plasminogen activ express hepatocellular cell carcinoma hcc common diagnos taiwan bioactiv compound potenti revers suppress prevent licochalcon lica characterist chalcon licoric root glycyrrhiza inflat report lica antiinflammatori antimicrobi antitumor properti effect lica migrat invas human hcc cell not yet report lica inhibit migratori invas abil skhep hat vgh cell dosedepend manner cell migrat matrigel cell invas assay casein zymographi western blot revers transcriptas polymeras chain immunofluoresc assay lica induc dosedepend inhibit upa activ express well mrna level skhep hat vgh cell lica inhibit express phosphorjnk phosphormkk skhep cell furthermor lica decreas upa level sptreat simkktransfect cell alongsid mark reduct cell migrat invas support notion inhibit mkk jnk result antimetastat effect moreov lica inhibit express nuclear nfkb well bind abil nfkb upa promot role lica suppress metastasi molecular mechan well lica promis antimetastat agent
curcumin regul colon inhibit pglycoprotein insitu colon perfus model pglycoprotein carri out world vide cell line like caco mdrllcpk mdrmdck invitro result fail produc result invivo curcumin inhibitori action pglycoprotein permeabl irinotecan colon curcumin add intrarect administ nnitroso nmethyl urea induc colon singl pass whole length colon insitu perfus carri out irinotecan influenc pglycoprotein modul like verapamil curcumin serv control perfus irinotecan propronolol red ii induc nmethyl nnitroso urea iii perfus irinotican iv perfus irinotican presenc verapamil pretreat curcumin perfus irinotican estim hplcuv effect permeabl coeffici qrtpcr western blot result confirm decreas express pglycoprotein pgp curcumin colon cell irinotecan cm verapamilcoperfus where curcumin pretreat irinotecan cm cm pglycoprotein inhibitori activ verapamil curcumin enhanc colon permeabl irinotecan safe suitabl pglycoprotein inhibitor irinotecan enhanc therapeut benefit colon 
design synthesi biolog new inhibitor bax bclxl interact cell describ synthesi seri new molecul triazol moieti compound abil inhibit bax bclxl interact cell bret assay induc cell death deriv exhibit promis activ potent compound acylpyrogallol abt preliminari result demonstr deriv famili attract new molecul potent anticanc activ
isosuillin isol suillus luteus induc phase arrest apoptosi human hepatoma smmc cell isosuillin natur isol suillus luteus inhibit growth cell line molecular mechan action compound poor understood purpos isosuillin inhibit prolifer induc apoptosi human hepatoma cell line smmc demonstr effect isosuillin cell prolifer apoptosi smmc cell appar normal human coloni format assay dimethylthiazolyl diphenyltetrazolium bromid mtt western blot express phaseregul apoptosisassoci protein level isosuillin smmc cell result indic isosuillin decreas viabil induc phase arrest trigger apoptosi smmccell taken togeth result potenti isosuillin candid 
hypoxia differenti regul cxcr cxcr signal colon hifalpha cxcr cxcl crucial role metastat signific target hifalpha cxcr cxcl axi prevent dissemin vitro cxcr cxcr mrna protein express human colon carcinoma modul express hypoxia hifalpha colon cell line migrat cell boyden chamber after cxcr inhibit sirna cxcr cxcl neutraligand chalcon cohort colon polyp chromosomeunst carcinoma express cxcr cxcr normal mucosa polyp earlystag carcinoma late stage carcinoma demonstr hypoxia strong induc express cxcr transcript protein cell membran regul hifalpha cxcr express independ hypoxia after transient hypoxia cxcr level stabl cell membran up hour furthermor cxcr express impair cxcl induc akt phosphoryl erk activ unchang cxcr express did not akt erk activ presenc cxcr cxcr sirna signific reduct cell migrat occur irinotecan inhibit cell migrat irinotecan chalcon inhibit demonstr hypoxia upregul cxcr not cxcr express cell cxcr receptor protein level cell membran cell return normoxia up hour addit interest inhibit cxcr signal inhibit hifalpha cxcr cxcl pathway cxcr relev target continu express normox hypox condit cell
proapoptot properti pomegran juic leukemia cell line pomegran great promis anticanc agent clinic trial pomegran juic pgj induc apoptosi preferenti alter cell cycl leukemia cell line compar nontumor control cell agent not yet fulli elucid leukemia cell line fraction pgj solid phase extract demonstr acetonitril fraction decreas adenosin triphosph atp level leukemia cell line acetonitril fraction activ caspas induc nuclear morpholog characterist apoptosi phase arrest induc acetonitril fraction match phase arrest whole pgj acetonitril fraction content whole pgj low level fraction liquid chromatographi mass spectrometri lcms demonstr acetonitril fraction enrich ellagitannin ellag hydroxycinnam deriv deplet anthocyanin individu compound demonstr ellagitannin punicalagin activ mimick acetonitril fraction bioactiv compon pomegran confin acetonitril fraction pgj enrich ellagitannin hydroxycinnam bioactiv pgj individu compound demonstr ellagitannin punicalagin activ agent highlight compound key bioactiv agent pgj
target esr subtyp esr esr er modul ovarian ovarian cell express esr esr hormon attract option few effect estrogen opposit effect express esr compar esr indic receptor subtyp oppos effect explain modest nonselect estrogen inhibit clinic practic effect target er subtyp ovarian growth ovarian cell line skov ov express er subtyp er modul sodium phenylaminocarbonyl tetrazolium bismethoxynitro benzen sulfon hydrat xtt assay reveal bishydroxyphenyl methyl piperidinylethoxyphenol hpyrazol dihydrochlorid mpp esr antagonist bishydroxyphenyl propionitril dpn esr agonist suppress cell growth cell line propyl pyrazoletriyl trisphenol ppt esr agonist phenylbistrifluoromethylpyrazolo pyrimidinyl phtpp esr antagonist enhanc cell growth result confirm xenograft model where skov cell inject sc ovariectom mice averag size xenograft dpntreat mpptreat smaller vehicletr addit phosphoakt express skov cell after mpp dpn indic akt pathway involv mpp dpn synergist effect suppress ovarian cell growth indic target er subtyp enhanc hormon women ovarian 
quinoxalinesubstitut chalcon new inhibitor breast resist protein abcg polyspecif bring seri chalcon substitut quinoxalin unit bring synthes test inhibitor breast resist proteinmedi mitoxantron efflux compound appear effici analog bring substitu naphthyl methylenedioxyphenyl intermedi inhibitori activ naphthyl case methoxi phenyl are produc maxim inhibit molecular model indic electrostat steric contribut potenc naphthyl methylenedioxyphenyl shift are methoxi substitu shift phenyl bring indic prefer polyspecif inhibit
trilobatin attenu lpsmediat suppress nfkb signal pathway antiinflammatori effect trilobatin flavonoid isol leav lithocarpus polystachyus rehd well molecular mechan trilobatin dosedepend inhibit lipopolysaccharid lps induc mrna express secret proinflammatori cytokin tnf interleukinbeta ilbeta interleukin il raw macrophag inhibit detect trilobatin western blot confirm mechan antiinflammatori effect correl inhibit lps induc inhibitor nuclear factorkappa alpha ikbalpha degrad nuclear factorkappa nfkb phosphoryl addit trilobatin signific inhibit lps induc tnf il mrna protein level mous model result trilobatin potenti inhibit lps induc suppress nfkb signal pathway
pterostilben suppress oral cell invas inhibit mmp express compound varieti natur plant exhibit antioxid free scaveng abil induc apoptosi cell effect pterostilben oral cell metastasi not clarifi antimetastat properti pterostilben human oral squamous cell carcinoma scc cell pterostilben inhibit migrat invas capac scc cell vitro result zymographi western blot reveal activ protein level mmp urokinasetyp plasminogen activ upa inhibit pterostilben western blot pterostilben inhibit phosphoryl akt erk erk mrna level realtim polymeras chain promot assay conduct inhibitori effect pterostilben mmp upa express scc cell inhibitori effect associ upregul tissu inhibitor metalloproteinas plasminogen activ inhibitor downregul transcript nfkb sp creb signal pathway pterostilben potenti agent against oral metastasi
natur androgen receptor antagonist induc cellular senesc cell natur occur androgen receptorspecif antagonist atrar aa inhibit transactiv androgen receptor ar androgenmedi growth arexpress human pca cell line aa live cell provok molecular chang ar signal addit deceler nuclear transloc block intramolecular amino carboxi termin interact ar furthermor highresolut confoc fluoresc microscopi speckl format ar line intranuclear mobil receptor decreas bind ar indic impair chromatin recruit ar prostatespecif antigen promot enhanc chromatin immunoprecipit inhibitor nonreceptor tyrosin kinas src akt known interact partner ar level androgen induc cellular senesc nongenom pathway induc cellular senesc aa pp aminochlorophenyl tbutylpyrazolo pyrimidin pyrimidin akt inhibitor inhibitor nonreceptor tyrosin kinas src akt known interact partner ar level androgen induc cellular senesc nongenom pathway induc cellular senesc aa lncap cell aa associ hypophosphoryl retinoblastoma suppressor express pp signal pathway not aa human pca tissu sampl aa ex vivo indic cellular senesc associ express not taken togeth indic aa exhibit novel featur inhibit ar amino carboxytermin interact armedi nuclear activ growth pca cell
fatti ester phloridzin induc apoptosi human cell alter gene express phloridzin phlorizin phloretin oglucosid known block intestin glucos absorpt anticarcinogen effect phloridzin novel deriv human cell line synthesis novel acyl deriv phloridzin six differ long chain fatti regioselect enzymat acyl candida antarctica lipas antiprolif effect new compound parent compound phloridzin aglycon phloretin six free fatti chemotherapeut sorafenib doxorubicin daunorubicin human hepatocellular carcinoma hepg cell human breast adenocarcinoma mdamb cell acut monocyt leukemia thp cell normal human hepatocyt fatti ester phloridzin inhibit growth carcinoma leukemia cell dose not normal human hepatocyt antiprolif potenc fatti ester phloridzin compar potenc chemotherapeut fatti ester phloridzin inhibit topoisomeras iialpha activ induc phase arrest induc apoptosi via activ caspas decreas atp level mitochondri membran potenti hepg cell cell decosahexaeno dha ester phloridzin gene express rtpcr human target array antiprolif effect dha ester phloridzin down regul antiapoptot gene bcl growth receptor ebfr famili igfr igf pdgfr downstream signal partner pik akt mtor ras raf mapk cell cycl machineri cdks tert topa topb well epigenet regul hdac result fatti ester phloridzin potenti chemotherapeut effect mediat attenu express key protein involv cell cycl regul topoisomeras iialpha activ epigenet mechan cell cycl arrest apoptosi
synthet chalcon deriv potenti inhibitor secretori phospholipas cyclooxygenas lipoxygenas proinflammatori cytokin arachidon lead generat key lipid mediat play fundament role inflamm inhibit enzym involv arachidon synergist antiinflammatori effect enhanc spectrum activ seri diphenylpropenon deriv antiinflammatori activ involv inhibit secretori phospholipas cyclooxygenas soybean lipoxygenas lipopolysaccharid induc secret interleukin tnf mous raw macrophag result abov mention assay exhibit synthes compound effect inhibitor proinflammatori enzym cytokin result reveal chalcon deriv methlyamino ethanol substitut signific inhibit enzym cytokin molecular dock carri out elucid molecular aspect inhibitori activ compound chalcon deriv serv start point design improv antiinflammatori agent
verbascosid promot apoptosi regul hipkp signal human role hipkp signal pathway tumorigenesi resist verbascosid vb crc vivo vitro primari human crc sampl normal intestin tissu patient hipk express immunohistochemistri ihc express correl against patient clinicopatholog characterist human crc hct cell implant balb nude mice mice xenograft random vehicl control vb fluorouracil fu hipk bax bcl express ihc vitro effect vb crc cell prolifer apoptosi measur cck assay flow cytometri hipk pp bax bcl measur western blot ihc human crc sampl normal intestin tissu hipk express invers correl duke stage depth invas crc vivo inhibit rate vb crc xenograft accompani express hipk bax decreas bcl express vitro vb inhibit prolifer crc cell line hct ht lovo sw dosedepend manner apoptosi rate vb hct cell ht cell summari vb enhanc protein express proapoptot hipk pp bax decreas antiapoptot bcl express crc cell hipk protein modul phosphoryl status level bax bcl crc vb effect activ hipkp signal pathway result crc cell apoptosi
natur daucan ester induc apoptosi leukaem cell ros continu research antiprolif agent plant extend interest compound isol ferula communi ferulago campestri new daucan de new deriv ph isol addit six daucan coumarin simpl cytotox activ against panel six human cell line deriv de result moder activ cell line mechan action de abl induc apoptosi concentrationdepend manner sem jurkat cell line de aftesrh ros coincub de ros scaveng cell viabil rosmedi downstream signal essenti antiprolif effect de later incub de induc mitochondri depolar well caspas activ apoptosi mitochondri pathway concomit ros remark decreas mrna express antioxid enzym intracellular gsh content detect cell compar control indic taken togeth result daucan ester induc apoptot cell death rosmedi mechan human leukemia cell
novel chalcon deriv hypoxiainduc hif inhibitor synthesi antiinvas antiangiogen properti novel seri chalcon deriv synthes biolog activ against hif compound exhibit clear inhibitori effect hif downregul express hifalpha hypox condit meanwhil suppress vegf induc migrat invas hepb huvec cell nontox addit tube format assay demonstr antiangiogenesi activ moreov vivo indic compound retard growth hepb xenograft model cd mmp express tissu final acut intraven well toler nontox up swiss mice support antiinvas antiangiogen potenti compound hif inhibitor
anthraquinonechalcon hybrid synthesi preliminari antiprolif dnainteract novel anthraquinon chalcon compound synthes start acetylanthraquinon claisenschmidt anticanc potenti against human cell line compound promis activ inhibit hela cell ic low cytotox against healthi mrc cell line effect compound produc cell cycl flow cytometri accumul cell phase dosedepend manner induc caspasedepend apoptosi compound exhibit calf thymus dnabind activ bind constant absorpt titrat mand ctdna ctdna ctdna togeth fluoresc displac design strong minor groov binder
hydroxynaphthochalcon hnc inhibit tnf induc invas downregul nfkbmediat mmp gene express control metastasi success prevent evid indic natur synthet chalcon exhibit antimetastat activ inhibit nuclear factorkb nfkb precis mechan occur hydroxynaphthochalcon hnc tnf tnf induc mmp mrna express gelatinolyt enzym activ action associ inhibit rela nfkb activ addit hnc inhibit tnf induc invas mdamb breast cell threedimension spheroid invas assay taken togeth demonstr hnc prevent tnf induc cell invas downregul nfkbmediat mmp gene express therebi naphthochalcon potenti effect molecul platform antimetastat agent
estradiol agonist inhibit human lovo colorectalcanc cell prolifer migrat effect betaestradiol via esr er direct er agonist human lovo cell bioresourc research center cultur redfre dmem sigma unit state effect er agonist cellular prolifer lovo cell erselect agonist subject mtt sigma assay effect er agonist cell western immunoblot out diversif signal pathway motil migrat wound heal assay transwel chamber neuro probe plate tase quantit measur count migrat cell wound area postwound cellular migrationregul urokinasetyp plasminogen activ upa tissuetyp plasminogen activ tpa matrix metalloproteinas mmp human lovo cell gelatin zymographi gelatinolyt activ visual coomassi blue stain result mean se statist student ttest structur compar er agonist lovo cell er agonist mol measur cell viabil mtt assay result betaestradiol er agonist human lovo cell activ upregul protein level inhibit downstream target gene cyclin regul cell prolifer taken togeth demonstr antitumorigenesi effect betaestradiol er agonist compound prove potenti altern human result demonstr betaestradiol er agonist downregul migrationrel protein signal pathway human lovo cell play role betaestradiol er agonistmedi protect activ against addit betaestradiol er agonist dramat inhibit cell migrat express upa tpa mmp well mmp activ lovo cell regul cell metastasi moreov pretreat inhibitor block antimigr effect er agonist lovo cell er agonist impair lovo cell migrat modul migrationrel via suppressor gene direct er prove attract altern human futur
carotenoid profil antiprolif activ foxtail millet common consum foxtail millet varieti jingu jingu compar term phytochem antioxid properti antiprolif activ cellular antioxid activ caa hepg cell cultiv antiprolif properti against hepg mda cell assay methylen blue assay total content tpc gallic equiv dw jingu jingu varieti ferul chlorogen caffeic pcoumar syring xanthophyl zeaxanthin detect peroxyl scaveng capac foxtail millet jingu jingu mol equiv caa foxtail millet varieti mol quercetin equiv dw prolifer mda hepg cell inhibit dosedepend manner after exposur jingu jingu extract
obtain grape pomac enzymat extract antiinflammatori properti grape pomac winemak industri byproduct rich sourc bioactiv compound proteas enzymat obtain watersolubl extract gpee biomolecul peptid carbohydr lipid solubl especi interest content flavonoid vitro potenti antiinflammatori effect gpee monitor express molecul microglia cell lipopolysaccharid lps gpee decreas mrna level molecul molecul induc nitric synthas ino tnf interleukinbeta ilbeta ioniz calcium bind adaptor moleculeiba toll like receptor tlr well ino protein level lpsstimul microglia result abil regul excess microgli activ gpee possess antiinflammatori properti act agent therapeut interest neurodegen diseas involv neuroinflamm propos gpee natur extract appli field compound
trend chalcon potenti antiprolif antiresist agent chalcon natur compound plant fruit veget compound biolog activ antioxid antimicrobi antiinflammatori antifung antihypertens report chalcon interfer point signal transduct pathway cellular prolifer angiogenesi metastasi apoptosi revers multidrug resist larg research articl patent chalcon alreadi indic lead compound articl gather effort elucid molecular mechan action chalcon associ anticanc anti resist potenti
fenofibr induc phase arrest modul ppar foxo kip pathway human glioblastoma cell fenofibr fibric deriv known possess lipidlow effect fenofibr induc ppar transcript activ report exhibit anticanc effect mechan poor understood mechan behind antiprolif effect fenofibr umg cell human glioma cell line wst cell prolifer assay kit furthermor genomewid gene express profil molecular network david onlin softwar fenofibr express gene express gene david fenofibr cell cycl pathway involv mtor signal pathway insulin signal pathway result flow cytometri indic fenofibr induc cell cycl arrest umg cell furthermor foxopkip signal axi involv fenofibr induc cell cycl arrest addit known lipidlow effect fenofibr antitumor agent glioma 
weichangan fluorouracil suppress mous model effect weichangan wca fluorouracil fu metastasi mous model quantit hesperidin effect compon wca decoct perform hplc vitro cytotox wca hct cell wca diluent serum extract receiv wca oral gavag wk mtt assay fortyeight nude mice receiv cecum implant block subcutan amplifi human colon cell line hct mice random control con wca fu wca fu patholog consist tissu section hematoxylin eosin stain size measur metastat lesion count serum carcinoembryon antigen cea level elisa express level genesi metastasisrel protein betacatenin matrix metalloproteinas mmp measur realtim quantit revers transcriptas polymeras chain rtpcr immunohistochemistri immunoblot cell fraction intracellular distribut betacatenin parenchym palpabl abdomen nude mice wk postimplant orthotop format rate fu alon decreas compar con vs wca alon rate metastasi vs wca fu effect vs size vs rate metastas vs serum cea level vs express betacatenin mmp decreas drugtreat compar control detect realtim quantit rtpcr immunohistochemistri immunoblot cell fraction assay reveal nuclear transloc betacatenin wca fu wca fu inhibit colon growth metastas decreas express betacatenin mmp 
demonstr pta particl effect cisplatin against cell cell viabil linear ta cell viabil gml abov pta cisplatin against cell addit pta particl much biocompat against fibroblast cell cell viabil linear ta gml 
phloretin amelior chemokin icam express via block nfkb pathway tnf induc hacat human keratinocyt phloretin antioxid antiinflammatori antitumor properti phloretin suppress intercellular adhes molecul icam chemokin downregul nuclear transcript kappab nfkb mitogenactiv protein kinas mapk signal pathway tnfstimul hacat human keratinocyt hacat cell phloretin cell tnf phloretin decreas il il ccl mdc tarc phloretin decreas icam protein mrna express suppress adhes monocyt thp cell hacat cell phloretin inhibit nfkb transloc nucleus suppress phosphoryl akt mapk signal addit phloretin heme oxygenas concentrationdepend manner result demonstr phloretin antiinflammatori effect inhibit chemokin icam express suppress nfkb mapk pathway human keratinocyt
apoptosi induc nad deplet inhibit kn camkiiindepend manner nicotinamid phosphoribosyltransferas nampt key enzym catalyz synthesi nicotinamid mononucleotid nicotinamid nam salvag pathway mammalian nad biosynthesi potent nampt inhibitor role intracellular nad therapeut nad deplet induc nampt inhibitor depolar mitochondri membran potenti apoptosi cell type mechan behind depolar not precis elucid apoptosi thp cell nampt inhibitor ca calmodulindepend protein kinas ii camkii inhibitor kn via unknown mechan inact analog kn kn exhibit activ camkiiinhibit cellperm autocamtiderel inhibitori peptid ii did not indic inhibit thp cell apoptosi not depend camkii mechan action confirm kn did not inhibit decreas nad level did inhibit decreas mitochondri membran potenti indic kn exert inhibit upstream mitochondri pathway apoptosi qpcr bcl famili protein bim effici express nampt inhibit kn did not inhibit express ltype ca channel blocker verapamil nimodipin partial inhibit apoptosi indic effect depend ca channel inhibit kn kn report inhibit ltype ca channel hand kn kn did not mark inhibit apoptosi induc anticanc agent etoposid actinomycin abt tw indic mechan inhibit specif apoptosi induc nad deplet result demonstr nad deplet induc specif type apoptosi effect inhibit kn seri compound
bisphenol epitheli mesenchym transit estrogen breast cell via foxa signal esr er breast associ risk metastasi rate recurr reveal nanomolar bisphenol bpa typic endocrin disrupt promot vitro migrat induc mesenchym transit emt erbreast cell pcr array reveal bpa down regul up regul gene involv regul signal transduct biolog pathway breast down regul gene foxa key endocrin down regul bpa via depend manner silenc foxa sirna trigger emt skbr cell over express foxa abolish bpa induc emt bpa phosphoryl erk pmapk akt skbr cell pik akt inhibitor ly attenu bpa induc down regul foxa ecadherin ecad over express akt suppress foxa express skbr cell pik akt mediat least partial bpa induc emt erbreast cell summari evid bpa promot emt erbreast cell down regul foxa
effect gallium curcumin gallium diacetylcurcumin complex structur stabil peroxidas enzym anticanc antibacteri activ curcumin spectrum biolog pharmacolog activ antiinflammatori antioxid antiprolif antimicrobi anticanc activ complex curcumin metal gain attent year improv stabil effect gallium curcumin gallium diacetylcurcumin structur stabil horseradish peroxidas hrp enzym spectroscop techniqu addit enzymat cytotox effect complex mcf breast lncap carcinoma cell line mtt assay furthermor antibacteri activ complex against aureus coli dilut test result complex improv activ hrp toler against condit after addit complex affin hrp hydrogen peroxid substrat decreas affin substrat circular dichroism intrins synchron fluoresc spectra enzym structur around catalyt heme becom less compact distanc heme tryptophan residu bind complex hrp whole conclud chang enzym structur bind gallium curcumin gallium diacetylcurcumin complex result antioxid effici activ peroxidis enzym result anticanc antibacteri activ complex exhibit potenti 
apigenin inhibit growth breast cell role esr her neu phytoestrogen plantderiv compound estrogenlik activ mammalian phytoestrogen bind esr er particip regul cell growth gene transcript report cytotox effect phytoestrogen differ cell line measur phytoestrogen activ against breast cell differ level er express elucid molecular pathway regul leader compound immunoblot transfect luciferas report vector mtt test demonstr absenc signific differ er er breast cell line cytotox stimuli dose phytoestrogen apigenin quercetin naringenin effici erposit erneg cell incub breast cell apigenin reveal cytotox compound contrari naringenin result low cytotox activ dose apigenin not display estrogenlik activ suppress er activ betaestradiol cultiv herposit breast skbr cell presenc apigenin result decreas her neu express accompani cleavag apoptosi substrat parp cytotox effect phytoestrogen not associ steroid receptor breast cell apigenin effect phytoestrogen strong inhibit growth breast cell herposit 
phloretin induc apoptosi nonsmal cell lung carcinoma cell via jnk mapk pathway phloretin ph exist appl pear veget known antitumor activ cell line littl known effect human lung cell see ph induc apoptosi nonsmal cell lung nsclc cell mechan action ph mark induc cell apoptosi nsclc cell line inhibit migrat cell dosedepend manner express level bax cleav caspas degrad parp bcl decreas after ph addit phosphoryl mapk erk jnk dosedepend manner parallel ph inhibit mapk jnk specif inhibitor abolish ph induc activ caspas vivo tumorsuppress assay indic ph display signific inhibitori effect xenograft growth indic ph abl inhibit nsclc cell growth induc apoptosi mapk jnk pathway prove adjuv nsclc
consumpt black raspberri anthocyanin constitu alter innat cell traffick esophag freezedri black raspberri brb compon anthocyanin ac brb ac protocatechu pca inhibit esophag induc carcinogen nnitrosomethylbenzylamin nmba compon inflamm esophagus plasma chang infiltr innat cell nmbatreat esophagus inject nmba control nmba fed brb powder acrich fraction brbs mol ppm pca biomark express plasma esophagus quantifi infiltr cell esophagus point brb ac pca cytokin esophagus plasma nmbatreat nmbaon control decreas express proinflammatori cytokin ilbeta express antiinflammatori cytokin il moreov express il cytokin activ cytolyt natur killer cd cell addit decreas infiltr macrophag neutrophil esophagus result mechan brbs ac pca inhibit nmba induc esophag tumorigenesi alter cytokin express innat cell traffick tissu
identif new inhibitor human adp atp carrier molecular dock vitro transport assay mitochondri carrier protein shuttl varieti nucleotid coenzym across inner mitochondri membran mitochondri adp atp carrier aac specif transloc atp synthes mitochondria cytosol exchang cytosol adp play key role energi promot cell viabil regul mitochondri permeabl transit pore open homo sapien gene code aac differ tissu distribut express pattern aac dysregul type employ known new aac inhibitor crucial induc mitochondrialmedi apoptosi cell albeit carboxyatractylosid catr bongkrek bka known power aac inhibitor abl induc mitochondri dysfunct molecular level poison physiolog level estim affin human recombin aac vitro transport assay inhibit constant catr bka nm new aac inhibitor perform dockingbas virtual screen inhous librari ligand show affin aac bind region test commerci avail molecul out predict candid name suramin chebulin competit aac inhibitor inhibit constant demonstr chebulin suramin aac inhibitor poor inhibit human mitochondri carrier name orc apc agc
dihydrochalcon compound isol crabappl leav anticanc effect human cell line dihydrochalcon compound isol leav malus crabappl cv radiant structur elucid uv ir esim hnmr cnmr analys compound trilobatin phloretin hydroxyphloretin phloretin rutinosid phlorizin ocoumaroyloglucopyranosylphloretin methoxyoferuloyoglucopyranosylphloretin belong phloretin deriv compound new rare dihydrochalcon compound result mtt cell growth inhibit assay demonstr phloretin deriv signific anticanc activ against human cell line human lung cell line bel cell line hepg human ileocec cell line ht human colon cell line signific effect cell line potenti applic phloretin deriv ad methoxyl phloretin dramat phloretin anticanc activ
phloretin antitumor efficaci intratumor deliv heatshock protein kda hsp murin model recombin hsp chaperon exert profound anticanc effect administ intratumor action abil hsp penetr cell extract endogen homolog enhanc efficaci hsp cycl employ phloretin flavonoid enhanc poreform activ chaperon artifici membran phloretin efficaci hsp penetr mous cell human erythroblast accompani transport endogen hsp plasma membran hsp phloretin led cell sensit cytotox compar chaperon alon incub cell biotinyl hsp phloretin amount chaperon cell chaperon cycl trigger specif antitumor effect hsp phloretin novel hspgel applic addit phloretin gel fivefold compar untreat mice life span anim extend surviv corrobor activ innat adapt interest hsp activ cd cellmedi gammaifn phloretin contribut larg cd cell hsp phloretin novel effici immunotherapi intract skin 
antioxid antitumor anticanc cytotox effect psidium guajava leaf extract context psidium guajava myrtacea leav tradit medicin inflamm ailment scientif valid tradit medic materi ferricreduc antioxid power frap diphenylpicryl hydrazil dpph assay estim antioxid activ guajava leaf extract methanol hexan chloroform antitumor vivo cytotox activ potato disc assay pda brine shrimp lethal assay human carcinoma cell line kbm scc incub differ dose extract anticanc activ estim mtt assay nfkb suppress activ electrophoret mobil shift assay emsa extract gcms total flavonoid content measur colorimetr assay discuss antioxid activ extract methanol chloroform hexan ic kbm scc cell hexan extract exhibit potent antitumor cytotox activ extract complet inhibit tnf induc nfkb activ kbm cell gcms result pyrogallol palmit compon methanol chloroform hexan extract signific differ total flavonoid content differ solvent extract demonstr guajava leaf extract play role against downmodul nuclear kb
inhibitori effect luteolin prolifer human breast cell line induc epiderm growth mechan inhibitori effect luteolin prolifer breast cell induc epiderm growth egf vitro mtt assay detect inhibitori effect luteolin prolifer mcf mdamb cell well effect prolifer mcf cell induc egf western blot detect effect luteolin express epiderm growth receptor egfr phosphatidylinositol kinas pik akt mitogenactiv protein kinas mapk extracellularsignalregul kinas erk signal transduc activ transcript stat mcf cell induc egf result luteolin inhibit prolifer mcf mdamb cell inhibitori effect mcf cell promin moreov luteolin inhibit prolifer mcf cell induc egf western blot result luteolin ag inhibitor egfr signal inhibit express pegfr pstat mcf cell induc egf luteolin ly inhibitor akt signal pd inhibitor erk signal inhibit express pakt perk mcf cell induc egf luteolin inhibit egf induc activ egfr signal pathway human breast cell line pik akt mapk erk stat signal pathway pathway mediat inhibitori effect luteolin egfr signal result theoret foundat luteolin antitumor 
disubstitut naphthyl betadxylopyranosid synthesi gag prime histon acetyltransferas hat inhibit xylosid compound induc glycosaminoglycan gag chain synthesi independ proteoglycan core protein xylosid hydroxynaphthylbetadxylopyranosid tumorselect growth inhibitori effect vitro vivo effect vitro correl reduct histon acetyl addit gag chain report inhibit histon acetyltransferas hat xylosid correspond xylosideprim gag chain hat inhibitor synthes seri naphthoxylosid carri structur motif moieti known hat inhibitor garcinol curcumin biolog activ disubstitut naphthoxylosid induc gag chain synthesi least free exhibit moder hat inhibit vitro histon acetyl cell cultur
capsaicin inhibit aggress phenotyp downregul tumorassoci nadh oxidas tnox pou domain transcript pouf capsaicin report preferenti inhibit activ tumorassoci nadh oxidas tnox belong famili growthrel plasma membran hydroquinon oxidas cell inhibitori effect capsaicin tnox associ cell growth attenu apoptosi transcript regul tnox protein express bioinformat indic tnox promot sequenc harbor bind motif pouf thought play role neuron differenti melanocyt growth differenti tumorigenesi capsaicinmedi tnox downregul cell migrat inhibit pouf protein express level pouf tnox correl overexpress pouf correspond upregul tnox enhanc prolifer migrat invas ag human gastric carcinoma cell knockdown pouf downregul tnox phenotyp not shed light molecular mechan anticanc properti capsaicin transcript regul tnox express potenti explain pouf associ tumorigenesi
antitumor activ benzylideneacetophenon deriv via proteasom inhibit cell chalcon deriv possess promis biolog properti antiinflamm antioxid antitumor activ deriv chalcon induc apoptosi differ kind cell involv mechan action not well defin purpos primari target benzylideneacetophenon deriv jc synthet compound deriv chalcon famili human cell work model jc inhibit proteasom activ indic vitro cellbas assay jcdimer potent monom aspect proteasom inhibit induc apoptosi cell owe role proteasom biolog human invas metastasi give clue novel antitumor agent
aminoglycosidederiv amphiphil nanoparticl molecular deliveri effect carrier lead improv outcom varieti diseas condit describ novel aminoglycosidederiv amphiphil nanoparticl deliveri eye ablat cell mpegpa nanoparticl abl carri signific amount doxorubicin dox presum mean hydrophob interact core cellbas indic mpegpa nanoparticl load doxorubicin abl induc signific loss viabil pc human mdamb human breast mb murin cell empti nanoparticl result neglig loss cell viabil condit taken togeth result indic mpegpa nanoparticl platform attract deliveri differ applic 
inhibit autophagi enhanc curcumin unit light irradi induc growth suppress human cell malign aggress skin carcinoma possess fast propag invas characterist curcumin natur compound biolog activ antiprolif apoptosisacceler impact cell unfortun therapeut activ cur sever hinder extrem low bioavail cooper low cur red unit blue light irradi perform inspect synergist effect apoptosi prolifer autophagi human cell result red unit blue light irradi efficaci synerg cur trigger stressmedi cell death induc apoptosi inhibit cell prolifer meanwhil western blot reveal disposur induc format autophagosom convers inhibit autophagi enhanc apoptosi obstruct cell cycl arrest induc revers prolifer arrest senesc cur red unit blue light irradi generat photochemoprevent effect via enhanc apoptosi trigger autophagi pharmacolog inhibit autophagi convert revers arrest cell senesc damag cell escap program death
structur effect flavonoid aglycon cell cycl hepg cell activ fisetin quercetin catecholomethyltransferas comt flavonoid abund plant kingdom extens manifold pharmacolog activ highlight cell cycl arrest play key role antiprolif effect differ cell structureact flavonoid poor influenc flavonoid aglycon well cell cycl distribut flavonoid extens cell hepg cell line appli potenti activ inactiv flavonoid test compound diosmetin fisetin apigenin lutelin quercetin provok spectacular extent phase cell cycl arrest inhibit catecholomethyltransferas enzym entacapon decreas antiprolif effect fisetin quercetin geraldol isorhamnetin omethyl fisetin quercetin demonstr antiprolif effect hepg cell compar parent compound result omethyl flavonoid modifi deriv suitabl candid 
curcumin inhibit ho induc invas migrat human pancreat via suppress erk nfkb pathway curcumin diferuloylmethan natur turmer possess spectrum pharmacolog properti antioxid antitumor metastat activ mechan curcumin suppress metastasi pancreat still not fulli elucid demonstr moder amount hydrogen peroxid ho abl promot pancreat invas curcumin suppress ho induc invas migratori abil human pancreat bxpc panc cell expos ho curcumin nacetylcystein nac scaveng free effect curcumin pancreat cell prolifer mtt assay intracellular ros ros dichlorodihydrofluorecein diacet cellular invas migratori abil transwel matrigel invas assay wound heal assay express matrix metalloproteinas mmp mmp qtpcr western blot mrna protein level activ pextracellular signalregul kinas erk pnuclear factorkb nfkb measur western blot curcumin inhibit cell prolifer dosedepend manner curcumin nac abl inhibit ho induc ros migrat invas decreas express mmp mmp pancreat cell addit hoinduc perk pnfkb bxpc panc cell curcumin nac pd erk inhibitor indic curcumin suppress pancreat migrat invas inhibit ros erk nfkb signal pathway curcumin potenti anticanc agent pancreat 
halogen naphthochalcon structur naphthopyrazolin antitumor activ halodimethoxyphenyl naphthylpropenon structur pyrazolin prepar vitro anticanc activ chalcon antiprolif low doubledigit micromolar ic against six cell line pyrazolin low singledigit micromolar ic against panel pyrazolin inhibit atpbind cassett efflux transport type pgp bcrp chalcon inhibit bcrp test compound induc accumul ht colon carcinoma cell phase cell cycl interf microtubul factin dynam chalcon induc apoptosi cell aftesrh
acryloylphenylcarboxamid new breast resist protein abcg modul chalcon easili synthes natur precursor secondari plant deriv biolog activ inhibit abc transport role inhibitor abcg discov abc transport involv multidrug resist inspir synthesi new structur divers deriv typic chalcon moieti chlorid amid linker ringa chalcon result compound cover spectrum substitut pattern allow structureact optim structur featur synthes acryloylphenylcarboxamid inhibitori activ against abcg behavior abcb abcc furthermor promis compound intrins cytotox abil revers abcgmedi multidrug resist 
preclin valid molecul quininib novel therapeut crc lead death molecular target eg bevacizumab improv surviv rate resist ultim newer requir quininib molecul antiangiogen activ vitro ex vivo vivo screen model quininib quinolinyl vinyl molecul molecular mol inhibit blood vessel zebrafish embryo vitro quininib endotheli tubul format cell migrat unaffect quininib cell surviv quininib ex vivo human crc explant quininib secret il il vegf ena groalpha tnf ilbeta mcp ex vivo quininib well toler mice administ intraperiton everi growth htluc crc xenograft compar vehicl control addit quininib signal alphavbeta integrin fluoresc probe after indic angiogen inhibit furthermor quininib express angiogen gene xenograft support quininib novel therapeut agent crc
design synthesi cytotox activ certain novel chalcon analog compound seri chalcon analog compound design synthes replac substitut enon ethylen bridg parent chalcon rigid heterocycl moieti substitut amin gave nineteen target compound cytotox activ screen against breast cell well breast normal cell target compound inhibit activ tubulin beta polymer target compound ad broad spectrum excel anticanc activ against mcf hepg compound tubb inhibit activ
design synthesi activ novel sorafenib analogu bear chalcon unit seri sorafenib deriv nmethylpicolinamideoxi chalcon ao ae synthes nmr ms target compound cytotox against hepg mcf pc cell line compound activ against vegfr kdr braf kinas result indic compound moder good antitumor activ compound well cytotox activ against hepg mcf pc cell line ic activ sorafenib compound good activ vegfr kdr kinas ic structureact sar dock indic replac urea sorafenib chalcon keton improv cytotox activ result halogen br methoxi substitut substitut benefit activ
molecular mechan antimetastat activ curcumin lead death occur local diseas morbid mortal rate abil cell breakoff primari spread distant organ main proport drugresist cell unpleas sideeffect still challeng curcumin natur compound main bioactiv constitu indian spice turmer indian chines medicin curcumin wellknown therapeut action antiinflammatori antimicrobi antioxid anticanc properti curcumin induc cell apoptosi regul signal pathway arrest cell cycl curcumin therapeut prevent action metastat not yet fulli understood review potenti antimetastat mechan curcumin inhibit transcript signal pathway eg nfkb app stat cytokin eg cxcl cxcl il il proteas eg upa mmps protein kinas eg mapk fak regul mirna eg mir mirb heat shock protein hlj addit synergist action curcumin discuss review
novel synthet chalcon induc apoptosi nonsmal cell lung cell harbor kras mutat seri novel chalcon synthes claisenschmidt condens tetralon indolecarboxaldehyd human lung cell line harbor kras mutat chalcon induc dosedepend apoptosi cell cycl analys western blot role chalcon interrupt transit cell cycl sar demonstr substitu indol atom anticanc activ chalcon methyl ethyl activ compound ec nm compound activ cell ec nm pc pancreat clr pan cell furthermor compound induc apoptosi lung cell ec did not measur normal lung bronchial epitheli cell hbec dose indic specif cell
apoptot effect chalcon deriv acetylthiophen human breast cell varieti chalcon demonstr cytotox activ cell line cytotox chalcon deriv acetylthiophen human breast cell line mcf mdamb cell synthes chalcon cytotox tetrazolium dye mtt live dead dapi assay chalcon decreas mcf mdamb cell viabil vitro dose depend manner after ic chalcon display cytotox activ test compound cytotox effect compound confirm live dead assay addit dapi stain reveal compound induc death apoptosi specul chalcon deriv acetylthiophen sourc therapeut agent human breast 
capsaicin synerg camptothecin induc apoptosi human cell lung via calpain pathway cell lung sclc excel radiat patient show shrinkag even remiss challeng sclc patient inevit relaps not respond line clinic camptothecinbas line sclc patient convent camptothecin recurr sclc poor surviv outcom improv therapeut index camptothecin valuabl sclc extens evid nutrit compound like capsaicin spici compound chili pepper improv anticanc activ chemotherapeut cell line anim model statist capsaicin synerg camptothecin enhanc apoptosi human sclc cell synergist activ camptothecin capsaicin classic variant sclc cell line vivo human sclc xenotranspl chicken chorioallanto membran cam model synergist activ capsaicin camptothecin mediat intracellular calcium calpain pathway foster hope novel nutrit sclc
design synthesi biolog coupl bioactiv scaffold potenti anticanc agent dual target dihydrofol reductas thioredoxin reductas dihydrofol reductas dhfr thioredoxin reductas trxr enzym involv cell growth surviv diaminodihydrotriazin scaffold wellestablish scaffold dhfr inhibit chalcon report inhibitor trxr novel compound design structur diaminodihydrotriazin chalcon scaffold via diether linker success synthes compound demonstr dual inhibit against dhfr trxr vitro enzym assay compound exhibit antiprolif activ against mcf hct cell potent analog inhibit cellular dhfr trxr activ hct cell compel evid exert anticanc properti via multitarget inhibit cellular level
ascofuranon inhibit lipopolysaccharid induc via nfkappab ap perk tnf il ilbeta raw macrophag natur fungal compound ascofuranon chloro ee dimethyloxotetrahydrofuranyl methyloctadienyl dihydroxymethylbenzaldehyd mw af isol ascochyta vicia known promot cell cycl arrest inhibit invas cell structur compound ascochlorin asc mw regard antiinflammatori activ lps raw macrophag antiinflammatori activ molecular differ af asc activ af asc uniqu trimethyl oxocyclohexyl structur af uniqu dimethyloxotetrahydrofuran structur af dosedepend inhibit ino cox mrna protein level raw cell addit af suppress mrna express level cytokin tnf il ilbeta rtpcr af clear inhibit nuclear transloc nfkb ap pcjun cytosol space phosphoryl ikb maintain activ nfkb decreas af moreov af suppress bind nfkb inhibit ikba phosphoryl degrad inhibit nuclear transloc immunofluoresc confoc microscopi reveal transloc nfkb ap pcjun decreas af af specif decreas express level perk not express level pp pjnk result af suppress target perk indic af regul lpsstimul nuclear transloc nfkb ap pcjun raw macrophag specif target perk af asc exert effect differ way probabl structur differ allow specif recognit inhibit target mapk result af natur bioactiv compound inflammationmedi patholog diseas
synthesi biolog novel pyrazol chalcon deriv novel hepatocellular carcinoma therapeut despit second mortal associ sorafenib fdaapprov chemotherapeut agent avail patient improv surviv few month pyrazol chalcon analog compound synthes potenti chemotherapeut agent hepatocellular carcinoma hcc modifi central pyrazol ring differ heteroaryl ring substitut pyrazol differ substitut chalcon moieti produc fouthi variant compound compound cytotox sulforhodamin assay real cell growth track inhibitori ic compound exhibit potent cytotox activ against cell line test cytotox activ wellknown chemotherapeut fu compound chosen panel hcc cell line flow cytometr hcc cell compound demonstr compound cell cycl arrest phase apoptot cell death impair cell growth realtim cell growth surveil consist result western blot hcc cell compound result molecular chang cell cycl protein where level independ level key mitosi cyclin cdk decreas chalcon deriv potent bioactiv modul express cellcycl protein result cellcycl arrest hcc cell line test indic compound preclin candid
pentabromophenol suppress tgfb signal acceler degrad type ii tgfb receptor via caveolaemedi endocytosi pentabromophenol pbp bromin flame retard bfr consum bfrs exert advers health effect neurotox endocrinedisrupt effect pbp suppress tgfb acceler turnov rate tgfb receptor pbp suppress tgfbmediat cell migrat pai promoterdriven report gene activ smad phosphoryl cell type furthermor pbp abolish tgfbmediat repress ecadherin express addit vimentin express ncadherin fibronectin upregul block tgfb induc epithelialmesenchym transit nmumg cell inhibit not congen tribromophenol triiodophenol tgfb superfamili member play key role regul biolog cell prolifer migrat well result vitro detail pbp modul tgfb signal pbp bfrs polybromin diphenyl ether pbdes addit laboratori mechanist perform bfrs potenti risk tumorigenesi tgfbrelat diseas
tnf il il express dispar action curcumin against cisplatin induc nephrotox cisplatin regular employ effect chemotherapeut agent type main drawback cisplatin kidney patient mechan believ involv kidney damag inflamm play signific role event curcumin antioxid antiinflammatori effect purpos protect effect curcumin cisplatin induc nephrotox femal random control curcumin cisplatin curcumin plus cisplatin pretreat cisplatin plus curcumin posttreat cisplatin bodi curcumin bodi blood urea nitrogen bun creatinin albumin tnf tnf interleukin il beta il il il express histolog chang th after cisplatin inject acut kidney damag evid bun creatinin level addit cisplatin mark proinflammatori reveal signific tissu level tnf il il decreas il level pretreat curcumin cisplatin induc nephrotox clear evid bun creatinin tnf il il level albumin il level addit support histopatholog kidney posttreat curcumin fail cut down express neglect express il dispar action curcumin after pre posttreat cisplatin induc nephrotox inabl posttreat tnf il besid concurr rise il express renal tissu
gm arrest flavokawain kava chalcon heroverexpress breast cell herceptin her neu breast predict mortal compris breast flavokawain fka preferenti viabil heroverexpress breast cell line ie skbr mcf her versus less her express ie mcf mdamb fka cytotox breast cell line minim effect growth nonmalign breast epitheli mcfa cell fka induc gm arrest cell cycl heroverexpress breast cell line inhibit cdc cdcc phosphoryl downregul express myt wee lead cdc kinas activ addit fka induc apoptosi skbr cell protein express bim bax decreas express bcl bclx xiap survivin fka downregul protein express her inhibit akt phosphoryl herceptin plus fka lead enhanc growth inhibitori effect her overexpress breast cell line downregul myt wee skp survivin xiap result fka promis novel apoptosi induc block agent herceptin enhanc heroverexpress breast 
abt enhanc damag apoptosi human tcell acut lymphoblast leukemia molt cell abt belong new anticanc agent name bh mimet abt competit bind surfac hydrophob groov antiapoptot protein bcl famili counteract protect effect natur inhibit prolifer induc apoptosi differ type cell design effect abt human acut lymphoblast leukemia cell vitro cytotox activ agent against molt leukemia cell coulter electr imped comet assay flow cytometri light microscopi western blot techniqu result show abt mark decreas cell viabil damag cell cycl perturb synergist enhanc apoptosi molt cell compar after applic singl agent moreov simultan leukemia cell abt result reduct mitochondri membran potenti protein level upregul bax bcl ratio indic abt promis approach acut lymphoblast leukemia 
novel diprenyl chalcon inhibit prolifer cell vitro induc cell apoptosi arrest cell cycl phase doubl claisen rearrang synthet strategi total synthesi dimethyl medicagenin compound seri analog prepar novel diprenyl chalcon ring replac azaheterocycl structur twentytwo newli synthes compound confirm nmr nmr esim vitro cytotox target compound cell notic compound exhibit broadspectrum cytotox pc cell mdamb breast cell mda hel erythroleukemia cell ic indic compound induc apoptosi arrest cell cycl phase abov mention cell line compound display potent inhibitori activ against prolifer hel cell ic compound slight induc apoptosi arrest cell cycl phase hel cell preliminari structureact indic cell line pyridinyl essenti cytotox
ginkgol inhibit migrat breast cell inhibit nemo sumoyl nfkb activ ginkgol ga alkyl crude extract ginkgo biloba leav known anticanc activ mode action not well understood antimigratori activ ga against breast cell molecular mechan behind activ ga mixtur inhibit wound heal mcf mdamb breast cell none compound mixtur cytotox cell line test resazurin assay inhibit nfkb activ hek blue null report cell line furthermor inhibit degrad nuclear klight polypeptid gene enhanc bcell inhibitor alpha ikbalpha sumoyl assay reveal ga inhibit sumoyl nfkb essenti modul nemo molecular dock sumoactiv enzym ga bound activ adenyl site calcul affin kcal mol quantit rtpcr mixtur signific downregul urokinas plasminogen activ upa plasminogen activ inhibitor pai cxc chemokin receptor type cxcr matrix metalloproteinas mmp conclud ga reveal consider antimigratori activ noncytotox indic antimetastat activ low effect explain inhibit nemo sumoyl lead inhibit ikbalpha degrad consequ reduct nfkb activ lead downregul metastasi gene upa pai cxcr mmp
bisphenol activ egfr erk promot prolifer spheroid format resist egfr pathway inhibit esrneg breast cell evid epidemiolog link environment exposur aggress breast subtyp clinic distinct type breast lethal phenotyp variant breast ibc overexpress epiderm growth receptor egfr her esr er common ibc cell instead solid mass rapid prolifer diffus cell cluster demonstr role adapt antioxid acquir resist egfrtarget ibc environment known induc result perturb signal transduct pathway interest potenti egfr mitogen effect ibc erneg ibc cell subset epa toxcast set effect egfr activ phenotyp assay demonstr endocrinedisrupt bisphenol bpa bisphydroxyphenyl trichloroethan egfr erk signal bpa correspond express sod antiapoptot bcl key antioxid antiapoptot bpa potenti clonogen growth spheroid format vitro reflect ibcspecif patholog characterist furthermor bpa abl attenu inhibitori effect egfr target longerterm anchorageindepend growth assay potenti mechanist environment bpa potenti hyperprolif deathresist phenotyp cell activ mitogen pathway cell addict surviv
protect effect propofol against tnf induc apoptosi mediat via inhibit ino maintain intracellular ca homeostasi mous hippocamp ht cell inflamm cytokin tnf induc apoptosi neuron cell hypothes propofol attenu tnf induc apoptosi mous hippocamp ht cell mechan mous hippocamp ht cell pretreat propofol tnf cell viabil measur cell count kit cck cell apoptosi flow cytometri effect propofol tnfmodul nitric measur nitrat reductas assay kit intracellular calcium mitochondri membran potenti mmp depolar measur flow cytometri express induc nitric synthas ino ebp homolog protein chop bcell lymphoma bcl famili caspas detect western blot compar control tnf timedepend ht cell apoptosi attenu mol propofol tnf ng induc overexpress ino nitric accumul intracellular ca endoplasm reticulum er lead mitochondri dysfunct effect allevi mol propofol demonstr propofol attenu tnf induc ht apoptosi indic mechan involv ino ca mitochondri dysfunct
identif novel chalcon deriv inhibit notch signal tcell acut lymphoblast leukemia notch signal ration target harbour notch gain mutat tcell acut lymphoblast leukemia tall design synthet chalconederiv possess notch inhibitori activ low micro molar tall cell line structureact afford chalcon scaffold short term compound result dosedepend decreas notch signal activ halt cell cycl induc apoptosi leukemia cell growth taken togeth indic novel notch inhibitor against notchdepend 
benzylideneacetophenon deriv induc apoptosi radiationresist human breast cell via benzylideneacetophenon deriv hydroxymethoxyphenyl heptenon jc elicit cytotox effect mdamb human breast cellsradi resist cell mdamb rr dosedepend manner ic jc jcmediat apoptosi confirm subg cell popul jc disrupt mitochondri membran potenti express antiapoptot cell lymphoma protein express proapoptot bclassoci protein lead cleavag caspas caspas poli adpribos polymeras addit jc activ mitogenactiv protein kinas specif inhibitor kinas abrog jc induc apoptot bodi jc level intracellular ros enhanc macromolecular damag via lipid peroxid protein carbonyl strand breakag jc effect against radiationresist human breast cell
cytotox effect novel naphthylchalcon against cell focus hematolog malign chalcon natur compound describ literatur properti cytotox activ against type search new chemotherapeut agent still necessari cytotox mechan involv cell death induc synthet chalcon differ cell chalcon cell viabil twelv cell line depend manner cytotox against acut leukemia cell interest compound non cytotox normal cell nonhemolyt normal red blood cell chalcon decreas express cell prolifer ki block phase jurkat cell line cell morpholog featur apoptosi latter pattern agaros gel extern phosphatidylserin caspas parp cleavag chalcon mitochondri membran potenti decreas express antiapoptot protein bcl survivin express proapoptot protein bax confirm involv intrins pathway mitochondri permeabl result aif cytochrom endonucleas mitochondria cytosol addit chalcon express fasr induc bid cleavag show involv extrins pathway final chalcon synerg effect cytarabin vincristin result interest compound strong antitumor activ
anticanc activ hydroxi sulfonamideazobenzen platinum complex cisplatinresist ovarian cell anticanc activ complex wildtyp cisplatinresist acp ovarian cell complex exhibit ic below display activ acp cell line indic not crossresist cisplatin
synthesi structur nucleas activ cytotox dft molecular dock nitrato bridg homodinuclear cucu znzn complex bipyridin chalcon deriv coligand bind metal ion oo atom antisyn mode metal center complex separ via bridg nitrato distanc structur absorpt spectra support comput densiti theori dft tddft complex exhibit nucleas activ cleav supercoil complex preferenti bind groov pathway complex bind minor groov via hydrolyt pathway complex inhibit topoisomeras relax activ ic molecular dock support groov bind topoisomeras bind complex complex signific cytotox against hela cell line cervic cell line vitro ic calcul compar complex complex induc cell apoptosi laterstag compar complex cell apoptosi topoisomeras inhibit complex enabl potenti candid futur anticanc 
sechium edul jacq swartz new cultivar antiprolif potenti human cervic hela cell line sechium edul perla negra cultivar recentlyobtain biolog materi whose progenitor edul var nigrum minor edul var amarus silvestri latter report antiprolif activ against hela cell line methanol extract fruit perla negra cultivar biolog activ methanol extract phytochem thin layer chromatographi tlc column chromatographi cc terpen flavonoid compound via perform liquid chromatographi hplc cucurbitacin terpen fraction rutin phlorizidin myricetin quercetin naringenin phloretin apigenin galangin flavonoid fraction biolog activ differ methanol extract hela cell line normal methanol extract inhibit prolifer hela cell ic gml extract ic gml fraction pool inhibit gml biolog effect methanol extract perla negra specif inhibit cell not normal cell unusu featur molecul potenti biomed agent
centella asiatica modul cachexia associ cytokin cell death leukaem thp cell peripher blood mononuclear cell pbmcs cachexia associ proinflammatori cytokin level centella asiatica asiatica possess antioxid antiinflammatori antitumor potenti modul antioxid cytokin cell death asiatica ethanol leaf extract cle leukaem thp cell normal peripher blood mononuclear cell pbmcs cytotoxc cle scaveng activ cle diphenyl picrylhydrazyl dpph assay glutathion gsh level caspas activ adenosin triphosph atp level luminometri assay level tnf interleukin il ilbeta il enzymelink immunosorb assay cle decreas pbmc viabil cle cle thp viabil cle scaveng activ cle pbmc tnf il level decreas cle pbmc il ilbeta cle decreas cle thp cell cle decreas ilbeta il il level cell line cle gsh caspas activ cle pbmcs decreas cle thp cell cle decreas caspas activ atp level cell line pbmcs thp cell cle prove effect modul antioxid activ cytokin cell death thp cell cle decreas proinflammatori cytokin level antiinflammatori cytokin level allevi cachexia
compar antiprolif properti ethanol leaf extract anogeissus leiocarpus dc guill perr against hepg hepatocarcinoma cell epidemiolog evid lead death folklor plant reliabl sourc healthrestor principl welldocu search plant activ against diseas continu report laboratorybas evid relev ethanol leaf extract anogeissus leiocarpus al natur quantit flavonoid content involv quercetin gallic standard spectrophotometri cytotox fluorometr propidiumiodidestain antioxid status adenosin triphosph atp level caspas activ mitochondri integr fluorometri luminometri antioxid assay demonstr al possess strong antioxid capac compar compound ascorb butyl hydroxytoluen buttress level quantit extract posttreat indic al modul prolifer hepg carcinoma cell concentrationdepend manner total nuclei area propidiumiodid nuclei area buttress modul cell prolifer al indic cell death apoptosi necrosi possess tendenc activ caspas posttreat mitochondri not mitotox compar al exhibit mitotox taken togeth al possess strong antiprolif activ prospect manag hepatocellular carcinoma deserv 
apoptosi cell cycl arrest flavokawain ht human colon adenocarcinoma via enhanc ros generat upregul gadd inactiv inhibitor apoptosi protein chalcon exhibit anticanc properti target molecular pathway interest flavokawain fkc natur occur chalcon isol kava piper methysticum forst root extract inhibitori effect fkc growth ht cell mechan action cell viabil ht cell sulforhodamin assay after fkc apoptosi morpholog biochem assay ros generat dichlorofluorescein fluoresc stain superoxid dismutas activ measur spectrophotometr western blot chang protein level fkc mark decreas cell viabil ht cell cell dramat chang cellular nuclear morpholog typic apoptot featur apoptosi correl well extern phosphatidylserin fragment decreas mitochondri membran potenti activ caspas parp cleavag associ ros decreas sod activ protein level xiap ciap ciap downregul gadd upregul after fkc fkc induc cell cycl arrest phase via upregul pindepend manner result evid fkc potenti chemotherapeut colon adenocarcinoma flavokawain inhibit growth ht human colon adenocarcinoma cell flavokawain induc apoptosi ht cell associ ros decreas sod activ flavokawain induc cell cycl arrest phase via upregul ht cellsht cell flavokawain downregul xiap ciap ciap upregul gadd
novel quinolon chalcon target colchicinebind pocket kill multidrugresist cell inhibit tubulin activ mrp agent target colchicinebind pocket usual minim drugresist issu albeit associ chalconebas compound bind colchicinebind site edibl fruit effect less synthes quinolon chalcon compound methoxyphenyl oxopropenyl quinolinh ctr methoxymethoxyphenyl oxopropenyl quinolinh ctr promis lead ctr effect against differ cell line origin differ tissu larg cellspecif manner ctr ctr revers bind colchicinebind pocket betatubulin interest ctrs effect against multidrugresist cell colchicin paclitaxel vinblastin not ctr overcom multidrugresist abil imped mrp maintain strong inhibit against microtubul activ mice engraft mdamb tripleneg breast cell ctr ctr possess strong anticanc activ alon paclitaxel notabl effect togeth demonstr ctrs effect safe against differ against multidrugresist 
anticarcinogen activ muntingia calabura leav methanol extract against azoxymethan induc colon involv modul colon antioxid system flavonoid leav muntingia calabura elaeocarpacea tradit medic practic scientif pharmacolog activ anticanc effect not thorough yet object effect memcl against azoxymethan aom induc colon involv endogen antioxid materi male spraguedawley inject intraperiton onc aom except normal receiv salin anim administ oral tween vehicl normal tween vehicl memc after colon sampl histopatholog quantif aberr crypt foci colon antioxid level memc subject hplc extract exert signific anticarcinogenesi activ indic decreas total aberr crypt format antioxid activ colon tissu antioxid ie superoxid dismutas sod catalas cat glutathion gsh ie malonaldehyd mda level hplc demonstr presenc rutin muntingia calabura leav exert anticanc effect against aom induc colon via action flavonoid colon tissu antioxid activ
apoptosisinduc effect preapoptot gallic simul comet assay techniqu cell line pc demonstr effect gallic ga molecul cell line pc comet assay alkalin electrophoresi techniqu effect apoptot bad bclassoci death promot bak bcl homolog antagonist killer bim bcllike protein via simul auto dock gromac softwar mtt assay pc cell ic ga around ic pc cell comet pictur alkalin electrophoresi analys casp version softwar result thereaft analys spss version statist softwar ic ga ratio tail head alkalin electrophoresi below ic ga measur percent result preapoptot bad bak bim perform simul absenc presenc ga ga protein structur instabl bad protein effect ga explain creation hydrogen bond protein ga compound plant suppress cell growth induc apoptosi pc cell ic apoptot properti ga induc preapoptot 
effect nonsteroid antiinflammatori recurr risk hepatocellular carcinoma metaanalysi nonsteroid antiinflammatori nsaid risk type epidemiolog evid associ nsaid intak risk hepatocellular carcinoma hcc controversi prevent benefit nsaid hcc simultan search databas pubm embas web scienc scopus screen elig public total twelv articl publish countri retriev risk hcc user nsaid did not nsaid pool hazard ratio hr confid interv ci evid public bias begg test egger test stratifi categori nsaid user nonaspirin nsaid hr ci not aspirin hr ci statist signific hcc nsaid recurr risk hcc hr ci statist signific associ nsaid hcc mortal hr ci taken togeth metaanalysi demonstr nsaid recurr risk hcc
sulforaphan epigallocatechin gallat restor esr express modul epigenet event breast cell line mdamb systemat review metaanalysi epigenet modif gene activ express alter sequenc environ influenc gene express modif meaning prevent chronic diseas bioactiv compound eg curcumin epigallocatechin gallat egcg isothiocyan eg sulforaphan sfn regul histon acetyl systemat review metaanalysi effect sfn egcg breast bc cell cultur vitro enorm variabl protocol innumer gene involv apoptot cell mdamb cell line effect size es comput ratio mean effect sfn mdamb cell es confid interv focus impact egcg es confid interv effect bioactiv compound sfn egcg effect bc cell restor esr gene express modul epigenet chang event interf growth rate public bias limit generaliz highqual need
intravas sw colon cell spheroid blood endotheli barrier inhibit clinic flavonoid vitro mechan crc cell penetr blood microvessel endothelia metastasis poor understood blood endotheli cell bec barrier breach crc emboli vitro assay measur becfre area underneath sw cell spheroid call circular chemorepel induc defect ccid appear consequ endotheli retract adapt support western blot eia erod luciferas report assay inhibit alox nfkb sw cell bec attenu ccid fda approv vinpocetin inhibit aloxdepend hete synthesi ketotifen inhibit nfkb carbamazepin fenofibr inhibit hete nfkb attenu ccid format low furesist swr bec model guanfacin nifedipin proadifen inhibit ccid stronger nave sw bec model indic swr cell former silent yet unidentifi gene becam express target cours resist acquisit fenofibr flavonoid hispidulin apigenin medicin plant spice herb fruit attenu ccid format nave resist model fdaapprov foodflavonoid inhibit acquir intravas pathway attenu bec barrierbreach vitro warrant test compound crc model vivo
effect aspirin nonaspirin nonsteroid antiinflammatori recurr adenoma systemat review metaanalysi trial sequenti omiz clinic trial effect aspirin nonaspirin nonsteroid antiinflammatori nsaid against recurr adenoma document systemat review result not uncertainti appropri dose aspirin adenoma prevent persist protect effect nsaid against recurr adenoma after cessat yet object updat systemat evid aspirin nsaid recurr adenoma take consider risk om error apprais qualiti evid grade grade recommend approach retriev trial cochran risk bias instrument metaanalyt estim calcul omeffect model om error trial sequenti tsa patient histori adenoma lowdos aspirin compar placebo taken year risk recurr adenoma risk rr ci confid interv tsa indic firm evid effect evid indic moder grade qualiti lowdos aspirin recurr advanc adenoma rr ci tsa indic lack firm evid effect highdos aspirin did not statist recurr adenoma rr ci cyclooxygenas cox inhibitor eg celecoxib associ signific decreas recurr adenoma rr ci advanc adenoma rr ci confirm effect lowdos aspirin recurr adenoma cox inhibitor effect prevent recurr adenoma
synthesi biolog molecular dock new seri chalcon naphthalen moieti anticanc agent seri chalcon naphthalen moieti ap synthes nmr nmr vitro anticanc activ screen compound display potent anticanc activ against hct hepg human cell line seri compound diethylamino para phenyl ring exhibit potent anticanc activ against hct hepg cell line ic preliminari structureact summar tubulin polymer indic effect inhibit tubulin polymer flow cytometr assay reveal arrest hepg cell phase dosedepend manner furthermor molecular dock bind colchicin bind site tubulin
inhibit aa adenosin receptor signal cell prolifer novel antagonist tp evid indic ubiquit nucleosid adenosin act aa ab receptor ar subtyp play crucial role adenosin effect cell prolifer depend engag differ receptor subtyp involv aaar human well human lung mrmt breast carcinoma prolifer view avail novel aaar antagonist affin name furanyl nmethoxybenzyl thiazolo pyrimidinediammin tp specif signal pathway trigger cell differ origin antagonist effect tp aaar protein express receptor bind assay furthermor effect aaar activ cell prolifer hour aaar agonist pcarboxyethylphenethylaminonethylcarboxamidoadenosin hydrochlorid cgs concentrationdepend induc cell prolifer mrmt cell effect potent antagon aaar antagonist tp well aaar blocker aminofuryl triazolo triazinylamino ethylphenol zm signal pathway recruit demonstr specif inhibitor signal transduct pathway effect aaar induc phospholipas plc protein kinas cdelta pkcdelta addit alphascreen surefir phosphop protein assay kinas enrol aaar cell prolifer involv protein kinas akt extracellular regul kinas erk cjun ntermin kinas jnks inde demonstr cgs stimulatori effect kinas strong presenc new potent compound tp well zm confirm role aaar aaar activ prolifer mrmt cell tp reveal capabl counteract effect aaar antagonist potenti new therapeut
regul polyamin curcumin prevent curcumin diferuloylmethan natur characterist yellow pigment spice turmer curcuma longa tradit known antioxid antiinflammatori anticarcinogen properti capabl promot carcinogenesi mechan curcumin potenti util human cell line curcumin decreas ornithin decarboxylas odc activ ratelimit enzym polyamin biosynthesi frequent upregul rapid prolifer tissu numer demonstr pretreat curcumin abrog carcinogen induc odc activ rodent tumorigenesi model target organ review summar result curcumin exposur regard modul polyamin discuss potenti util natur compound conjunct exploit dysregul polyamin chemotherapeut set
ros enhanc synergist selfassembl metalphenol network nanoparticl engin nanomateri therapeut efficaci minimum effect becom promis strategi ros enhanc platform design via biocompat metalpolyphenol network selfassembl encapsul doxorubicin dox platinum prodrug nanoparticl dox platinum activ nicotinamid adenin dinucleotid phosphat oxidas generat superoxid oÃ­ superoxid dismutaselik activ catalyz generat oÃ­ final hoÃ­ free generat fenton ros hoÃ­ synerg cascad bioreact positron emiss tomographi imag zrlabel asprepar doxpt prodrug fe nanoparticl dppf nps prolong blood circul accumul furthermor dppf nps effect inhibit growth effect anticanc novel ros promot synergist nanomedicin platform 
vitexin induc mphase arrest apoptosi via akt mtor signal pathway human glioblastoma cell glioblastoma common primari brain aggress malign result poor outcom short surviv mortal vitexin activ ingredi natur report inhibit cell growth induc cell apoptosi cell line hepatocellular carcinoma oral esophag best author knowledg anticanc effect vitexin human glioblastoma cell potenti mechan demonstr vitexin inhibit cell viabil dose timedepend manner vitexin induc cell cycl arrest demonstr flow cytometri cell apoptosi vitexin indic morpholog alter flow cytometri detect cleavedpoli adpribos polymeras demonstr vitexin inhibit racalpha serin threonineprotein kinas akt mechanist target rapamycin kinas mtor signal human glioblastoma cell result demonstr vitexin induc cell cycl arrest apoptosi inhibit akt mtor signal human glioblastoma cell vitexin futur therapeut agent malign glioblastoma
nanostructur peptidotoxin natur prooxid induc cell death via amplif melittin mel host defens peptid deriv venom honeybe demonstr anticanc properti attribut augment ros generat littl report prooxid capac ros amplifi nanodevic fabric direct complex natur prooxid mel condens epigallocatechin gallat pegcg nanocomplex nc cover phenylboron derivat hyaluron pha rosrespons boron ester coordin bond produc phanc undergo receptormedi endocytosi cell inner core phanc partial uncov onc pha corona degrad hyaluronidas escap lysosom virtu cytolyt mel ros level cytoplasm disrupt boron ester bond facilit mel pegcg synergist amplifi prolong ros retent cell lead enhanc anticanc efficaci ros cascad amplifi coordin bond inher prooxid properti natur ingredi detect intracellular ros signal potenti move away homeostasi vulner compar report chemosynthet prooxid ros selfsuffici system fulli compos natur medicin new insight 
effect doxorubicin induc oral keratinocyt cytotox anticanc potenc against oral cell normal human oral keratinocyt sensit anticanc doxorubicin epigallocatechin gallat tannic compound report cardioprotect effect doxorubicin unknown protect normal human oral keratinocyt against doxorubicin induc cytotox weaken cytotox potenti against oral cell effect compound doxorubicin induc cytotox normal human oral keratinocyt effect doxorubicin potenc hsc human oral squamous cell carcinoma cell cell viabil apoptosi necrosi chang intracellular ros earli stage after result reveal doxorubicin addit augment doxorubicin cytotox type cell epigallocatechin gallat tannic certain mitig doxorubicin induc keratinocyt doxorubicin induc necrosi normal human oral keratinocyt weaken doxorubicin anticanc efficaci exact mechan still unknown intracellular ros not sole report effect epigallocatechin gallat tannic doxorubicin induc cytotox normal oral keratinocyt oral cell epigallocatechin gallat tannic doxorubicin certain mitig doxorubicin induc keratinocyt cytotox weaken doxorubicin anticanc efficaci
nutrit antiprolif activ differ solvent fraction ethanol extract cyphomandra betacea tamarillo fruit solvent extract cyphomandra betacea tamarillo known tree tomato bioactiv constitu antioxid activ effect cell death type cell line breast cell nutrit tamarillo phytochem profil gcms ethanol tamarillo extract conduct differ fraction nbutanol ethyl acet aqueous fraction ethanol extract tamarillo fraction subject quantif total tpc flavonoid content tfc free scaveng activ sa antioxid activ aox assay betacaroten bleach bcb assay final capabl ethanol extract tamarillo differ fraction anticanc properti reveal nutrit ash protein carbohydr total fiber miner level calcium magnesium potassium iron tamarillo moder crude ethanol extract tamarillo total flavonoid content ftir reveal presenc alkan carboxyl alkan carboxyl nitro compound twelv bioactiv constitu tamarillo gcms cytotox activ potenti ethanol extract tamarillo effect breast cell reveal tamarillo antioxid activ well anticanc properti
appl phloretin inhibit breast cell migrat prolifer via inhibit signal type glucos transport human tripleneg breast tnbc aggress poor understood subclass breast glucos transport glut requir glucos uptak malign cell ideal target inhibit glut tnbc cell appl phloretin ph specif antagonist glut protein human tnbc cell interest ph inhibit cell growth arrest cell cycl mdamb cell mutantdepend manner confirm pretreat cell pspecif dominantneg express vector ph decreas migratori activ mdamb cell inhibit paxillin fak src alpha smooth muscl actin alphasma activ ecadherin furthermor antitumorigen effect ph dmso twice six demonstr vivo balb nude mice bear mdamb xenograft decreas ncadherin vimentin ecadherin detect tissu inhibit glut appl ph potenti suppress tnbc cell growth metastasi
biophys evid differenti gallat green tea catechin bind membran type matrix metalloproteinas interactor membran type matrix metalloproteinas mtmmp transmembran mmp trigger intracellular signal regul extracellular matrix proteolysi tumorassoci angiogenesi inflamm green tea catechin epigallocatechin gallat egcg effect prevent mtmmpmediat lack structurefunct evid direct interact mtmmpmediat biolog activ impact cellular biophys assay ungal catechin gallat counterpart mtmmpmediat molecular bind partner concanavalina cona trigger mtmmpmediat prommp activ express mtmmp endoplasm reticulum biomark grp glioblastoma cell conamedi mtmmp inhibit egcg catechin gallat cg grp inhibit egcg cg gallocatechin gallat gcg prommp activ inhibit egcg gcg surfac plasmon reson direct interact catechin mtmmp interactor gallat catechin interact ungal analog mtmmp well mtmmp bind partner mmp timp mtcbp lrpclusteriv structurefunct evid support role galloyl moieti direct indirect interact green tea catechin mtmmpmediat oncogen 
identif ugt bcrp potenti pharmacokinet natur flavonoid alpinetin alpinetin natur flavonoid show varieti pharmacolog effect antiinflammatori antitumor hypolipidem activ role udpglucuronosyltransferas ugt breast resist protein bcrp disposit alpinetin glucuronid potenti alpinetin pool human microsom phlm pool human intestin microsom phim express ugt enzym supplement cofactor udpga activ correl analys bank individu hlms perform main contribut ugt isozym glucuronid alpinetin effect bcrp alpinetin disposit hela cell overexpress ugta helaa cell alpinetin underw extens glucuronid phlm phim generat glucuronid test ugt enzym ugta activ alpinetin intrins clearanc clintvmax min nmol ugta clintl min nmol ugta clintl min nmol ugtb clintl min nmol ugta clintl min nmol glucuronid alpinetin correl glucuronid estradiol activ ugta chenodeoxychol activ ugta propofol activ ugta hydroxyrofecoxib activ ugtb confirm role ugta ugta ugta ugtb alpinetin glucuronid inhibit bcrp specif inhibitor ko excret alpinetin glucuronid lead signific decreas cellular glucuronid alpinetin ugt bcrp alpinetin pharmacokinet
amentoflavon potent broadspectrum inhibitor human udpglucuronosyltransferas amentoflavon amf abund natur biflavonoid medicin plant display effect antiinflammatori antioxid anticanc despit extens pharmacolog activ undesir effect amf rare report inhibitori effect amf human udpglucuronosyltransferas ugt care amf display strong inhibit human ugt ugta ic inhibit constant ki amf against human ugt vari demonstr amf competit inhibitor ugta mediat muoglucuronid addit amf competit inhibitor ugta mediat tfpnglucuronid ugta human microsom competit inhibitor ugta mediat propofol muoglucuronid demonstr amf strong broadspectrum natur inhibitor human ugt addit novel insight mechan amfassoci perspect ugt inhibit
effect curcumin cisplatin induc testicular apoptosi immunohistochem techniqu cisplatin effect antineoplast agent cisplatin restrict effect allevi effect restrict cisplatin effect curcumin cisplatin induc testicular apoptosi thirtyf wistar albino male adult weigh random control cisplatin curcumin curcumin posttest th sacrif test remov section formalin fix paraffin embed testi tissu stain hematoxylineosin histolog immunohistochem express apoptot pathway protein bax cas bcl histolog damag cisplatin cas bax protein immunostain intens hscore bcl slight decreas cisplatin compar control bax cas decreas compar cisplatin bcl decreas curcumin bax bcl cisplatin decreas favor control cas express cisplatin cisplatin apoptosi germ cell cisplatin testicular apoptosi cas bax apoptot protein pathway cisplatin induc testicular apoptosi prevent curcumin 
natur sirtuin modul flavonoid secondari synthes plant fungus pharmacolog effect plethora biolog activ extens modul activ nad depend histon deacetylas sirt sirt implic longev dnarepair reduct interest target diseas well flavonoid alter sirt activ structur depend manner catechin deriv galloyl moieti display signific inhibit potenc against sirt potent sirt activ cyanidin belong anthocyanidin produc sirt activ compar cyanidin sirt express caco cell result dock indic bind site inhibitor activ inhibitor like bind manner disturb nad bind putat activ bind site next loop near acetyl peptid substrat bind site case activ chang conform loop play role sirt activ
tannic induc endoplasm reticulum stressmedi apoptosi endoplasm reticulum er intrigu target signific clinic interfer er lead accumul unfold protein detect transmembran sensor instig unfold protein upr control induc upr via er natur compound novel therapeut strategi manag tannic natur occur er mediat upr pathway cell tannic inhibit growth clonogen invas migratori potenti cell tannic demonstr activ er protein kinas rlike endoplasm reticulum kinas perk inositol requir enzym ire alter regulatori protein atf bip pdi express tannic affirm upregul apoptosisassoci bak bim cleav caspas cleav parp downregul prosurviv protein bcl bclxl tannic exhibit popul pinkc pwaf cip express cyclin express inhibit reduct mmp mmp reinstat ecadherin signifi antimetastat potenti compound altogeth result demonstr tannic promot apoptosi via er mediat upr pathway indic potenti candid 
food target peptidyl prolyl cis tran isomeras pin search inhibitor against prolyl isomeras pin food prevent cure pin diseas diabet cardiovascular diseas alzheimerss diseas creat librari consist ingredi healthi food beverag like epigallocatechin gallat egcg green tea brown alga pin inhibitor egcg deriv caffeic deriv tannic inhibit pin activ result step food beverag target pin diseas
synthesi biolog alphabromoacryloylamido indolyl pyridinyl propenon potent apoptot induc human leukaemia cell pharmacophor singl molecul adopt synthesi new anticanc molecul influenc pyridin nitrogen biolog activ differ seri alphabromoacryloylamido indolyl pyridinyl propenon ah ad design synthes pharmacophor hybrid approach antiprolif activ against panel six human cell line hybrid molecul prepar alphabromoacryloyl moieti seri indoleinspir chalcon analogu possess indol deriv pyridin ring link propenon system structureact insert alkyl benzyl moieti indol nucleus newli synthes display antiprolif activ against molt nalm leukaemia cell line onedigit doubledigit nanomolar ic antiprolif activ pyridinyl deriv fh reveal nbenzyl indol analogu general exhibit activ compar nh nalkyl deriv ab ce moreov cellular mechan elucid compound induc apoptosi decreas mitochondri membran potenti activ caspas concentrationdepend manner
antioxid activ cistus pomegran rich extract cistus herb cistus incanus pomegran peel punica granatum exhibit signific antioxid activ cell cultur chines hamster lung fibroblast cistus extract intracellular content ros pomegran extract human breast mcf colon lovo cell line cistus pomegran extract decreas cell growth drugsensit cell resist doxorubicinresist dx sublin extract induc apoptosi test cell line proapoptot impact extract drugsensit drugresist sublin result potenti test rich extract peopl expos potenti adjuv human need 
new generat ferrociphenol lead great divers reactiv exhibit remark antiprolif properti organometal compound bear redox motif ferrocenylenephenol promis antiprolif properti improv incorpor pertin substitu abl engend new mechan novel ferrociphenol bear hydroxypropyl chain exhibit strong antiprolif effect case much cisplatin tamoxifen describ ferrociphenol devoid termin oh illustr case compound ic nm mdamb tripl breast cell nm cisplatinresist acisr human ovarian cell gi nm seri renal cell line nci panel interest hydroxypropylferrociphenol yield kind quinon methid qms readili react nucleophil glutathion give adduct proton quinon methid generat numer reactiv lead eventu rearrang cleavag unpreced fulli profil involv electrophil react cell macromolecul link remark profil antiprolif activ new seri inde great divers unexpect reactiv allow adapt situat cell novel strategi ration design anticanc molecul open way new organometal potent anticanc candid chemoresist 
propofol inhibit hela cell impair autophag flux via ampactiv protein kinas ampk activ endoplasm reticulum regul calcium propofol antitumor effect against mechan action propofol hela human cervic cell not elucid hela human cervic cell differ propofol cell viabil cell count kit apoptosi annexin vfluorescein isothiocyan propidium iodid stain flow cytometri autophagosom format microtubuleassoci protein light chain lc convers light chain puncta format autophagosom clearanc protein level autolysosom generat propofol decreas cell viabil autophagosom generat hela cell autophagosom format lc convers lc puncta format autophagosom clearanc protein level ampk mtor signal pathway activ propofol induc autophagosom accumul fluoresc lysotrack dye reveal propofol block autophagosomelysosom fusion rapamycin autophagosom clearanc propofoltr hela cell addit propofol induc endoplasm reticulum er disrupt intracellular ca balanc therebi enhanc autophagosom accumul suppress er tauroursodeoxychol tudca enhanc effect cytotox propofol er evid propofolmedi autophagi regul mechan propofol regul hela cell 
role epigallocatechin gallat regul mitochondri epigallocatechin gallat egcg isol green tea exhibit biologybenefit effect minimum sever advers egcg known mitochondriontarget medicin agent regul mitochondri mitochondri biogenesi mitochondri bioenerget mitochondriamedi cell cycl apoptosi egcg exhibit antioxid activ prevent against prooxid activ counteract cell depend cellular situat cell type egcg research gain promis review discuss interact egcg mitochondrion
perspect green tea discoveri evid expand role green tea tradit beverag sourc pharmacolog activ molecul divers health benefit clinic result need elucid cancerprevent therapeut effect green tea gtps area cover author describ gtps biotransform discoveri focus therapeut effect review gtpload nanoparticl gtp prodrug expert opinion gtps possess potent anticarcinogen activ interf phase challeng eg poor bioavail gtps therapeut agent nanoparticlebas deliveri system uniqu advantag over purifi gtps still need actual magnitud pharmacolog mechan gtps encapsul nanoparticl address newli safeti issu associ potenti local overdos effect proepigallocatechingal proegcg prodrug appear offer improv vitro stabil well vivo bioavail efficaci anim potenti therapeut agent 
gpaba gper ligand compar red via ligandbas virtual screen coupl molecular dynam simul antiprolif effect breast cell report demonstr role proteincoupl esr gper growth prolifer breast cell coupl gper estrogen tamoxifen fulvestr trigger cellular signal pathway pik erk cell prolifer effort new therapeut strategi against breast perform silico bind pose set design analogu compound red carboxyl instead acetyl amid moieti affin gper target compound submit silico admet ligand coupl gper ligandbas virtual screen final achiev molecular dynam simul best molecul gper well red recognit properti silico admet dock best molecul name gpaba asrbr bromobenzo dioxolyl abtetrahydrohcyclopenta quinolinecarboxyl synthes assay vitro breast mcf mdamb normal mcfa cell line assay target compound abl decreas cell prolifer show ic mcf mdamb mcfa cell line after interest target compound ic red red interfer gpaba action gper mcf cell pcr explain cell prolifer effect concentrationdepend inhibit cell prolifer occur gpaba assay cell line action gper
extract brava extra virgin oliv oil cytotox effect mcf breast cell work profil brava extra virgin oliv oil potenti natur adjuv total content extract gallic equival total antioxid capac trolox equival diphenylpicrylhydrazyl free ferric antioxid power trolox equival antioxid capac assay secoiridoid compris total compound main secoiridoid oleuropein main isom oleuropein aglycon main secoiridoid ligstrosid main isom ligstrosid aglycon extract signific decreas cell viabil mcf breast cell dose depend manner htreatment differ extract induc intracellular ros generat cell death
curcumin induc fatal energet impair cell vitro vivo inhibit atpsynthas activ curcumin report inhibit inflamm growth angiogenesi metastasi decreas cell growth induc apoptosi inhibit nuclear kappab nfkb master regul inflamm report indic potenti effect energi cell curcumin inhibit activ atpsynthas isol mitochondri membran lead dramat drop atp reduct consumpt vitro vivo model effect curcumin atpsynthas independ inhibit nfkb ikb kinas inhibitor sc not atpsynthas activ glycolyt enzym hexokinas phosphofructokinas pyruv kinas lactat dehydrogenas slight cell type specif manner energi impair translat decreas cell viabil moreov curcumin induc apoptosi promot generat ros malondialdehyd mda lipid autophagi least activ ampactiv protein kinas ampk vitro antitumor effect curcumin bodi delay vivo growth like energi impair reduct angiogenesi result atpsynthas central enzym cellular energi target antitumor lead inhibit cell growth general reprogram 
identif esr antagonist natur via vitro silico approach esr success target erposit breast report relev diseas esr modul serm good therapeut effect clinic resist effect serm discoveri new serm attent virtual screen valid effect novel bioactiv molecul ligandbas machin learn structurebas molecular dock perform identif esr antagonist inhous natur librari naiv bayesian recurs partit model kind descriptor built valid train set test set extern test set util distinct activ inact compound total compound predict er antagonist molecular dock dock score compound esr competitor assay luciferas report gene assay daidzein phloretin ellag ursol epigallocatechingal kaempferol naringenin exhibit differ level antagonist activ against esr valid feasibl machin learn predict bioactiv ligand insight natur act esr modul lead compound futur new design
overview natur plant hepatocellular carcinoma fifth common diagnos second lead death hepatocellular carcinoma report primari second common mortal death document annual risk hcc chronic infect hbv hcv virus chronic diseas alcohol well carcinogen aflatoxin rate estim occur asia africa effect manmad agent chronic diseas not satisfactori uninvit effect herbal medicin extens over world still vast gap accept scientif communiti plant rich secondari phytochem nondietari sourc natur plant potent therapeut well chemo prevent agent numer chronic diseas like cardiovascular neurodegen neoplast diseas phytochem curcumin quercetin silibinin ntransferuloyloctopamin lycopen emodin caffein urolithin phloretin hcc diseas report estim anticanc medic natur sourc deriv plant play essenti role prevent pleiotrop abil scaveng free inhibit cell growth induc apoptosi
vitro antioxid activ oleanol mango peel cytotox effect cell line mango peel main byproduct juic possess appreci quantiti bioactiv compound worthi util work report hplc vitro antioxid mango peel mpps cytotox effect lung cell line result indic mango peel total content mgmiddotkgminus dri mango peel dmp consist vanil aldehyd caffeic chlorogen gallic procyanidin oleanol antioxid assay mpps strong antioxid activ dpph scaveng rate abt inhibit rate mum trolox equival per kgminus dmp ferric power gallic possess stronger antioxid capac vitro cytotox test mango peel extract mpe ic mgmiddotmlminus mpps stronger inhibitori effect cell line oleanol exhibit strongest cytotox ic mum control fluorouracil
methoxyresveratrol allevi age induc inflamm via ragemedi nfkb nlrp inflammasom pathway advanc glycat end age interact receptor age rage steril danger signal induc inflamm primemethoxyresveratrol primemr deriv dipterocarpacea not antiinflamm effect sought protect role primemr age induc model raw macrophag primemr inhibit gene express proinflammatori cytokin chemokin interleukin beta ilbeta interleukin il tnf monocyt chemoattract protein mcp well typic proinflammatori enzym induc nitric synthas ino cyclooxygenas cox besid primemr decreas demonstr level ros protein carbonyl advanc protein via downregul nadph oxidas primemr attenu rage overexpress induc mgobsa block downstream signal agerag mapk jnk nfkappab activ addit primemr abat activ nodlik receptor pyrin domain nlrp inflammasom nlrp cleav caspas secret matur ilbeta taken togeth result antiinflammatori effect primemr suppress ragemedi mapk nfkappab signal pathway nlrp inflammasom activ primemr novel therapeut agent inflammationrel diseas
mitochondri deliveri substructur trigger mitochondri depolar apoptosi cell antitumor challeng medicin chemistri research focus exploit biochem differ cell normal cell effect antitumor efficaci mitochondri transmembran potenti cell compar nottransform cell favor intramitochondri accumul cation former featur exploit allow deliveri antineoplast cell work design synthet deriv join triphenylphosphonium tpp cation wellknown vector mitochondri target design tppderiv remark cytotox activ against differ cell line less against normal cell differenti cytotox reli mitochondri biogenesi oxidativephosphoryl former mitochondri mass energet level intramitochondri ros tppderiv induc mitochondria depolar trigger caspas mediat apoptosi limit cell work rational tppderiv target mitochondria new anticanc tool
green tea egcg suppress wnt betacatenin signal promot gskbeta ppaindepend betacatenin phosphoryl degrad epigallocatechingal egcg green tea report inhibit wnt betacatenin pathway aberr upregul precis mechan action sensit cellbas system demonstr egcg suppress betacatenin transcript crt activ wntacondit medium wntacm promot degrad intracellular betacatenin egcg induc betacatenin ntermin phosphoryl ser residu promot degrad effect not oncogen betacatenin pharmacolog inhibit deplet glycogen synthas kinasebeta gskbeta did not abrog egcgmedi betacatenin degrad egcg did not activ express protein phosphatas ppa consist phosphoryl degrad betacatenin adenomat polyposi coli apc mutat colon cell after egcg egcg repress express cyclin cmyc betacatenin tcell factordepend gene inhibit prolifer colon cell egcg exert cancerprevent anticanc activ against colon cell promot phosphoryl proteasom degrad betacatenin mechan independ gskbeta ppa
protect role carotenoid patient head neck head neck global health problem approxim patient per year diagnos type addit head neck exhibit recurr rate readili second primari locat yield poor prognosi medic surgic option result consider impair speak swallow effect nausea vomit bone marrow suppress renal damag therebi impair patient qualiti life prevent therapeut intervent strategi head neck vital phytochem uniqu abil protect cell damag modul cell repair activ phytochem demonstr associ antioxid properti intercellular communic via gap junction play role regul cell cycl differenti apoptosi stagnat cell growth phytochem regul cell signal pathway invas metastasi cell protect normal cell damag radiotherapi effect phytochem carotenoid review mechan carotenoid pps prevent head neck effect radiotherapi improv patient surviv rate occurr rate second primari 
new complex curcumin sulfobutylethesrcyclodextrin vitro cytotox antioxid activ hepg cell curcumin cr natur antioxid antiinflammatori anticanc properti therapeut potenti hinder lowwat solubl bioavail work new solubl inclus complex cr sulfobutylethesrcyclodextrin sbebetacd prepar solut solid state differ prepar techniqu result clear indic cr react sbebetacd hostguest complex appar format constant final vitro test human cell line hepg complex influenc curcumin anticanc antioxid activ
vitro approach regul cytochrom cyp express paclitaxel rifampicin second lead mortal rate slow narrow therapeut index multidrug resist paclitaxel taxol superior outcom term rate progressionfre surviv numer patient resist test hypothesi cytochrom cypa gene paclitaxel downregul mediat lipopolysaccharid lps proinflammatori cytokin tnf tnf attenu human cypa gene rifampicin primari mous hepatocyt pretreat lps min paclitaxel vehicl rna extract cell trizol cdna synthesi realtim pcr paclitaxel induc gene express cypa attenu lpstreat sampl downregul cypa enzym impact paclitaxel patient where mediat activ nuclear receptor pregnan receptor pxr play role cyp enzym mechan regul human cypa gene cotransfect hepg cell human cell line cypaluciferas construct pxr express plasmid cell proinflammatori cytokin tnf prototyp cypa induc rifampicin well rifampicin activ pxr lead cypa cypaluciferas activ rifampicin attenu tnf describ vitro approach entail primari cultur hepatocyt realtim pcr transcript activ transfect assay molecular regul cypa play pivot role numer chemotherapeut genet induc variat cypa pxr express contribut resist chemotherapeut agent patient
synergist inhibit colon cell growth atorvastatin phloretin atorvastatin atst common level cholesterol lowdens lipoprotein prospect agent prevent patient hyperlipidemia atst compon promis strategi growth inhibitori effect atst phloretin pt sw hct colon cell result mtt assay indic pt atst mark cell surviv cell line compar pt atst administ individu interact index pt atst interact pattern comput medianeffect equat interact index pt atst pair indic strong synergist effect compound flow cytometri western blot cleavedpoli adpribos polymeras indic synergist effect result apoptosi cell cycl arrest checkpoint furthermor pt atst mark downregul express cyclin upregul express phosphocdc myt activ cdc downregul strategi enhanc anticanc activ atst low dosag prevent patient hyperlipidemia
new cytotox germacranolid carpesium divaricatum bioassayguid search cytotox compound plant south korea new sesquiterpen germacranolid type name cardivin isol aerial carpesium divaricatum structur compound elucid spectroscop techniqu compound cytotox human cell nonsmal cell lung skov ovari skmel skin xf central nervous system hct colon
curcumin effect diseaseassoci cftr mutant clinic implic curcumin compon asian food soybean curri turmer compound intens biolog featur confer anticanc activ curcumin potenti effect diseaseassoci cftr mutant gd effect curcumin gdcftr exhibit gate defect abnorm protein synthesi traffick patchclamp techniqu curcumin addit effect potenti gdcftr signific synergist effect minimum result consist idea mechan involv action cftr potenti review revisit pharmacolog curcumin cftr propos new pharmaceut implic compound cf pharmacotherapi
antitumor activ verbascosid load gold nanoparticl verbascosid vb bioactiv constitu tsoong herb attract great deal attent pharmacolog properti demonstr inhibitori effect vbload gold nanoparticl vbau growth cell vitro vivo gold nanoparticl au vb vbau decreas viabil cell promot apoptosi cell implant mous model intraven inject vbau effect inhibit growth induc apoptosi cell result demonstr vbau nanoparticl effect strategi control cell growth
autophagi accompani bisdemethoxycurcumin induc apoptosi nonsmal cell lung cell effect bisdemethoxycurcumin bdmc nonsmal cell lung nsclc cell line metastat lung cell cck assay effect bdmc cytotox flow cytometri apoptosi western blot electron microscopi quantif gfplc punctuat test effect bdmc autophagi apoptosi lung cell bdmc inhibit viabil nsclc cell cytotox effect lung airway epitheli cell saec apoptot cell death induc bdmc accompani autophagi nsclc cell blockag autophagi autophagi inhibitor methyladenin ma repress growth inhibitori effect apoptosi bdmc addit bdmc decreas smoothen smo transcript gliomaassoci oncogen gli express furthermor deplet gli sirna cyclopamin specif smo inhibitor induc autophagi aberr activ hedgehog hh signal implic human lung direct evid bdmc induc autophagi play prodeath role nsclc inhibit hedgehog signal
inhibit breast cell migrat cyclotid isol pombalia calceolaria new bracelet cyclotid root pombalia calceolaria potenti anticanc activ work cyclotid poca known cyo de novo sequenc malditof tof mass spectrometri ms ms spectra amino sequenc purifi peptid test cytotox effect cell migrat mdamb tripleneg breast cell line isol cyclotid cell concentrationrel cytotox ic poca poca cyo addit inhibit cell migrat woundheal assay exhibit cyo interest activ profil abl inhibit cell migrat subtox distribut cyclotid root maldi imag demonstr compound phloem cortic parenchyma region
isosuillin suillus flavus induc apoptosi human cell lung cell line suillin isoform isosuillin natur isol petroleum ether extract fruit bodi mushroom suillus flavus inhibit effect cell effect human cell lung cell line cell viabil measur dimethylthiazolyl diphenylhtetrazolium bromid assay cellular morpholog chang apoptosi necrosi electron microscop hoechst stain detect invert microscop flow cytometri detect cell apoptosi cell cycl distribut mitochondri membran potenti protein express western blot describ abil isosuillin inhibit growth cell dosedepend way isosuillin obvious impact normal human prolifer low mol promot prolifer mol after differ isosuillin mol apoptosi rate cell isosuillin compar control express apoptot protein mitochondri pathway cytochrom caspas upregul compar control contrari bcl bax ratio downregul compar control besid express proapoptot protein death receptor apoptosi pathway fasassoci protein novel death domain caspas express caspas downstream regulatori protein apoptosi compar control inhibitor caspas caspas revers apoptosi cell vari degre result isosuillin induc cell apoptosi mitochondri pathway deathreceptor pathway isosuillin potenti applic novel lung 
inhibitori effect topic applic green tea fraction promot mous skin green tea fraction abil inhibit polycycl hydrocarbon promot phorbol ester skin cd mice topic applic green tea fraction inhibit benzo pyren dimethylbenz anthracen induc well otetradecanoylphorbolacet tpa induc promot topic applic green tea fraction inhibit tpa induc inflamm ornithin decarboxylas activ hyperplasia hydrogen peroxid format individu compound green tea indic topic applic epigallocatechingal epigallocatechin epicatechin gallat inhibit tpa induc inflamm mous epidermi
microrna tumorsuppressor gene regul ilf pancreat carcinoma interleukin enhanc bind ilf mark upregul pancreat carcinoma involv pathogenesi pancreat carcinoma ilf potenti target yet regulatori mechan ilf pancreat carcinoma larg elus demonstr ilf oncogen regul epithelialmesenchym transit emt associ gene pancreat carcinoma panc cell microrna mir suppress ilf mrna express protein level panc cell contrari ilf mirna tumorsuppressor gene regul emtassoci gene panc cell curcumin natur isol rhizom plant curcuma longa promis anticanc therapeut agent curcumin mir express suppress ilf protein panc cell ilf new downstream target gene curcumin result reveal ilf regul mir downregul mir ilf overexpress pancreat carcinoma
farmer pharmacist curcumin antiinvas antimetastat agent huge compound distribut natur possess medicin biolog pharmacolog activ curcumin deriv rhizom underground stem curcuma longa linn member ginger famili common known turmer culinari spice therapeut india thousand year induc color flavor food well array diseas origin turmer spice folklor medicin old lost legend curcumin pharmacolog effect not limit antimicrobi antiinflammatori antioxid antivir antiangiogen neurodegen diseas alzheim diseas antidiabet activ curcumin possess immens antitumorigen effect prevent invas metastasi anim model model lung stomach colon breast esophag etc invas metastasi hallmark biolog pertin applic curcumin antiinvas antimetastat agent vitro vivo ex vivo well associ molecular mechan discuss review curcumin demonstr abil improv patient outcom clinic trial
xanthorrhizol induc apoptosi via upregul bax hela cell xanthorrhizol sesquiterpenoid compound extract curcuma xanthorrhiza known local temulawak tradit xanthorrhiza antibacteri anticanc antiinflammatori activ rhizom inflamm postpartum uterin bleed antiprolif assay methylen blue stain reveal xanthorrhizol inhibit prolifer cervic cell line hela ec microg xanthorrhizol apoptosi hela cell tdtmediat dutp nick endlabel tunel assay nuclear morpholog hoechst stain western blot confirm immunostain result impli upregul suppressor protein proapoptot protein bax xanthorrhizol xanthorrhizol did not express antiapoptot protein bcl viral oncoprotein henc xanthorrhizol promis antiprolif anticanc agent induc baxdepend apoptosi hela cervic cell
phytochem modul apoptosi autophagi strategi overcom chemoresist leukem stem cell bone marrow microenviron advanc scientif research target regim improv surviv rate over past few decad type leukemia acut lymphoblast acut myeloid leukemia mortal rate continu rise chemoresist leukem stem cell lscs contribut act induc apoptosi cell ineffect target quiescent lscs nich bone marrow known leukem nich behav sanctuari where lscs acquir resist review role bone marrow environ mainten lscs contribut chemoresist research potenti phytochem overcom chemoresist modul signal pathway involv surviv death leukem clonal cell leukem stem cell phytochem tradit chines medicin name baicalein chrysin wogonin constitu scutellaria baicalensi curcumin constitu curcuma longa constitu polygonum cuspidatum zhng induc apoptosi leukem cell line curcumin cell death via autophagi nonapoptot pathway effect elimin lscs target signal pathway wnt betacatenin notch hedgehog report induc apoptosi leukem cell inhibit notch sonic hedgehog signal pathway show potenti lscs interest lack report research modulatori effect phytochem autophag cell death pathway leukemia signal pathway involv mainten lscs highlight need work area
curcumin revers cellmedi adapt dysfunct tumorbear host dysfunct well document like contribut evas cd cytotox ctls involv antigenspecif destruct cd cell essenti help cd celldepend erad target inhibit tcell escap surveil dysfunct loss effector memori cell bias type cytokin expans regulatori treg cell curcumin antitumor activ research address immunoprotect potenti plantderiv tumorbear host role curcumin prevent induc dysfunct cellbas sever loss effector memori tcell popul downregul type upregul type decreas prolifer effector cell presenc curcumin turn prevent loss cell expand central memori cell tcm effector memori cell tem popul revers type bias attenu induc inhibit tcell prolifer tumorbear host reveal burden upregul treg cell popul immunosuppress cytokin growth tgf beta il cell curcumin inhibit suppress activ treg cell downregul tgfb il cell curcumin enhanc abil effector cell kill cell uniqu properti curcumin exploit success attenu induc suppress cellmedi 
curcumin lung cancera review curcumin diferuloylmethan compon spice turmer deriv rhizom east indian plant curcuma longa curcumin extens ayurved medicin centuri nontox varieti therapeut properti antioxid analges antiinflammatori antisept activ curcumin anticanc properti via effect varieti biolog pathway involv apoptosi prolifer chemo radiotherapi sensit invas metastas curcumin effect adjunct solid organ properti regul oncogen like egr cmyc bclxl etc transcript like nfkb stat ap protein kinas like mapk enzym like cox lox lung common malign lead cancerrel death seventyf percent lung advanc stage where exist not effect result tremend patient morbid result signific interest adjunct augment avail protocol allow decreas effect compromis therapeut efficaci curcumin potenti candid review overview vitro vivo curcumin lung  frequent simultan epigenet inactiv tp pathway gene acut lymphoblast leukemia aberr methyl frequent alter patient acut lymphoblast leukemia methyl bead array methyl status gene implic sampl diagnosi gene methyl sampl interest express gene implic tp pathway downregul hypermethyl direct indirect activ tp pathway azadeoxycitidin curcumin nutlin induc apoptosi cell result patient valid retrospect second cohort newli diagnos patient methyl least gene implic tp pathway patient correl relaps mortal rate independ prognost diseasefre surviv dfs surviv os multivari indic tp pathway alter epigenet mechan patient correl prognosi compound revers epigenet abnorm activ direct pathway new therapeut altern patient
curcumin potenti doxorubicin induc apoptosi hc cardiac muscl cell generat ros doxorubicin dox agent advers effect dox patient onset cardiomyopathi heart failur ros propos dox cardiotox curcumin natur compound extract curcuma longa known antioxid properti apoptosi cell line doxorubicin few effect curcumin doxorubicin normal cardiac cell effect curcumin apoptosi induc dox cardiac muscl cell pretreat curcumin dox induc apoptosi cardiac muscl cell down regul bcl upregul caspas caspas bax bcl ratio aftesrh pretreat curcumin well curcumin ros generat dox dox nfkb activ curcumin abl inhibit nfkb activ result indic pretreat nontox curcumin sensit hc cell doxmedi apoptosi generat ros
phloretin induc apoptosi human esophag via mitochondriadepend pathway trihydroxyhydroxyphenyl propiophenon phloretin appl tree leav manchurian apricot potent compound exhibit antiinflammatori antioxid antitumor activ effect phloretin esophag cell not welldefin phloretin induc apoptosi human esophag cell ec cell cultur dulbecco modifi eagl medium incub phloretin cell prolifer measur mtt assay cell apoptosi rate measur flow cytometr propidium iodid pi stain protein express level western blot phloretin decreas viabl cell dose timedepend manner induc apoptosi ec cell addit phloretin exhibit potent anticanc activ vitro evidenc downregul antiapoptosisassoci molecul bcell lymphoma bcl level apoptosisassoci molecul bcllike protein protein phloretin express apoptot proteas activ protein direct bind inhibitor apoptosi protein low pi xlink inhibitor apoptosi protein result indic phloretin inhibit ec cell growth induc apoptosi mediat mitochondriadepend pathway
formononetin inhibit neuroinflamm esr beta esr protein express bv microglia formononetin bioactiv nonsteroid varieti plant effect formononetin neuroinflamm lpsstimul bv microglia result formononetin tnf il ilbeta nitrit pge well protein level ino cox report gene assay formononetin produc inhibit nfkb luciferas activ hek cell tnf immunoblot reveal inhibit ikkalpha phosphoryl result attenu phosphoryl degrad ikbalpha lps formononetin produc inhibit nuclear transloc bind nfkb lps rnai transfect bv microglia esr sirna result loss antiinflammatori action formononetin mtt assay map immunoreact formononetin produc signific neuroprotect activ prevent bv microglia condit media induc ht neuron effect formononetin mcf breast cell reveal compound erluciferas activ effect prolifer modest formononetin inhibit neuroinflamm target nfkb signal pathway bv microglia mechan involv esr formononetin appear modul esr mcf breast cell limit prolif effect formononetin serv scaffold novel compound neuroprotect action brain
inhibit hexokinas ii mediat glycolysi nonsmal cell lung via target akt signal pathway deregul glycolysi human cell report intens model profound antitumor effect human nonsmal cell lung nsclc via regul glycolysi impair hexokinas ii hk mediat glycolysi mark inhibit anchoragedepend independ growth nsclc cell exposur decreas egfr downstream kinas akt erk erk activ moreov reveal impair glucos inhibit express hk mediat akt signal pathway exogen overexpress constitut activ akt nsclc cell rescu induc glycolysi suppress vivo indic obvious suppress growth xenograft mous model result target hk enzym appear new approach clinic nsclc prevent 
lutein hormonereleas hormon agonist triptorelin antagonist cetrorelix inhibit egf induc cfos express human gynecolog spontan epiderm growthfactor induc prolifer human gynecolog cell line dose timedepend lutein hormonereleas hormon lhrh agonist triptorelin antagonist cetrorelix antiprolif activ probabl direct mediat lhrh receptor express cell interact growthfactordepend mitogen signal transduct epiderm growthfactor egf induc express earli gene cfos lhrh analog human endometri ishikawa heca ovarian efo efo skov breast cell line mcf render quiescent incub absenc fetal calf serum red min incub absenc presenc lhrh agonist triptorelin nm antagonist cetrorelix nm cell min egf nm cfos mrna express semiquantit rtpcr synthet fragment intern standard cfos protein synthesi sdspage semiquantit western blot cell deriv endometri ovarian maxim cfos mrna express ninefold over basal level min after egf breast cell line mcf effect min after egf line express lhrh receptor egf induc cfos mrna express well cfos protein synthesi dosedepend lhrh agonist antagonist nm lhrh analog cfos express baselin level effect lhrh analog egf induc cfos express ovarian cell line skov not express lhrh receptor result bind lhrh agonist antagonist receptor inhibit mitogen signal transduct pathway egf receptor endometri ovarian breast cell line coupl signal transduct system mediat antiprolif effect lhrh analog
vitro antiprolif effect ethyl gallat against human oral squamous carcinoma cell line kb known possess anticanc activ against differ cell line apoptosi mode antiprolif effect ethyl gallat against human oral squamous carcinoma cell line kb not until now antiprolif effect ethyl gallat dimethylthiazolyl diphenyltetrazolium bromid assay paclitaxel generat ros mitochondri membran potenti loss damag apoptosi diacetyldichlorofluorescein fluoresc uptak rhodamin mitochondria comet assay acridin orang ethidium bromid dualdy stain ethyl gallat paclitaxel exhibit cytotox dosedepend manner inhibitori ethyl gallat paclitaxel volum ethyl gallat effect control cell prolifer lead acut apoptosi
inhibitori effect curcumin nanoparticl free curcumin human telomeras revers transcriptas gene express breast telomeras express breast curcumin compound herb curcuma longa anticanc effect effect low poor water solubl improv solubl deliveri util betacyclodextrincurcumin inclus complex cytotox effect cyclodextrincurcumin free curcumin mtt assay cell equal cyclodextrincurcumin free curcumin telomeras gene express level compar realtim pcr mtt assay demonstr betacyclodextrincurcumin enhanc curcumin deliveri td breast cell level telomeras gene express cell cyclodextrincurcumin cell free curcumin result cyclodextrincurcumin complex effect free curcumin inhibit telomeras express
antiprolif effect flavonoid halophyt vitex rotundifolia human cell flavonoid luteolin vitexicarpin artemetin salt marsh plant vitex rotundifolia test antiprolif activ ag mcf ht human cell line compar control mtt assay effect ic microm against ag ht cell inaddit mrna express level apoptosisrel gene bcl andbax ag cell reversetranscript polymeras chain rtpcr compound not enhanc remark express level suppressor gene proapoptot gene bax microm suppress express level antiapoptot gene bcl shift bax bcl ratio favor apoptosi
licochalcon induc apoptosi endoplasm reticulum via phospholipas cgamma ca rosdepend pathway hepg human hepatocellular carcinoma cell licochalcon lica estrogen flavonoid induc apoptosi type cell molecular mechan anticanc effect lica hepg human hepatocellular carcinoma cell lica induc apoptot cell death activ caspas express endoplasm reticulum er stressassoci protein ebp homolog protein chop inhibit er chop knockdown er inhibitor salubrin phenylbutyr lica induc cell death lica induc ros accumul antioxid nacetylcystein lica induc cell death chop express addit lica level cytosol ca block aminoethoxydiphenyl borat antagonist inositol trisphosph receptor baptaam intracellular ca chelat aminoethoxydiphenyl borat baptaam inhibit lica induc cell death interest lica induc phosphoryl phospholipas cgamma plcgamma inhibit plcgamma cell death er moreov multitarget receptor tyrosin kinas inhibitor sorafenib sunitinib lica induc cell death er cytosol ca ros accumul final lica induc phosphoryl vascular endotheli growth receptor vegfr cmet receptor inhibit receptor cotransfect vegfr cmet sirna revers lica induc cell death ca chop express taken togeth er via plcgamma ca rosdepend pathway mechan lica induc apoptosi hepg hepatocellular carcinoma cell
revers effect curcumin multidrug resist mnng hos human osteosarcoma cell vitro vivo regul pglycoprotein pglycoprotein pgp encod atpbind cassett subfamili membesr abcb gene kind atpdepend transport play role multidrug resist mdr human osteosarcoma curcumin natur color compound origin rhizom curcuma longa prove possess antitumor biolog activ revers mdr effect molecular mechan curcumin osteosarcoma mdr human osteosarcoma drugresist cell line mnng hos mtx puls exposur methotrex mtx verifi new cell line crossresist anticanc agent cytotox assay revers mdr mnng hos mtx mol curcumin detect mechan curcumin revers mdr realtim pcr western blot assay rhodamin rh transport test final effect curcumin revers mdr vivo mnng hos mtx cell xenograftnud mice model mnng hos mtx prove human osteosarcoma mdr cell line mtt chemosensit test indic mol curcumin attenu half maxim inhibitori ic resist index ri mtx diamminedichloroplatinum ddp adriamycin adm ifosfamid ifo epirubicin epi mnng hos mtx cell realtim pcr western blot assay demonstr curcumin downregul pgp express mnng hos mtx cell rh transport test curcumin inhibit transport pgp vitro vivo curcumin display featur sensit antitumor inhibit prolifer invas metastasi osteosarcoma mdr cell downregul pgp inhibit pgp efflux pump contribut mdr revers induc curcumin vitro vivo
flavonoid glycosid isol smilax china rhizom vitro anticanc effect human cell line anticanc activ eight crude extract smilax china rhizom scr against hela cell mtt assay clonogen assay fraction rich flavonoid good activ against hela cell bioassayguid separ extract lead detect kaempferolobetadglucosid belong flavonoid glycosid display mark anticanc activ vitro cytotox antiprolif effect panel cell line mtt assay clonogen assay induc hl cell apoptosi demonstr morpholog chang fragment flow cytometr fluoresc stain hoechst fragment condens chromatin hl cell flow cytometr hl cell result appear hypodiploid peak region probabl presenc apoptos cell apoptot bodi content less quantit hypodiploid cell dosedepend result good fragment assay agaros gel electrophoresi result cell cycl arrest phase induc apoptosi mechan exert antiprolif effect
curcumin inhibitor histon acetylatransferas histon acetyltransferas hat cbp implic cell growth surviv hat novel therapeut relev molecular target demonstr molecul natur curcumin whose medicin properti long recogn india southeast asia hat inhibitor furthermor indic alpha beta unsatur carbonyl curcumin chain michael site michael acceptor curcumin requir hat inhibitori activ cell curcumin promot proteasomedepend degrad close cbp protein hat pcaf gcn addit induc degrad curcumin inhibit acetyltransferas activ purifi histon substrat radiolabel curcumin coval associ tetrahydrocurcumin display inhibitori activ consist michael reactiondepend mechan final curcumin abl effect block histon hyperacetyl pcm cell peripher blood induc histon deacetylas inhibitor ms medicin natur curcumin novel lead compound therapeut cbpspecif hat inhibitor
curcumin inhibit trinitrobenzen sulphon induc coliti activ pparg curcumin spice antiinflammatori anticanc properti report curcumin held therapeut effect coliti inhibit nuclear kappa nfkappab pparg pparg nuclear receptor antitumor antiinflammatori effect activ inhibit nuclear transloc nfkappab pparg ligand therapeut effect coliti report alter pparg trinitrobenzen sulphon tnbs induc coliti curcumin administ curcumin intraperiton inject immedi after coliti induc inject last effect curcumin coliti induc trinitrobenzen sulphon tnbs curcumin administ intraperiton after coliti induc last therapeut effect dexamethason dex alon effect curcumin dex curcumin improv longterm surviv rate diseasebear promot bodi recoveri decreas macroscop score coliti express level pparg deoxydprostaglandin dpgj prostaglandin pge express level cyclooxygenas cox decreas after curcumin dex improv pparg express inhibit express cox dpgj pge effect curcumin dex dex summari curcumin therapeut effect tnbs induc coliti mechan curcumin exert effect involv activ pparg ligand
resist apoptosi hcw cell overcom curcumin vincristin induc mitot catastroph term mitot catastroph becom describ death cell sever mitot spindl damag not abl bypass mitosi cell hlderiv hcw line resist apoptosi curcumin vincristin undergo mitot catastroph final caspas activ oligonucleosom degrad curcumin natur dye deriv curcuma longa induc cell death cell decreas cell prolifer cell surviv arrest cell phase cell cycl induc morpholog chang cell enlarg micronucl catastroph cell compris separ subpopul less evidenc flow scan cytometri subpopul mpm thymidin block cell arrest phase cell cycl curcumin effect induc mitot catastroph curcumin not vincristin act hcw cell inhibit express survivin modul cell divis apoptosi altogeth result apoptosi resist overcom induc mitot catastroph hcw cell
inhibitori effect curcumin protein kinas activ induc otetradecanoylphorbolacet nih cell curcumin pigment yellow color curri potent inhibitor promot induc otetradecanoylphorbolacet tpa mous skin mous fibroblast cell nih tpa alon protein kinas pkc transloc cytosol fraction particul fraction micron curcumin min inhibit tpa induc pkc activ particul fraction did not level pkc protein curcumin inhibit pkc activ cytosol particul fraction vitro compet phosphatidylserin inhibitori effect curcumin after preincub thiol compound suppress pkc activ contribut molecular mechan inhibit tpa induc promot curcumin
isoliquiritigenin inhibit growth isoliquiritigenin compon root glycyrrhiza glabra member flavonoid known antitumor activ vitro vivo antitumor effect isoliquiritigenin vitro du lncap cell line target effect isoliquiritigenin cell prolifer cell cycl regul cell cycleregul gene express effect isoliquiritigenin gadd mrna protein express promot activ isoliquiritigenin inhibit prolifer cell line dosedepend timedepend manner fluorescenceactiv cell sort fac indic isoliquiritigenin induc phase arrest isoliquiritigenin enhanc express gadd mrna protein associ cell cycl arrest isoliquiritigenin transcript activ gadd promot dosedepend isoliquiritigenin candid agent gadd play role isoliquiritigenin induc cell cycl arrest cell growth inhibit
ethanol extract bark salix aegyptiaca amelior dimethylhydrazin induc colon mice ethanol extract bark eeb salix aegyptiaca musk willow inhibit prolifer motil induc apoptosi colon cell tandem mass spectrometri reveal eeb rich catechin catechol salicin effect hplcfingerprint eeb dimethylhydrazin dmh induc aberr crypt foci acf format mice dmh bodi inject subcutan mice eeb bodi oral th th after colon tissu histolog biochem dmh induc acf eeb acf restor goblet cell mucin accumul eeb supplement improv inflamm myeloperoxidas neutrophil infiltr eeb amplifi apoptosi neoplast cell colon mucosa dmhtreat mice level earli event egfr nuclear betacatenin cox colon cell line ht hct innocu eeb up mice reinforc potenti agent
vitro anticanc activ nonpolar fraction gynostemma pentaphyllum thunb makino gynostemma pentaphyllum thunb makino gpm tradit chines medicin tcm diseas focus primarili polar fraction gpm anticanc activ nonpolar fraction eaa gpm potent growth inhibitori activ against cell line ic Ã¨Ã£Ã¹g Ã¨Ã£Ã¹g furthermor eaa inhibit growth breast cell mdamb timedepend well coloni format abil eaa induc apoptosi mdamb cell dosedepend timedepend flow cytometri verifi western blot apoptosi cleav nuclear polyadpribos polymeras cparp addit eaa induc cell cycl arrest phase compon eaa gcms reveal nonpolar fraction gpm compound alkaloid organ ester terpen catechol compound not report gpm summari nonpolar fraction eaa gpm inhibit cell growth apoptosi regul cell cycl shed light new anticanc activ gpm feasibl new anticanc agent medicin plant
antiprolif antiestrogen activ bonediol alkyl catechol bonellia macrocarpa purpos antiprolif activ bonediol alkyl catechol isol mayan medicin plant bonellia macrocarpa bonediol growth inhibit androgensensit lncap androgeninsensit pc metastat androgeninsensit pcm human cell normal cell line hek hedgehog pathway competit hestradiol ligand bind assay perform addit antioxid activ nrfare pathway bonediol induc growth inhibit cell line ic interest bonediol bind esr esr esr displac nativ ligand betaestradiol signific activ hedgehog pathway addit activ bonediol nrfare pathway bonediol induc activ detoxif enzym propos compound bonediol serv potenti therapeut potenti against 
onepot laccasecatalys synthesi dihydroxyl benzo furan catechol deriv anticanc activ commerci laccas suberas novozym catalys synthesi dihydroxyl benzo furan catechol deriv yield case enzymat electrochem synthes synthesis deriv screen against renal tk uacc breast mcf cervic hela cell line gi tgi lc report anticanc screen cytostat effect dihydroxyl benzo furan effect against uacc cell line compound exhibit potent growth inhibitori activ compound activ anticanc agent etoposid compound exhibit potent activ against renal tk cell line exhibit potent activ against breast mcf cell line result encourag dihydroxyl benzo furan potenti applic anticanc 
idaein chlorid induc depend apoptosi cervic cell inhibit viral oncoprotein host depend express earli hpv oncoprotein play central role format cervic carcinoma cyanidin analog idaein chlorid induc dose depend apoptosi icÃÃÃg hpv hela cell flow cytometr arrest cell cycl phase sub cell popul th exposur record express level cell cycl protein cyclin cdk cdk confirm occurr cell cycl arrest phase addit idaein chlorid inhibit express protein result reexpress henc trigger depend apoptosi support record variat express pattern waf prb ef regulatori protein case mitochondri apoptot express bax restor bcl level got decreas th cleav caspas parp after Ãh interest epigenet regulatori enzym dnmts inhibit idaein chlorid idaein chlorid potent sourc against cervic carcinoma
antisept effect pelargonidin hmgb induc vitro vivo certain nucleosom proteinhigh mobil box hmgb late mediat sepsi therapeut window pharmacolog intervent pelargonidin pel wellknown red pigment plant biolog activ potenti human health pel modul hmgbmediat human umbil vein endotheli cell huvec mice antiinflammatori activ pel measur permeabl leukocyt adhes migrat activ proinflammatori protein hmgbactiv huvec mice well effect pel surviv rate mous sepsi model pel effect inhibit lipopolysaccharid lps induc hmgb suppress hmgbmediat septic hyperperm adhes migrat leukocyt express cell adhes molecul furthermor pel inhibit hmgbmediat tnf interleukin il well activ nuclear factorkb nfkb extracellular signalregul kinas erk erk result indic pel sever vascular diseas via inhibit hmgb signal pathway
triterpen glycosid polar constitu shea vitellaria paradoxa kernel bioactiv meoh extract defat shea vitellaria paradoxa sapotacea kernel constitu fifteen oleananetyp triterpen glycosid steroid glucosid pentanediol glucosid compound sugar isol structur triterpen glycosid elucid spectroscop bioactiv isol compound compound potent moder inhibitori activ against melanogenesi cell induc alphamelanocytestimul hormon alphamsh generat diphenylpicrylhydrazyl dpph against epsteinbarr virus earli antigen ebvea activ induc oteradecanoylphorbol acet tpa raji cell tpa induc inflamm mice prolifer hl az skbr human cell line western blot paradoxosid inhibit melanogenesi regul express microphthalmiaassoci transcript mitf tyrosinas tyrosinaserel protein trp trp addit tieghemelin demonstr exhibit cytotox activ against cell ic apoptosi flow cytometri extract defat shea kernel constitu valuabl potenti antioxid antiinflammatori skinwhiten anticanc agent
purif novel antitumor protein antioxid deoxyribonucleas activ edibl mushroom pholiota nameko novel antitumor protein edibl mushroom pholiota nameko pnap purifi twostep chromatograph procedur sp cation exchang chromatogram superdex gel filtrat approxim molecular demonstr Ãkda sdspage ultracentrifug ntermin sequenc detect agrtfigyng edman degrad biochem exhibit signific antioxid activ effect scaveng hydroxyl diphenylpicrylhydrazyl compar standard antioxid butyl hydroxi anisol pnap deoxyribonucleas activ optimum ph temperatur Ãc well act doublestrand singlestrand preferenti doublestrand pnap display antitumor activ against cell line mcf hela cell human breast mcf cell pnap produc typic apoptot morpholog chang chromatin condens accumul subg cell altern mitochondri permeabl pnap induc apoptosi mcf cell entail loss mitochondri membran potenti result cytochrom cytosol activ caspas caspas execut apoptosi impli intrins signal pathway involv pnap induc apoptosi
antioxid anticanc activ extract betula platyphylla var japonica antioxid anticanc properti medicin plant betula platyphylla var japonica total methanol extract platyphylla var japonica protect effect against hydrogen peroxid ho chines hamster lung fibroblast cell line induc apoptot cell death human promyelocyt leukemia hl cell cell line platyphylla var japonica extract cell viabil against ho extract diphenylpicrylhydrazyl dpph scaveng activ ic microg lipid peroxid inhibitori activ ic below microg furthermor platyphylla var japonica extract cell arrest ho activ cellular antioxid enzym superoxid dismutas catalas glutathion peroxidas platyphylla var japonica extract induc cytotox apoptosi hl cell nucleosom fragment subdiploid cell popul fluoresc microscopi platyphylla var japonica extract gradual express proapoptot bax led activ caspas cleavag parp platyphylla var japonica exhibit potenti antioxid anticanc properti
carvacrol induc rosmedi apoptosi cell cycl arrest human cell carvacrol monoterpenoid origanum thymus exhibit antiprolif anticanc properti few nevertheless detail mechan action compound not elucid yet anticanc activ mechan action carvacrol against human cell du cell carvacrol decreas cell viabil timedepend manner antiprolif action carvacrol lead apoptosi confirm nuclear condens annexin vfitc pi cell caspas activ addit carvacrol augment ros generat disrupt mitochondri membran potenti not report carvacrol moreov carvacrol induc apoptosi cell accompani signific amount growth arrest phase cell cycl not document sum up carvacrol promis chemotherapeut agent direct practic implic translat relev patient origanum consumpt retard 
effect alkylaminophenol growth inhibit apoptosi bone cell work report anticanc properti seri synthes alkylaminophenol against human osteosarcoma uo cell line assay cytotox inhibitor kinet cell migrat annexinv pi doubl stain ros caspas assay conduct cell line cytotox dihydroquinolinh ylptolylmethylphenol ic against uo cell inhibit cell growth timedepend manner potent activ lead compound against growth cell line uo hekt confirm osteosarcoma cell specif inhibit indic compound inhibitor metastat properti cell induc apoptosi agent abil ros induc caspas confirm contribut program cell death uo hekt cell addit compound indolinylarylmethyl nitrophenol core cytotox ic work demonstr anticanc properti deriv ad entri promis chemotherapeut agent 
pleuropterus multiflorus hasuo mediat straightforward ecofriend synthesi silver gold nanoparticl anticanc activ lung cell line pleuropterus multiflorus hasuo medicin plant korea china amnesia isnomia heart throb etc construct idea promot widespread usag multiflorus propos indirect usag biolog activ silver pmagnp gold nanoparticl pmaunp synthes nanoparticl predomin spheric crystallin zaverag hydrodynam diamet nm nm protein player involv synthesi stabil pmagnp cytotox lung cell pmaunp not cytotox normal keratinocyt lung cell even addit anticanc activ new nanoparticl migrat apoptosi pmagnp potenti therapeut effect lung cell best knowledg report dissect out abil endem multiflorus synthesi bioactiv silver gold nanoparticl open up door extens usag medicin field
oleocanth exert antitumor effect human colon cell ros generat health properti mediterranean well recogn principl sourc fat mediterranean extravirgin oliv oil evoo oleocanth oc natur occur minor compound isol evoo potent antiinflammatori activ mean abil inhibit cyclooxygenas cox enzym cox cox larg bodi evid indic exhibit anticanc activ potenti anticanc effect oc hepatocellular carcinoma hcc carcinoma crc model panel human hcc hepg huh hepb plc prf crc ht sw cell line cell oc cell viabil apoptosi compar classic commerci avail cox inhibitor ibuprofen indomethacin nimesulid oc effect induc cell growth inhibit hcc crc cell moreov oc inhibit coloni format induc apoptosi confirm parp cleavag activ caspas chromatin condens oc dose dependentmann induc express gammahax damag intracellular ros mitochondri depolar moreov effect oc suppress ros scaveng nacetyllcystein final oc not primari normal human hepatocyt oc exert potent anticanc activ against hcc crc cell taken togeth preclin support chemotherapeut potenti evoo against 
hydroquinon analog tetrahydrohpyranyl oxi Ãphenol induc colon cell apoptosi inhibit growth inÃvivo tetrahydropyranyl oxi xgd hydroquinon analog vaccinium vitisidaea known antioxid properti level safeti antitumor activ elucid anticanc effect xgd inÃvitro inÃvivo cytotox xgd against murin colon carcinoma cell occur concentrationdepend manner littl effect normal cell line hk oral xgd Ãmg effect growth tumorbear mice furthermor mark apoptosi hoechst stain flow cytometr annexinÃpropidium iodid doubl stain xgd downregul express cell lymphomaÃ bcl express level bclassoci Ãprotein activ caspas caspas polyadenosin diphosphateribos polymeras demonstr best knowledg xgd inhibit cell growth via apoptosi abl inhibit growth inÃvivo result demonstr xgd potenti natur agent low 
grimmedi stat activ induc prolifer cytotox cervic tumorderiv cell line natur produc red grape berri peanut exert anticanc effect activ signal transduc activ transcript stat mechan suppress stat signal pathway elucid effect grimstat signal hela cell deriv cervic hela cell western blot express level stat stat grim betaactin cell viabil mtt assay result suppress prolifer stat phosphoryl hela cell induc express gene associ retinoid induc mortal grim protein overexpress grim suppress stat signal pathway hela cell stat signal pathway activ downregul grim express short interf rnas sirna suppress cell prolifer effect decreas sirna suppress stat phosphoryl decreas sirna best knowledg grim stat signal target elucid mechan antitumor activ 
norcantharidin enhanc abt induc apoptosi hepatocellular carcinoma cell transcript repress mcl smallmolecul cellperm bcl bclxl antagonist abt novel therapeut agent potent induc apoptosi certain cell abt bind mcl low affin abtmedi apoptosi signal inhibit hepatocellular carcinoma hcc cell solid cell express mcl strategi target mcl overcom abtresist report norcantharidin nctd smallmolecul anticanc deriv chines tradit medicin blister beetl mylabri induc transcript repress mcl consider enhanc abttrigg cell viabil inhibit apoptosi hcc cell line moreov enhanc abtmedi apoptosi nctd associ activ mitochondri apoptosi signal pathway involv cytosol cytochrom cleavag caspas caspas addit knockdown bax bak key effector permeabil mitochondri outer membran attenu enhanc indic mitochondri apoptosi pathway play essenti role execut apoptosi final knockdown mcl potenti abtmedi apoptot cell death confirm potenc mcl repress nctd enhanc abt induc apoptosi result nctd overcom abt resist enhanc abt therapeut efficaci human hcc
murraya koenigii leaf extract inhibit proteasom activ induc cell death breast cell inhibit proteolyt activ proteasom proteindegrad machin now novel promis approach interest proteasom inhibitor demonstr kill cell enhanc sensit cell chemotherapeut agent flavonoid report inhibit proteasom activ murraya koenigii spreng medicin herb indian origin centuri ayurved system medicin murraya koenigii leav curri leav rich sourc inhibit proteolyt activ cell proteasom cell death hydromethanol extract curri leav cle prepar total content tpc folinciocalteaus human breast carcinoma cell line mcf mdamb normal human lung fibroblast cell line wi cytotox cle mtt assay effect cle growth kinet coloni format assay growth arrest cell cycl apoptosi annexinv bind flow cytometri inhibit endogen proteasom intact cell cell extract substrat specif proteasom enzym cle decreas cell viabil alter growth kinet breast cell line dosedepend manner signific arrest cell phase albeit cell annexin bind cell death via apoptot pathway cell line cle decreas activ proteasom not normal cell koenigii leav potent sourc proteasom inhibitor lead cell death identif activ compon leaf extract lead anticanc agent differ type 
induc mmp cell migrat via kinas pik pathway ht human fibrosarcoma cell transtrihydroxystilben grape plant food red wine grape antiinflammatori anticarcinogen antioxid antiag properti matrix metalloproteinas mmps key enzym involv degrad extracellular matrix express regul metastasi effect mmps cell migrat mechan action ht human fibrosarcoma cell inhibit ht cell viabil detect mtt assay fac dramat activ express mmp doseand timedepend manner gelatin zymographi assay western blot discov enhanc migratori abil ht cell wound heal assay decreas phosphoryl kinas moreov akt kinas inhibit ht cell inhibit akt kinas sb ly induc mmp well cell migrat ht cell result regul mmp migratori abil kinas pik pathway ht human fibrosarcoma cell
soy phytoestrogen prevent growth bg ovarian cell induc betaestradiol bisphenol via inhibit cell cycl endocrin disrupt edc global health concern effect gen bisphenol bpa betaestradiol induc cell growth gene alter bg ovarian cell express esr er vitro cell viabil assay bpa growth bg cell prolif activ revers ici wellknown er antagonist cell prolifer promot presenc propyl pyrazol triol ppt esr agonist result impli cell prolifer bpa mediat er esr bpa clear act xenoestrogen bg ovarian cell mimick action gen effect suppress bg cell prolifer promot bpa inhibit cell cycl bpa express cyclin cell cycl transit decreas express potent cyclindepend kinas cdk inhibitor arrest cell cycl phase promot prolifer bg cell repress effect cell growth gen decreas express cyclin augment bpa hand gen express downregul bpa gen phytoestrogen inhibitori effect growth estrogendepend promot bpa
apoptot effect protocatechu human breast lung cervix cell potenti mechan action apoptot effect protocatechu pca micromol human breast mcf cell lung cell hepg cell cervix hela cell lncap cell result pca concentrationdepend decreas cell viabil lactat dehydrogenas leakag enhanc fragment mitochondri membran potenti na atpas activ cell pca concentrationdepend caspas activ cell agent micromol caspas activ pca concentrationdepend decreas intercellular adhes molecul level test cell inhibit cell adhes micromol pca concentrationdepend level interleukin il il cell agent micromol suppress vascular endotheli growth pca potent anticanc agent apoptosi retard invas metastasi cell
inhibit stat signal pathway nifuroxazid improv antitumor impair carcinoma metastasi carcinoma crc common consider metastat potenti explain need new candid inhibit metastasi signal transduc activ transcript stat signal pathway role crc valid promis anticanc target crc report nifuroxazid antidiarrh agent inhibitor stat nifuroxazid decreas viabil crc cell line induc apoptosi cell concentrationdepend manner moreov western blot demonstr occurr apoptosi correl activ bax cleav caspas decreas express bcl addit nifuroxazid mark impair crc cell migrat invas downregul phosphorylatedstattyr impair express matrix metalloproteinas mmp mmp furthermor nifuroxazid inhibit metastasi lung abdomen metastasi model colon meanwhil nifuroxazid prolifer index induc apoptosi impair metastasi notabl nifuroxazid myeloidderiv suppressor cell blood spleen accompani infiltr cd cell mark decreas mtype macrophag abdomen metastasi model taken togeth result indic nifuroxazid effect inhibit metastasi mediat stat pathway therapeut potenti crc
biolog activ compound triterpenoid gall terminalia chebula nine compound carboxyl hydrolyz tannin eight triterpenoid oleananetyp triterpen glucosid isol meoh extract gall terminalia chebula retz myrobalan tree combretacea inhibitori activ against melanogenesi cell induc alphamelanocytestimul hormon alphamsh against epsteinbarr virus earli antigen ebvea activ induc otetradecanoylphorbol acet tpa raji cell against tpa induc inflamm mice diphenylpicrylhydrazyl dpph radicalscaveng activ cytotox activ against human cell line compound exhibit potent inhibitori activ against melanogenesi melanin content low cell cell viabil westernblot reveal isoterchebulin protein level mitf microphtalmiaassoci transcript tyrosinas trp tyrosinerel protein concentrationdepend manner eight triterpenoid potent inhibitori effect ebvea ic mol ratio pmol tpa compound exhibit dpph scaveng activ ic hand nine compound exhibit potent radicalscaveng activ ic weak inhibitori effect ebvea ic mol ratio pmol tpa tannin triterpenoid inhibit tpa induc inflamm mice id arjungenin exhibit inhibitori effect skintumor promot vivo twostag mouseskin carcinogenesi test dimethylbenz anthracen dmba tpa promot compound against hl cell line compound against az cell line compound against skbr cell line moder cytotox activ
hispidulin mediat apoptosi human renal cell carcinoma induc ceramid accumul hispidulin flavonoid extract tradit chines medicin plant involucrata exhibit antitumor effect array human cell growth inhibit apoptosi cell cycl arrest precis anticanc mechan molecular mechan contribut hispidulin induc apoptosi human clearcel renal cell carcinoma ccrcc line caki achn hispidulin mol decreas viabil ccrcc cell dose timedepend manner normal tubular epitheli cell moreov hispidulin dosedepend level cleav caspas caspas inhibitor caspas caspas abrog hispidulin induc apoptosi hispidulin trigger apoptosi via extrins intrins pathway moreov hispidulin inhibit activ sphingosin kinas sphk consequ promot ceramid accumul lead apoptosi cell pretreat kpc activ sphk overexpress sphk attenu antiprolif proapoptot effect hispidulin addit hispidulin dosedepend activ ros jnk signal led cell apoptosi demonstr caki xenograft nude mice inject hispidulin mgÃ kgÃ d ip dosedepend suppress growth accompani decreas sphk activ ceramid accumul tissu reveal new explan antitumor mechan hispidulin sphk ceramid serv potenti therapeut target ccrcc
vitro effect molecular mechan galangin quercetin human gastric cell line sgc natur flavonoid proven power against few potenti effect flavonoid galangin quercetin human gastric cell line sgc vitro growth inhibit apoptosi flavonoid sgc cell well potenti mechan apoptosi report assay result flavonoid mmol hour confer cell viabil dose timedepend manner hour enhanc proport apoptot cell galangin power quercetin inhibit cell growth induc apoptosi decreas mitochondri membran potenti mmp oligonucleotid micro array realtim rtpcr westernblot analys reveal express chang gene protein cell clarifi mechan apoptosi flavonoid activ caspas cleav bid tbid simultan bax transfer cytosol mitochondria decreas mmp consequenti cytochrom mitochondria activ caspas caspas activ caspas execut apoptosi apoptosi occur via mitochondri pathway involv caspas bid bax activ
curcumin inhibit prolifer induc apoptosi ht cell line rosdepend mechan curcumin natur pigment extract curcuma longa anticarcinogen activ cell line molecular mechan apoptosi induc curcumin still unknown role ros curcumin apoptosi ht cell curcumin cell viabil induc apoptosi activ caspas activ concentrationdepend ros inhibit ros generat scaveng suppress apoptosi bcl express induc curcumin indic role ros apoptot caspas inhibitor zvadfmk couldnt complet inhibit curcumin induc apoptosi indic ros mediat apoptosi caspaseindepend togeth ros play signific role apoptosi induc curcumin ht cell
curcumin induc endoplasm reticulum stressassoci apoptosi human papillari thyroid carcinoma bcpap cell via disrupt intracellular calcium homeostasi thyroid common endocrin demonstr curcumin induc apoptosi human papillari thyroid carcinoma bcpap cell underlin mechan not clear elucid endoplasm reticulum er organell synthesi matur protein well larg store ca overcom chronic activ er trigger proapoptot pathway unfold protein upr novel strategi therapeut uncov er pathway involv apoptosi curcumin bcpap cell differ dose curcumin Ã´Ã§Ã¨m annexin pi doubl stain cell apoptosi rhod am calcium fluoresc probe assay perform measur calcium level endoplasm reticulum western blot express er ebp homolog protein chop glucoseregul protein grp xbox bind protein xbp splice revers transcriptasepolymeras chain rtpcr curcumin inhibit anchorageindepend cell growth induc apoptosi bcpap cell curcumin induc er upr dose timedepend manner chaperon phenylbutyr pba partial revers antigrowth activ curcumin moreov curcumin inositolrequir enzym alpha irealpha phosphoryl xbp mrna splice induc subset er chaperon cleavag activ transcript atf enhanc express downstream target chop furthermor curcumin induc intracellular ca influx inhibit sarcoendoplasm reticulum atpas serca pump cytosol ca bound calmodulin activ calcium calmodulindepend protein kinas ii camkii signal lead mitochondri apoptosi pathway activ ca chelat bapta partial revers curcumin induc er growth suppress confirm involv calcium homeostasi disrupt curcumin inhibit thyroid cell growth least partial er stressassoci apoptosi provok er activ promis therapeut target thyroid 
curcuminoid gefitinib mediat apoptosi autophagi human oral sas cell vitro sas cell xenograft mice vivo gefitinib patient curcumin cur demethoxycurcumin dmc bisdemethoxycurcumin bdmc induc cell apoptosi report gefitinib cur dmc bdmc induc cell apoptosi autophagi human oral cell effect gefitinib cur dmc bdmc cotreat cell viabil apoptot cell death autophagi mitochondria membran potenti mmp caspas activ flow cytometri assay autophagi acridin orang ao stain human oral sas cell result indic gefitinib cotreat cur dmc bdmc decreas total viabl cell cell apoptosi autophagi decreas level mmp caspas activ sas cell western blot indic gefitinib cur dmc bdmc led decreas bcl protein express antiapoptot protein atg beclin sqstm lc express associ cell autophagi sas cell gefitinib cur dmc led volum sas cell xenograft nude mice did not total bodi gefitinib cur dmc bdmc potenti anticanc agent human oral futur
curcumin enhanc anticanc effect pari saponin ii lung cell synergist mechan pari saponin ii psii curcumin cur lung chang cellular uptak cur psii apoptosi cell cycl arrest cytokin level analys differ lung cell display synergist anticanc effect promot cellular uptak cur differ lung cell hoechst stain fac assay indic psii cur induc cell cycl arrest apoptosi western blot cytokin antibodi microarray activ death receptor dr cd cdl fasl tnf induc cell apoptosi upregul igfbp lead inhibit pik akt pathway induc phase arrest ncih cell meanwhil suppress pcna nfkb pathway kind lung cell activ phosphoryl jnk inhibit pik ncih ncih cell enhanc phosphoryl jnk ncih cell phosphoryl erk suppress pik ncih cell psii cur synergist anticanc effect lung cell rational curcumin psii lung futur
curcumin suppress prolifer invas nonsmal cell lung modul mtamedi wnt betacatenin pathway curcumin natur occur compound divers antitumor activ demonstr curcumin inhibit invas metastasi activ suppressor dnajlik heat shock protein hlj specif role mechan curcumin regul malign behavior nonsmal cell lung nsclc cell still curcumin inhibit prolifer invas nsclc cell induc phase arrest metastasisassoci protein mta overexpress detect varieti aggress play role cell invas metastasi result curcumin effect inhibit mta express nsclc cell research mechan curcumin inhibit prolifer invas nsclc cell mtamedi inactiv wnt betacatenin pathway wnt betacatenin signal report play cooper role promot lung tumorigenesi novel insight mechan curcumin inhibit nsclc cell growth invas potenti therapeut strategi nsclc
curcumin inhibit growth angiogenesi orthotop mous model human pancreat pancreat malign neoplasm origin cell aris tissu pancrea best chemotherapeut agent pancreat gemcitabin gemcitabin associ effect novel strategi involv less agent pancreat necessari curcumin agent inhibit prolifer angiogenesi varieti cell modul cell signal pathway curcumin play antitumor effect mia paca cell vitro curcumin inhibit prolifer enhanc apoptosi mia paca cell test antitumor activ curcumin vivo generat orthotop mous model pancreat inject mia paca cell nude mice place mice curcumin mice smaller control downregul transcript tnf nfkbregul gene indic curcumin great potenti human pancreat modul nfkb pathway
cytotox proapoptot activ leaf extract croton bonplandianus baill against lung cell line aceton extract ace croton bonplandianus baill exot weed euphorbiacea famili cytotox apoptosi cell cycl arrest cell line antioxid capac mtt assay acridin orang ethidium bromid ao eb stain cell cycl dpph scaveng assay cytotox activ extract test apoptot effect ao eb hoechst stain apoptosi chromatin condens fragment stage cell death cell cycl perform flow cytometri ace arrest phase dose depend manner cell phase concurr accumul cell sub gÃ´Ã©Ã§ gÃ´Ã©uphas indic apoptosi gm phase free scaveng activ ace against dpph consider signific cytotox apoptot antioxid effect ace well correl presenc potent free scaveng secondari flavonoid Ã¡g tannin Ã¡g cell sensit ace Ã¡g compar standard cisplatin result croton bonplandianus serv potenti sourc altern therapeut agent research requir isol activ principl compound anticanc properti
antitumor activ novel flavonoid oncamex preclin breast model natur myricetin induc cell cycl arrest apoptosi preclin model hypothesis myricetinderiv flavonoid enhanc redox properti improv cell uptak mitochondri target potenti antitumor agent effect secondgener flavonoid analogu oncamex panel breast cell line appli western blot gene express fluoresc microscopi immunohistochemistri xenograft tissu mechan action prolifer assay oncamex Ã´Ã§Ã«h cell viabil induc cytotox apoptosi concomit caspas activ microarray oncamex associ chang express gene control cell cycl apoptosi fluoresc microscopi compound mitochondri target rosmodul properti induc superoxid associ antiprolif effect preliminari vivo mice implant mdamb breast xenograft oncamex inhibit growth tissu viabil ki prolifer sign untoward effect anim oncamex novel flavonoid capabl specif mitochondri deliveri redox modul antitumor activ preclin model breast support potenti prototyp candid continu anticanc agent
inhibit breast cell surviv xanthohumol via modul notch signal pathway vivo vitro natur compound deriv plant sourc numer clinic anticanc agent nevertheless limit indic xanthohumol xn prenyl flavonoid hop plant humulus lupulus possess anticarcinogen properti purpos clarifi antitumorigen effect mechan xn breast vivo vitro breast mous model xn suppress growth detect tumorigen assay vivo addit vitro reveal xn decreas cell viabil induc cell cycl arrest apoptosi mcf mdamb cell confirm mtt assay flow cytometri western blot indic anticarcinogen activ xn against breast furthermor immunohistochemistri perform confirm inactiv notch signal pathway notch ki vivo consist xn decreas activ notch signal pathway apoptot regul bcell lymphoma bcl bclextra larg caspas western blot vitro xn potenti agent breast hyperplasia carcinogenesi act via regul notch associ apoptot regul vivo vitro
phloretin induc apoptosi hras mcfa human breast cell activ via jnk mitogenactiv protein kinas signal mutat ras play role human breast antiprolif effect natur occur dihydrochalcon phloretin trihydroxyhydroxyphenyl propiophenon hrastransform mcfa human breast epitheli hras mcfa cell phloretin suppress hras mcfa cell prolifer dosedepend manner induc nuclear condens cell indic phloretin induc cell death occur via apoptosi promin upregul bax cleavag poli adp ribos polymeras detect phloretintr cell final phloretin mark caspas activ well jnk mitogenactiv protein kinas signal phloretin induc apoptosi breast cell contribut potenti phloretin against breast 
coumarinchalcon hybrid instig damag minor groov bind stabil post translat modif coumarinchalcon hybrid possess antiprolif antitumor effect trigger apoptosi report role damag signal pathway induc cell death damag potenti bind minor groov led phosphoryl activ atm dnapk not atr earlier point repair induc damag trigger activ phosphoryl key residu pharmacolog inhibit pikk abrog induc phosphoryl sesr damag induc phosphoryl result proteasom degrad disrupt pmdm interact addit dock reveal contribut cellular level occupi bind pocket mdm posttransl modif led enhanc affin element pre promot region target gene transcript effici togeth result cleav minor groov bind eventu activ pikk associ damag signal promot stabil enhanc transcript activ posttransl modif key residu
dihydroartemisinin inhibit endotheli cell prolifer suppress erk signal pathway disrupt angiogenesi serv strategi dihydroartemisinin dha semisynthet deriv artemisinin exhibit potent antiangiogen activ molecular mechan effect not fulli understood role dha endotheli cell prolifer essenti angiogenesi human umbil vein endotheli cell huvec dha prolifer apoptosi activ extracellular signalregul kinas erk signal pathway prolifer huvec inhibit dha apoptosi dha phosphoryl erk erk downregul mrna protein express erk erk huvec addit dha suppress transcript protein express erk erk downstream effector cfos cmyc electr cellsubstr imped sens realtim demonstr erk signal inhibitor pd compris antiprolif effect dha dha inhibit endotheli cell prolifer suppress erk signal pathway strengthen potenti dha angiogenesi inhibitor 
dimension stage breast breast dimension solid few spheric hypothes calcul greatest diamet not accur reflect volum dimension measur stage invas carcinoma measur cm less measur diamet note volum calcul geometr model spheric pi prolat spheroid pi oblat spheroid pi ellipsoid pi ellipsoid correct volum shape case stratifi tnm stage system differ mean volum calcul sphere ellipsoid subclass student test reclassif ellipsoid formula seventysix differ diamet six true sphere ident diamet mean volum ta tb tc demonstr statist signific overestim volum util sphere formula instead ellipsoid formula differ volum dramat diamet total move smaller subclass node patient volum demonstr greatest diamet poor reflect true volum lesion consist overestim volum ellipsoid formula accur calcul volum dimension util signific relev stage invas breast 
risk malign analges abus effect longterm intak aspirin nonsteroid antiinflammatori nsaid eg aspirin indomethacin report epidemiolog risk potenti malign effect nsaid preval abus mix analges aspirin phenacetin caffein codein analges abus autopsi compar control evid analges abus match sex age year autopsi perform abus risk malign compar control exclud patient urinari tract analges abus risk decreas statist signific effect patient result encourag prospect control risk patient
total intraven anesthesia patient complic myoton dystrophi total intraven anesthesia propofol fentanyl ketamin pfk patient complic myoton dystrophi case yearold femal underw hemithyroidectomi anesthesia induc slowli intraven ketamin propofol her tracheal intub perform smooth muscl relax anesthesia maintain propofol infus mgkgh ketamin infus mgkgh fentanyl microgram total she regain conscious minut after end propofol infus minut later her trachea extub troubl case yearold femal underw remov left parotid anesthesia induc slowli ketamin propofol intraven anesthesia maintain propofol infus mgkgh ketamin infus mgkgh fentanyl microgram total muscl relax surgic procedur anesthesia minut after end propofol infus her trachea extub nasogastr tube pull out her respir stop sudden she intub hour troubl case serum cpk level rectal temperatur stabl pfk choic patient myoton dystrophi
disappear toler interferon tnf athlet natur immunostimul effect nonspecif immunostimul basketbal player subject extens physic effort toÃ¥pa torf prepar ttp natur immunostimul appli oral tablet daili cycl separ hiatus blood sampl after ttp cycl after second hiatus whole blood assay spontan induc interferon ifn tnf level cytokin measur microbioassay ttp synthesi ifn tnf whole blood cultur after oral administraton ttp leukocyt athlet hyporeact ifn ttp lesser extent superinducera mixtur phytohemagglutinin bacteri lipopolysaccharid hyporeact state disappear spontan toler tnf did not ttp immunoglobulin igm igg acut phase proteinalphaantitrypsin late phase cytokin level earli immunoprophylaxi furthermor ifn tnf associ extens physic effort
redox cycl induc epiderm keratinocyt varieti compound util industri phenolformaldehyd resin paint lacquer cosmet pharmaceut skin exposur industri known skin rash dermal inflamm contact dermat leucoderma promot biochem mechan cytotox compound not well understood hypothes enzymat oneelectron compound result generat phenoxyl contributor cytotox effect phenoxyl readili thiol ascorb intracellular reduct eg nadh nadph regener parent compound henc compound undergo enzymat driven redoxcycl test hypothesi endogen thiol lipid peroxid total antioxid reserv normal human keratinocyt expos newli cisparinar acidbas procedur assay sitespecif membran phospholipid subtox microm phosphatidylcholin phosphatidylethanolamin not phosphatidylserin keratinocyt incub ascorbatepreload keratinocyt produc electron paramagnet resonancedetect signal ascorb redoxcycl oneelectron phenoxyl involv effect cytotox keratinocyt expos microm microm conclud subtox signific 
prime sensit alcohol diseas articl proceed symposium isbra meet yokohama japan chair dysregul tnf signal alcohol diseas peroxisom prolifer bezafibr prevent superoxid anion sinusoid after acut ethanol role kupffer cell gutderiv endotoxin alcohol injuri
phytoestrogen hormon replac sever effect classic hormon replac hrt challeng phytoestrogen soy red clover deriv advertis esr modul serm desir undesir estrogen effect evid case scarc climacter complaint did not effect propos effect mammari unproven indic putat effect cardiovascular system question fact estradiol whichlik isoflavonesincreas hdl decreas ldl appear not prevent arteriosclerosi human urogenit tract vagina soy red clover deriv effect
nonsteroid antiinflammatori systemat review metaanalysi anim laboratori regular nonsteroid antiinflammatori nsaid risk associ conduct systemat review metaanalysi publish januari deriv summari oddsratio or fix random effect model perform subgroup analys sourc heterogen report retrospect prospect aspirin report invers associ statist signific summari associ aspirin confid interv test homogen vari retrospect prospect measur exposur mixtur nsaid less consist epidemiolog evid strong consist laboratori evid underlin need addit epidemiolog confirm direct magnitud associ
red clover practic clinician view subject phytoestrogen against background controversi surround role hormon replac phytoestrogen deriv red clover help hot flush common menopaus complaint insuffici evid recommend bone protect women risk
anesthet manag propofol pheochromocytoma resect bispectr index monitor patient undergo pheochromocytoma resect propofol fentanyl anesthesia bispectr index bis monitor hypnot effect patient arteri blood propofol measur perform liquid chromatographi hplc compar estim blood until resect propofol infus rate hr after resect propofol dosag hr keep bis around rapid infus fluid norepinephrin requir maintain blood pressur after remov patient patient blood pressur maintain well rapid infus fluid vasopressor arteri blood propofol after resect equal estim blood vs microg patient rapid infus fluid patient rapid infus fluid arteri blood estim blood vs microg anesthet depth not estim accur hemodynam chang patient undergo pheochromocytoma resect bis monitor recommend adjust propofol dosag after pheochromocytoma resect
atherosclerosi longterm chronic diseas associ crp fibrinogen peripher origin effect coronari arteri diseas cad prevent requir agent act beyond lowdens lipoprotein cholesterollow appear comprehens address common clinic phenotyp cad risk patient st centuri syndrom type diabet low highdens lipoprotein cholesterol triglycerid dens lowdens lipoprotein proinflammatori procoagul state
general versus spinal anesthesia differ sedat patient undergo retropub prostatectomi result prospect random impact spinal anesthesia spa differ conscious sedat intraop postop outcom patient undergo retropub prostatectomi rrp organ confin pca total consecut patient pca undergo rrp random random general anesthesia patient lumbar lumbar interspac spa diazepam sedat agent spa propofol spa midazolam intraop periop paramet muscl relax throughout rrp not differ bleed spa regardless sedat patient report best postop satur percentag puls oximetri sedat score df df shortest wait postop hold area df lowest pain postop df frequenc flatus passag df patient abl carri out unassist ambul df conscious sedat coupl spa safe reliabl effect procedur patient undergo rrp propofol sedat agent offer advantag over type conscious sedat general anesthesia
consumpt fruit veget whole grain rich antioxid phytochem associ risk chronic diseas coronari heart diseas diabet alzheim diseas cataract agedrel declin exampl main antioxid phytochem grain human health corn zea may stapl food world antioxid activ corn type diphenylpicryhydrazyl free dpph scaveng activ total content tpc antioxid capac lipidsolubl acl absorb capac orac typic mutant genotyp typic waxi typic highamylos dpph scaveng activ min methanol extract hcl methanol extract corn dpph scaveng activ alkalin hydrolys corn tpc ferul equiv corn methanol hcl methanol extract tpc alkalin hydrolys ferul equiv corn acl trolox equiv corn methanol hcl methanol extract orac trolox equiv corn methanol hcl methanol extract orac alkalin hydrolys trolox equiv corn alkalin hydrolys corn phydroxybenzo vanil caffeic syring pcoumar ferul ocoumar level dpph scaveng activ tpc acl orac hcl methanol extract obvious methanol extract signific loss antioxid capac corn dri temperatur degre postharvest compar dri ambient temperatur degre alkalin hydrolys tpc acl orac compar methanol hcl methanol extract highamylos corn antioxid capac did typic nonmut corn genotyp
routin aspirin nonsteroid antiinflammatori primari prevent us prevent servic task forc recommend statement statement summar us prevent servic task forc uspstf recommend support scientif evid routin aspirin nonsteroid antiinflammatori primari prevent complet inform statement evid tabl avail accompani articl issu uspstf web site http wwwpreventiveservicesahrqgov uspstf redesign recommend statement feedback primari care clinician uspstf plan later new updat recommend statement easier read incorpor advanc uspstf methodolog recommend statement below interim version exist languag element new format definit grade element revis
secondari barrett esophagus celecoxib result random trial barrett esophagus premalign condit risk esophag adenocarcinoma diseas whose rapid aspirin nonsteroid antiinflammatori celecoxib decreas risk esophag effect longterm celecoxib patient barrett esophagus dysplasia barrett esophagus trial cbet phase iib multicent random placebocontrol trial celecoxib patient barrett esophagus low highgrad dysplasia patient random assign celecoxib placebo administ oral twice daili stratifi grade dysplasia primari outcom chang baselin proport biopsi sampl dysplasia celecoxib placebo arm secondari tertiari outcom chang histolog express level relev biomark statist test twosid april june patient regist cbet low highgrad barrett dysplasia random assign celecoxib placebo after differ median chang proport biopsi sampl dysplasia lowgrad median chang celecoxib interquartil iqr placebo iqr highgrad median chang celecoxib iqr placebo iqr stratum statist signific differ total surfac area barrett esophagus prostaglandin level celecoxib twice daili not appear prevent barrett dysplasia 
mechan proteoglycan aggreg degrad cartilag oncostatin potenti synergist differenti effect cytokin proteoglycan aggreg catabol cartilag bovin articular cartilag explant maintain organ cultur subject cytokin aggrecan link protein hyaluronan ha degrad effect hyaluronidas inhibitor apigenin cytokin mixtur cleavag aggrecan aggrecanas action appar abolish hyaluronidas inhibitor apigenin addit presenc osm low molecular aggrecan cytokin aggrecan cartilag take place via proteolysi aggrecan core protein via depolymer ha latter induc osm osm associ joint inflamm particip account rapid loss aggrecan articular cartilag arthritid compar osteoarthr
risk chronic ill oper medic case control result melbourn associ risk chronic ill oper medic case age sexmatch control deriv larg comprehens populationbas conduct melbourn australia statist signific deficit case hypertens heart diseas stroke chronic chest diseas chronic arthriti statist signific excess haemorrhoid case differ consist colon rectal male femal statist signific differ twice breast case control uterin case control statist signific deficit case aspirincontain medic supplement consist colon rectal male femal statist signific excess larg bowel polypectomi case model signific associ simultan logist regress equat indic hypertens heart diseas chronic arthriti aspirin independ effect consist colon rectal male femal effect independ risk describ melbourn 
lung regular aspirin nonaspirin nonsteroid antiinflammatori lung lead death us evid risk site associ aspirin asa nonaspirin nonsteroid antiinflammatori nansaid object associ regular asa nansaid lung hospitalbas casecontrol case lung control noncanc diagnos asa nansaid regular occur last month logist regress estim oddsratio oddsratio confid interv regular asa correspond estim regular nansaid evid decreas risk strata age sex year educ interview year associ strata durat recenc cigarett smoke status packyear cigarett smoke histolog type produc or differ hypothesi regular asa nansaid risk lung not support 
patient prefer evid aspirin celecoxib risk crc harm effect patient prefer celecoxib aspirin particip complet computerbas patient decisionmak questionnair educ compon outlin benefit harm celecoxib aspirin condit take celecoxib take aspirin male femal take aspirin patient risk myocardi infarct gastrointestin event primari reason unwilling take celecoxib aspirin subject not take after benefit harm particip six like take aspirin celecoxib serv inform physician research variabl patient prefer crc 
polybromin diphenyl ether pbdes risk thyroid thyroid report world unit state past decad evid demonstr polyhalogen hydrocarbon phah polybromin diphenyl ether pbdes alter thyroid hormon homeostasi thyroid dysfunct few conduct test exposur pbdes phah risk thyroid hypothes exposur phah pbdes risk thyroid explain thyroid past decad variat result differ individu suscept pbdes phah thyroid hypothesi lead improv role pbdes phah thyroid tumorigenesi real mean prevent dead diseas
monitor exposur infant pollut hous dust health risk babi pollut hous dust greater adult young ingest dust up ten vulner exposur hous dust main exposur sourc infant allergen lead pbdes well sourc exposur pesticid pah gramneg bacteria arsenic cadmium chromium phthalat edc mutagen carcinogen median upper percentil hous dust lead pesticid pah exceed healthbas standard north america earli contact pollut young associ rate chronic ill asthma loss intellig adhd children adult potenti infant live area soil contamin automot industri emiss protect improv home clean hand wash babi live hous built prospect need protect against lead exposur home built even lead exposur risk pollut hous dust soil near hous infant exposur lifetim health cost improv earli learn adult intervent rapid payback larg evid home visit exposur children poor control asthma trigger return invest yr health cost tool famili home visit design dust exposur vacuum cleaner dirt finder hepa filtrat allergi control bed cover highqual door mat hepa air filter infant receiv exposur pollut dust home where spend where famili mitig control normal vacuum clean allow deep dust build up carpet where brought surfac becom airborn result activ carpet vacuum dirt finder allow famili threespot test monitor deep dust reinforc good clean habit motiv famili receiv home visit train outreach worker monitor dust exposur wk cost visit low reduct risk achiev improv home clean result famili receiv home visit mhes chws believ proven intervent exposur infant pollut hous dust recogn much learn improv effect 
effect propofol haemodynam propofol probabl popular intraven anaesthet daili practic known associ dosedepend cardiovascular compromis effect singl dose propofol cardiovascular eightysix asa ii patient sex schedul elect thorac surgeri enrol midazolam premed patient receiv epidur paravertebr cathet surgeri swanganz cathet map co svi pap pcwp svri pvri lvswi rwswi cpp measur after propofol microg fentanyl spontan respir propofol heart rate pap pvri pcwp decreas map ci svi lvswi rvswi cpp decreas svri unchang result indic propofol moder compromis cardiac contractil afterload right ventricl signific effect coronari perfus pressur cardiovascular compromis clinic insignific caution requir propofol administ larger dose
acut postischem esr agonist esrbeta agonist improv myocardi recoveri after ischemia reperfus injuri femal heart demonstr improv recoveri compar male protect role estrogen acut postischem betaestradiol attenu myocardi dysfunct unknown esr er mediat acut cardioprotect hypothes postischem infus esr agonist propylh pyrazoletriyl trisphenol ppt esr agonist bishydroxyphenyl propionitril dpn improv myocardi after injuri isol perfus heart langendorff adult male subject minut ischemia minut reperfus heart per random infus perfus ppt dpn nmol throughout reperfus after heart tissu tnf tnf interleukin il beta vascular endotheli growth vegf lactat dehydrogenas ldh postischem nmol ppt improv myocardi addit nmol dpn myocardi recoveri after injuri maximum benefit nmol dose trend level ldh note dpn ppttreat after injuri ppt dpn myocardi tnf ilbeta level myocardi vegf note ppttreat compar control esr esr involv mediat induc rapid cardioprotect after injuri er subtyp benefit male femal myocardi ischemia
mass balanc pop hazard municip solid wast inciner amount differ persist organ pollut pop input wast inciner compar output case rotari kiln inciner hazard wast grate furnac inciner municip solid wast msw grate furnac coinciner plastic wast electr electron equip weee automot shredder residu asr msw mass balanc pcbs rotari kiln indic pop destroy effect inciner grate furnac sink sourc pcdd fs pcbs depend inciner wast compar total amount pop input output methodolog wherebi amount pop weigh minim risk dose mrds potenc inciner pcdd fs pcbs polyaromat hydrocarbon pah main contributor total weigh pop output msw pcdd fs pbdd fs polybromin diphenyleth pbdes main contributor weigh pop input ratio weigh popinput over output clear indic rotari kiln inciner hazard wast weigh pop sink grate furnac inciner msw weigh pop sink sourc depend popconcentr wast differ output input limit eg asr plastic weee pbdes pcbs coinciner grate furnac clear weigh pop sink
angiotensin convert enzym inhibitor protect against cardiac complic anthracyclin doxorubicin dox despit cardiac anthracyclin chemotherapeut agent play role breast angiotensinconvert enzym inhibitor acei protect against cardiac patient receiv dox total patient receiv dox mason comprehens clinic univers minnesota multig blood pool imag muga scan echocardiogram perform review patient absolut drop eject fraction ef below compar did not declin ef impact patient variabl concurr medic ef drop logist regress median age year old femal diagnosi breast lymphoma spite baselin ef patient patient signific drop ef dox adjust age oddsratio ef drop associ acei acei protect effect cumul dox dose betablock aspirin did not appear predict protect not statist signific acei dox protect against dox warrant 
risk colon associ genet polymorph smad genomewid associ gwas smad associ singl nucleotid polymorph snp smad gene rs rs rs gwas larg populationbas casecontrol colon rs associ statist signific risk colon oddsratio confid interv ci linear trend tt genotyp compar cc genotyp cc genotyp rs snp invers associ colon ci tt genotyp signific differ associ polymorph stratifi age site sex famili histori oddsratio smad colon individu report aspirin nonsteroid antiinflammatori ci cc genotyp rs polymorph ci tt genotyp rs polymorph result compar oddsratio ci rs ci individu did not aspirin nonsteroid antiinflammatori signific associ rs snp snps smad result corrobor gwas colon point smad reinforc interest snps gene
cerb express esr progesteron receptor prognost paramet endometri carcinoma endometri carcinoma ec common malign femal genit tract immunohistochem ihc analys er pr cerbb perform ec case detect stain erbb case statist signific cerbb pr not statist signific cerbb stain er not statist signific differ cerbb histolog grade level cerbb grade case not statist signific cerbb menstrual status myometri invas lymph node status stage surviv addit evid potenti prognost role cerbb prospect control requir valid clinic 
effect electroacupunctur differ acupoint sevofluran anesthesia patient undergo resect supratentori effect electroacupunctur ea differ acupoint sevofluran anesthet requir resect supratentori speed postoper recoveri total case supratentori resect patient random equal alloc general anesthesia ga eaproxim acupoint eapa eadist acupoint eada supratentori patient anesthet sevofluran surgeri proxim acupoint fengchi gb tianzhu bl cuanzhu bl yuyao exhn formesr acupoint lattesr acupoint penetr needl distant acupoint hegu li waiguan te jinmen bl taichong lr zusan st qiuxu gb craniotomi ea hz hz toler electr strength begin anesthesia till end surgic oper patient anesthet inhal propofol sufentanil microg vecuronium bromid maintain sevofluran endtid sevofluran minimum alveolar mac bispectr index bis speed recoveri record ga endtid anesthesia mainten timepoint post skull drill dura incis intracrani oper eapa timepoint post skull drill skull open dura incis intracrani oper eada mac sevofluran timepoint skull drill eada skull open dura incis intracrani oper dura sutur eapa eada ea proxim distant acupoint expir mac sevofluran anesthesia mainten acceler recoveri after ceas anesthesia supratentori resect patient
nonsteroid antiinflammatori risk associ nsaid epidemiolog evid effect medic hundr twentyseven subject Ã¢melanomafre control complet structur interview risk unadjust oddsratio oddsratio nonaspirin nsaid ci subject control after adjust risk ci aspirin user unadjust ci adjust ci pilot evid signific associ analges risk potenti confound conflict report literatur metaanalysi appropri
subchron oral cardiovascular safeti pharmacolog natur occur prevent activ subchron oral cd receiv daili gavag dose beagl dog receiv daili capsul dose induc minim consist doserel reduct bodi gain femal sex dog statist signific bilirubin level dose clinic hematolog ophthalmolog neurotox batteri organ gross patholog biolog signific evid dose cardiomyopathi microscop chang histopatholog chang dog limit minim infiltr kidney urinari not toxicolog signific cardiovascular safeti pharmacolog telemetri dog reveal evid bodi effect advers effect level noael dog appar cardioprotect activ demonstr potenti activ extend beyond efficaci prevent
phytochem antioxid capac decoct adenanthera pavonina thespesia populnea decoct prepar bark adenanthera pavonina thespesia populnea herbal formul prescrib sri lanka patient year design phytochem antioxid properti total flavonoid folinciocalteau aluminum chlorid colorimetr gallic content decoct highperform liquid chromatographi antioxid properti diphenylpicrylhydrazyl dpph assay nitric scaveng assay deoxyribos power decoct total flavonoid gallic decoct gallic equival epigallocatechingal equival ec dpph nitric scaveng deoxyribos assay power decoct decoct prepar pavonina populnea nutraceut
nonaspirin nonsteroid antiinflammatori primari nongastrointestin summari evid evid aspirin effect pharmacodynam nonsteroid antiinflammatori nsaid site discuss literatur uncertainti actual effect nsaid aspirin nongastrointestin summar best avail evid primari effect nonaspirin nsaid nongastrointestin inclus criteria narrat systemat review clinic guidelin not primari control effect nonaspirin nsaid prevent nongastrointestin healthi individu retriev databas guidelinesgov bmj clinic evid trip databas uptod medlin cancerlit embas cinahl isi web scienc scopus independ review elig extract review crosscheck nondupl articl elig report conflict result statist signific associ nonaspirin nsaid risk lung ovari skin head neck risk renal cell carcinoma statist signific methodolog limit confid result did not suffici evid support nonaspirin nsaid primari varieti nongastrointestin scenario caution routin nonaspirin nsaid addit wellconduct control evid issu concern risk exposur
histogram wholeles enhanc differenti clear cell papillari subtyp renal cell compar histogram voxelbas wholeles wl enhanc qualit regionofinterest roi enhanc discrimin renal cell rcc subtyp clear cell rcc ccrcc papillari rcc prcc institut review boardapprov hipaacompli retrospect patient underw magnet reson mr imag prior surgeri rcc januari januari threedimension fatsuppress tweight gradientecho corticomedullari phase acquisit after agent transfer workstat autom registr semiautom segment rcc perform percent enhanc comput pervoxel sipost sipr sipr where sipr sipost indic signal intens after enhanc wl quantit paramet mean median third quartil enhanc histogram distribut paramet kurtosi skew comput lesion wl enhanc paramet compar roibas qualit regard diagnost accuraci interread agreement differenti ccrcc prcc prccs ccrccs patholog ccrcc wl mean median third quartil enhanc compar prcc hade kurtosi skew third quartil enhanc accuraci area curv discrimin ccrcc prcc accuraci qualit not roi enhanc wl enhanc paramet interread agreement compar roi enhanc qualit discrimin ccrcc prcc wl enhanc histogram feasibl potenti differenti ccrcc prcc
tapentadol er manag moder sever chronic pain chronic noncancerrel pain larg proport adult popul difficult manag effect opioid analges reliev chronic pain differ etiolog opioid associ effect patient qualiti life lead complianc treatmenttapentadol central act analges mechan action Ã®opioid receptor agon norepinephrin reuptak inhibit avail extendedreleas formul manag chronic pain review efficaci tapentadol extend er manag moder sever chronic nocicept neuropath pain efficaci result summar phase tapentadol er patient moder sever chronic osteoarthr knee pain clinicaltrialsgov nct nct low back pain nct pain diabet peripher neuropathi dpn nct oneyear phase tapentadol er patient moder sever chronic osteoarthr pain low back pain nct pool patient osteoarthr knee pain low back pain summari compar toler tapentadol er activ compar oxycodon control cr tapentadol er bid effect manag moder sever chronic osteoarthr knee pain low back pain pain dpn tapentadol er bid compar pain relief oxycodon hcl cr bid chronic osteoarthr knee pain low back pain over up year tapentadol er bid associ improv toler profil gastrointestin toler profil rate discontinu advers eventrel discontinu compar oxycodon hcl cr bid over up year patient osteoarthr knee pain low back pain differ design durat phase limit efficaci result nevertheless demonstr broad tapentadol er differ type nocicept neuropath pain tapentadol er bid moder sever osteoarthr pain low back pain pain dpn efficaci oxycodon hcl cr bid patient osteoarthr low back pain tapentadol er associ gastrointestin toler complianc oxycodon cr tapentadol er option longterm manag chronic pain
effect fibrin clot inhibitor immunomodulatori efficaci bacillus calmetteguÃ£rin nonmuscleinvas differ clinic outcom nonmuscleinvas patient take fibrin clotinhibit fci medic aspirin clopidogrel warfarin receiv bacillus calmetteguÃ£rin bcg compar counterpart not take anticoagul review boardapprov databas queri patient receiv cours bcg patient minimum month followup recurrencefre surviv rfs cystectomyfre surviv surviv diseasespecif surviv kaplanmei stratifi fci status logist regress predict rate bcg fci status patient patient take aspirin clopidogrel warfarin bcg specif fci associ differ cystectomyfre surviv surviv diseasespecif surviv likelihood recurr warfarin clopidogrel rfs patient take aspirin trend rfs not statist signific pÃ¢ contrari postul inhibitori molecular effect fci bcgbind activ did not signific impact bcg efficaci concomit medic bcg aspirin potenti toÃ¢ bcg warrant 
exfoli sulfon graphen sheet sgss altern graphen graphen deriv synthes particl nontox across Ã®g intern sgss mean optic electron microscopi not highresolut transmiss scan electron microscopi reveal variant intern behavior where sgs becam compartment tight bundl cellular organell abil 
aspirin primari prevent evid aspirin effect primari prevent cardiovascular event chang way inde evid longterm aspirin patient even known cardiovascular diseas theoret argument aspirin prevent cardiovascular event propag thrombus counter evid plaqu haemorrhag vasa vasorum plaqu growth instabl evid aspirin serious bleed brain gut aspirin detract benefit definit cardiovascular benefit angiotensinconvert enzym inhibitor metaanalysi prone bias favour aspirin public bias bias trial endpoint bias interpret metaanalysi not reli prefer adequ power clinic trial unfortun benefit aspirin exist larg inde requir demonstr benefit outweigh risk evid aspirin intrigu reli trial conduct decad ago aspirin dose reliabl evid aspirin fashion dose benefit common clinic set
despit rise public awar rate white popul rise constant decad systemat improv knowledg biolog pigment cell everyday apigenin quercetin curcumin potenti qualiti compound vari result earli report activ statin fibrat not prove result random clinic trial casecontrol influenc nsaid risk not confirm antitumor activ clinic trial involv care target popul well identif specif biomark prognost predict essenti 
review summar evid relev hypothes mode action moa ppar activ induc rodent hepatocarcinogenesi gap knowledg moa chemicalspecif mechanist support concord tempor doserespons key event associ ppar activ phthalat ester plastic diethylhexyl phthalat dehp gemfibrozil biolog plausibl human hypothes key event rodent moa ppar activ unlik induc human toxicodynam biolog differ minim effect growth pathway hepatocellular prolifer human hamster guinea pig cynomolg monkey appropri human surrog mice overlap dose level panel conclud signific quantit differ ppar activ induc effect format exist rodent human quantit differ workgroup felt rodent moa not relev human member conclud moa unlik relev human differ level confid perceiv limit quantit mechanist knowledg differ panel member strong support cannot preclud absenc effect unlik exposur scenario
statin aspirin prevent hepatocellular carcinoma level evid analys larg cohort statin aspirin risk hepatocellular carcinoma hcc natur flaw confound indic immort bias review clinic trial conduct cardiovascular domain effect statin type convinc evid need support potenti prevent effect aspirin hcc clinic trial achiev patient risk
influenc supplement systemat review second common after lung evid lifestyl play crucial role biolog tumorigenesi good model look agent diseas preval slowli natur long latenc period agent gain consider attent receiv much public media review key evid avail potenti nutrient methodolog review involv pubm search keyword nutrit epidemiolog prevent red meat fat milk intak minimis appear risk fruit veget prevent need draw solid clarifi role patient diagnosi selenium supplement cannot advoc prevent inde dose associ wors prognosi specif evid benefit probiot prebiot wealth evid avail recommend randomis control trial requir need care design confound heterogen popul
separ chalcon angelica keiskei highspe countercurr chromatographi angelica keiskei shinsun cho edibl plant prevent effect hypertens coronari heart diseas bioactiv chalcon shinsun cho xanthoangelol hydroxyderricin separ simultan highspe countercurr chromatographi twophas solvent system compos nhexaneetoacmeohho nonconsum solvent fraction sephadex lh column chromatographi conduct prestep xanthoangelol puriti nm hydroxyderricin puriti nm puriti nm success purifi extract keiskei structur compound confirm cnmr 
effect stellat ganglion block hemodynam chang intrapulmonari shunt periop patient esophag studyÃ¢ effect stellat ganglion block sgb hemodynam chang intrapulmonari shunt onelung ventil olv thirti asa iii patient undergo elect esophag surgeri random general anesthesia general anesthesia sgb patient receiv left sgb radial arteri cannul arteri blood pressur abp monitor blood sampl swanganz cathet pulmonari arteri via right intern jugular vein local anesthesia ecg map hr cvp continu cardiac output cco index bis continu monitor anesthesia general anesthesia induc propofol sufentanil Ã®g rocuronium endobronchi occlud place blind after tracheal indub correct verifi auscult fiberopt bronchoscopi patient mechan ventil ventil condit fio vt respiratori rate adjust maintain petco mmhg twolung ventil tlv olv anesthesia maintain continu infus propofol kgÃ¢h sufentanil Ã®g kgÃ¢h vecuronium kgÃ¢h bis maintain blood sampl taken radial arteri sg cathet blood gas interv spontan breath patient awak min after tracheal indub min after patient place later min after min after rib brace min cours olv lung ventil min qs qt calcul svri map hr compar qs qt after patient place later olv calcul qs qt tÃ¢ pao after olv start reach lowest level gradual signific differ qs qt pao point sgb effect suppress work stabl blood dynam not qs qt arteri olv sgb safe techniqu anesthesia general thorac surgeri
mediterranean low grade inflamm result molisani low grade inflamm rais absenc overt symptom recogn risk chronic diseas cardiovascular cerebrovascular neurodegen diseas low grade inflamm mitig health promot behaviour healthi eat pattern physic activ bodi mainten tobacco cessat date larg scale focus circul littl evid avail cellular biomark molisani prospect cohort recruit men women age year general popul molis region southern italian area purpos genet environment risk protect cardiovascular cerebrovascular diseas cohort score low grade inflamm plasmat creactiv protein cellular leukocyt platelet count granulocyt ratio biomark propos valid score account effect overcom potenti bias link multicollinear variabl notic molisani address tradit mediterranean platelet leucocyt count cellular biomark low grade inflamm review paper discuss main deriv molisani associ low grade inflamm mediterranean eat pattern emphasi associ 
effect statin aspirin patholog complet rate neoadjuv chemoradi rectal retrospect potenti impact statin aspirin acut patholog complet pcr rate rectal patient receiv neoadjuv longcours radiat lcrt concurr retrospect review perform patient undergo neoadjuv lcrt rectal adenocarcinoma region servic septembesr june demograph detail date radiolog tnm stage diagnosi medic taken rt lcrt surgic histolog pcr lcrt neoadjuv lcrt administ patient rectal period concurr omit signific comorbid tnm stage radiolog diagnosi patient lcrt take statin take aspirin patient achiev pcr surgeri logist regress pcr not associ statin aspirin nsaid tstage nstage signific correl statin aspirin rectal actuari maximum rectal not differ statin user nonus larger retrospect seri did not improv pcr rate statin aspirin rectal patient undergo lcrt potenti benefit set best prospect larg random trial
sclerosi ms demyelin neurodegen diseas neurolog disabl young adult indic proremyelin effect potenti addit benefit sclerosi
proinflammatori cytokin senior hors vitro senior hors exhibit chronic lowgrad inflamm system term inflammag inflamm associ afflict common hors lamin osteoarthr common nonsteroid antiinflammatori nsaid flunixin meglumin phenylbutazon longterm nsaid result effect bioactiv curcuminoid quercetin pterostilben hydroxypterostilben heparin blood via jugular venipunctur senior hors peripher blood mononuclear cell pbmc isol ficol densiti gradient pbmc incub curcuminoid quercetin pterostilben hydroxypterostilben dissolv dmso achiev aforement pbmc last incub period phorbol myrist acet pma ionomycin brefeldin bfa pbmc stain intracellular via flow cytometri oneway varianc anova viabil pbmc incub compound compar pbmc incub dmso alon control cell viabil did not differ control viabil did not differ control perform effect common nsaid cytokin senior hors vitro chronic inflamm hors
updat evid endoscop resect earli japan endoscop resect earli egc play central role egc japan still room improv necessari summar knowledg japan improv conduct pubm search relev articl year until septembesr keyword endoscop endoscop submucos dissect endoscop mucos resect polypectomi filter articl type clinic clinic trial articl automat keyword polypectomi articl endoscop mucos resect articl endoscop submucos dissect articl endoscop articl relev articl japanes chosen articl categor equip prepar sedat complic prevent therapeut outcom co insuffl propofol sedat prevent postendoscop submucos dissect esd ulcer bleed achiev postesd ulcer heal intens longterm outcom endoscop mucos resect esd report favor outcom endoscop resect egc still ideal pursu reliabl safer faster minim invas 
variat applic low dose rate intracavitari brachytherapi cervic prospect know effect variat applic dose receiv volum organ rectum correl variat clinic outcom patient histolog proven cervic undergo intracavitari brachytherapi icbt octobesr decembesr subject pair orthogon xray film taken prior load sourc after remov sourc patient up per rtog criteria median durat insert hour median up period month translat variat applic patient sd patient later anteroposterior direct rotat variat degre sd patient transvers sagitt plane detail sourc movement chang median dose point point point rectum rectum rectal variabl rectal point rectal pearson later displac anteroposterior displac rectal beta angl geometr icbt applic structur vari cours low dose rate brachytherapi sourc movement result signific dose alter term rate complic impact cure rate need futur
polyphenolinspir facil construct smart assembl atp phrespons mr optic imag phototherm smart assembl attract interest area novel stimulirespons theranost commerci avail natur tannic ta iron nanoparticl fe nps util model construct smart magnet assembl polyphenolinspir npsphenol selfassembl nps ta interest magnet assembl special disassembl adenosin triphosph stronger affin fe nps ta replac surfac coordin ta disassembl facilit environ henc remark chang transvers relax potent turnon fluoresc fl signal assembl specif sensit magnet reson fl dualmod imag phototherm after intraven inject assembl success employ work not selfassembl nps open new insight facil construct versatil assembl extend biomed applic
novel polymorph tmema gene system lupus erythematosus chines han popul associ singl nucleotid polymorph snps six gene irf tmema ikzf ormdl gsdmb zpbp system lupus erythematosus sle chines han popul sampl carri out casecontrol patient sle healthi control autoimmun diseas genet isol blood subject standard phenolchloroform tagsnp genotyp panel han chines beij hapmap project haploview program genotyp assay conduct sequenom massarray iplex gold platform frequenc allel genotyp calcul haplotyp perform genotyp frequenc rs rs differ sle patient healthi control compar common homozyg genotyp ct genotyp rs ac genotyp rs risk sle snps locat tmema gene associ sle suscept chines han popul
tpmt comt acyp genet variant paediatr patient cisplatin induc ototox cisplatin ototox children catecholomethyltransferas comt thiopurin methyltransferas tpmt aycp genet variant associ ototox contradictori associ care phenotyp cohort uk children perform systemat review metaanalysi recruit children uk centr retrospect cohort design particip clinic phenotyp care genotyp perform acyp rs tpmt rs rs rs comt rs rs variant ctcae grade hear loss worst ear ear chang grade hear loss diagnos worst ear versus ear tpmt comt singlenucleotid polymorph snps associ ototox acyp snp rs associ ototox worst ear metaanalysi report pool oddsratio oddsratio statist signific comt snp rs confid interv acyp snp rs confid interv associ acyp polymorph cisplatin induc ototox not tpmt comt metaanalysi statist signific comt rs acyp rs snps grade hear children asymmetr hear loss requir addit clarif
effect hydroethanol root extract zanthoxylum zanthoxyloid hematolog paramet cyclophospamid anim pretreat oral dose extract coadminist cyclophosphamid ld extract antioxid enzym assay cat anim cp compar cp cp gpx cp compar cp control sod cp compar control wbc cp cp cp cp administ compar control ldl chol cp cp
childhood measur adipos young girl compound environment potenti endocrinedisrupt capabl longitudin associ childhood exposur manmad natur sourc measur adipos girl enrol research program baselin age year urinari creatinin bodi mass index height waist circumfer percent bodi fat measur annual semiannu linear mixedeffect regress estim baselin tertil chang girl adipos measur age year enterolacton invers associ bodi mass index waist circumfer percent bodi fat dichlorophenol associ measur nonmonoton associ triclosan girl adipos effect modif baselin overweight status triclosan associ adipos overweight girl result exposur specif childhood influenc adipos adolesc
primari biliari cholang advanc manag diseas primari biliari cholang known primari biliari cirrhosi rare diseas women fifth seventh decad life chronic autoimmun diseas damag interlobular bile duct lead ductopenia chronic cholestasi bile retent even diseas usual long asymptomat phase slow patient faster cirrhosi complic year mortal greater diseas human immunodefici virus virus coinfect breast ursodeoxychol avail today even effect counteract diseas patient approxim not abl decreas effect alkalin phosphatas surrog diseas activ obetichol receiv european medicin agenc condit approv add patient non respond intoler ursodeoxychol paper illustr opinion work compos clinic pharmacologist gastroenterologist hepatologist specif expertis primari biliari cholang patient associ state art futur perspect diseas manag agreement document reach expert meet
sedat endoscopi room oper room endoscop submucos dissect neoplasm upper gastrointestin tract perform compar safeti sedat endoscop submucos dissect esd endoscopi room versus oper room total patient gastrointestin underw esd januari decembesr retrospect review patient underw esd endoscopi room propofol versus oper room propofol patient procedur characterist advers event outcom compar patient characterist age comorbid size histolog not differ esd procedur compar anesthesia equival signific differ advers event esd procedur desatur occur recoveri after esd longer vs min decreas desatur rate shorter recoveri after esd advantag sedat oper room propofol compar sedat endoscopi room warrant advantag safe effect esd upper gastrointestin neoplasm oper room
oncolog communiti reject bias come repurpos measur propos combat challeng financi care strategi lowerpr instead expens altern oncolog communiti ignor readili reject cheaper care compar expens altern commentari exampl lowerpr reject ignor oncolog communiti expens where persist optim despit clinic trial result argu held rigor standard not skeptic absenc sound evid suspens prematur judgement happen case repurpos 
induc senesc compound senolyt face nrfactiv adjuv reactiv senesc clearanc senesc intervent describ vitro vivo effect cellular senesc light avail literatur conclud mean potenti adjuv natur compound human take account exist few clinic trial uncertain result need therapeut potenti compound display senolyt activ
endocrin disrupt compound vertebr neural network multielectrod array bisphenol bisphenol bpa bisphenol bps polymer agent plastic numer everyday classifi endocrin disrupt compound edc estradiollik properti longterm exposur edc even low dose link health defect behavior disord infertil greater vulner earli development period effect bpa neuron vitro neuron network deriv earli chick embryon brain model system avail market variat electrod type qualiti electrod array softwar basic principl across differ system limit twodimension vitro cultur mea system improv enabl vivo network activ brain slice detail protocol embryon exposur record neuron network activ synchroni result
intak food sourc mexican teacher cohort descript intak flavonoid publish europ usa insuffici still avail latinamerican countri where differ type food consum differ habit goal crosssect estim intak grand total total per subclass individu compound main food sourc mexican women mexican teacher cohort femal teacher year older twelv state mexico urban rural area period valid ffq individu intak estim food phenolexplor databas median total intak baja california lowest yucatan main consum Ã¢Ã¢ total flavonoid Ã¢Ã¢ intak subclass stilben lignan insignific coffe fruit food sourc flavonoid intak total differ individu estim fortytwo consum amount larg consum caffeoylquin ferul hesperidin proanthocyanidin larg heterogen intak individu mexican women moder heterogen across mexican state main food sourc differ state
mucosa human detrusor impair contract betaadrenoceptormedi relax elucid impact mucosa detrusor muscl forc contract stimulatori condit relax catecholamin detrusor tissu patient undergon cystectomi strip intact mucosadenud muscl set up forc measur prepar precontract kcl carbachol electricfield ef precontract strip relax catecholamin absenc presenc subtypeselect betaadrenoceptor ar blocker cgp betaar ici betaar betaar forc kcl Ã¢mm carbachol Ã¢Ã®m ef larger absenc mucosa intact muscl strip forc contract mucosadenud strip detach urothelium incub chamber low intact strip noradrenalin relax precontract detrusor strip larger extent denud intact strip cgp did not noradrenalin induc relax denud intact strip ici did not influenc noradrenalin induc relax denud strip abolish differ denud intact strip antagon relax effect noradrenalin slight smaller intact denud strip mucosa human detrusor strip impair forc kcl carbachol ef mucosa blunt relax effect catecholamin latter effect not involv betaar betaar betaar mediat relax human detrusor
disord innat human age effect nutraceut declin age account risk infect chronic diseas autoimmun human innat adapt compromis age peopl attempt correct dysfunct goal modern medicin review special emphasi place age innat potenti modifi impair innat princip nutraceut illustr micronutri preprobiot elder clinic trial abov scanti
spot novel streamlin microarray platform cellular trna level place transfer rna trna housekeep molecul heart fundament cellular embryon discoveri conting concomit abl deliv highqual trna profil describ proof concept escherichia coli coli origin trna platform name spot streamlin platform trna approach compris step coli cultur spike radioact orthophosph second label total rnas trizolextract third rna sampl hybrid inhous print microarray spot signal proxi trna level quantifi phosphorimag featur reproduc specif trna subpopul dynam sensit overexpress specif trna spot not requir amplif postextract label adapt organ modular easili streamlin popular techniqu polysom fraction profil trnas interact ribosom activ engag translat biolog relev discuss regard codon usag trna gene copi genom
influenc freezethaw cycl rna integr gastrointestin match adjac tissu compar rna express profil adjac noncancer tissu research highqual rna essenti consist reliabl result identif impact freezethaw cycl qualiti rna pair adjac tissu still influenc freezethaw cycl rna integr histomorpholog pair adjac noncancer tissu gastrointestin match adjac noncancer tissu frozen thaw twice extract rna total rna sampl extract trizol reagent rna integr rna integr rin agil bioanalyz light microscopi tissu morpholog rin sampl tend correl frequenc freezethaw rin cutoff rna extract tissu not qualifi after freezethaw moreov rna extract adjac noncancer tissu nonqualifi rin score after freezethaw except tissu microscop sampl display qualifi tissu morpholog regardless freezethaw frequenc freezethaw rna integr not tissu morpholog gastrointestin pair adjac noncancer tissu furthermor rna extract adjac noncancer tissu easili degrad tissu
prevent supplement fresh preserv peach attenu ccl induc inflamm tissu damag elabor compar prevent effect differ peachderiv preserv fruit syrup preserv pulp peach ppp fresh peel pulp peel fresh pulp peach fpp model renal inflamm induc carbon tetrachlorid ccl tissu damag carbonyl thiobarbitur reactiv sulfhydril antioxid enzym activ catalas superoxid dismutas paramet tnf tnf interleukin il beta level receptor advanc glycat endproduct rage nuclear nfkbp immunocont demonstr peel ppp fpp daili oral gavag confer protect against ccl induc antioxid enzym antioxid antiinflammatori effect associ abund carotenoid peachderiv enrich freshfruitderiv prepar peel fpp ppp result evid supplement peach protect against organ interest candid antioxidantenrich food
septic endarter intraarteri cathet outbreak ii risk clinic featur manag iii guidelin prevent cluster case staphylococc septic endarter origin percutan insert brachial arteri cathet region prompt epidemiolog clinic bacterem infect associ therapeut modal nine case over year period catheter staphylococcus aureus cluster discontinu hexachlorophen scrub extrem prior cannul phagetyp case patient own strain staphylococcus infect produc distinct clinic syndrom facilit implic cathet genesi fever occur patient receiv intraarteri earli local pain hemorrhag osler node distal later local inflamm purul sign system sepsi less equal durat cannul did not influenc suscept infect difficult cannul need reposit cathet prior radiat leukopenia less hypoalbuminemia less associ septicemia month implement specif control measur catheterrel septicemia catheter less guidelin prevent manag infect 
ntp toxicolog carcinogenesi pentachlorophenol cas feed pentachlorophenol herbicid algicid defoli wood preserv germicid fungicid molluscicid pentachlorophenol nomin nation institut carcinogen test widespread wood preserv potenti enter environ pentachlorophenol residu soil water air sampl food human anim tissu bodi fluid likelihood bioaccumul environ pentachlorophenol persist soil halflif up year technic report result year pentachlorophenol perform ntp bcf mice male femal expos pentachlorophenol approxim pure feed year genet toxicolog conduct vitro salmonella typhimurium cultur chines hamster ovari cell vivo mous bone marrow cell male femal ppm pentachlorophenol equival averag daili dose approxim pentachlorophenol bodi male femal feed except male femal expos ppm surviv until end final mean bodi bodi gain male expos ppm femal expos ppm less control expos ppm lost feed consumpt ppm male less control throughout absolut ppm male expos femal greater control compar control minim mild hepatocyt degener male femal expos ppm greater centrilobular hepatocyt hypertrophi ppm year male femal fed ppm pentachlorophenol equival averag daili dose approxim stopexposur male femal receiv ppm equival feed after anim receiv undos feed remaind year male femal control ppm month surviv bodi feed consumpt year surviv ppm male greater control mean bodi ppm male femal general less control exposur pentachlorophenol discontinu mean bodi ppm male femal control end mean bodi control general feed consumpt expos control patholog year malign mesothelioma origin tunica vaginali greater ppm male control exceed histor control nasal squamous cell carcinoma control male ppm male ppm male ppm male year ppm male exceed histor control month interim centrilobular hepatocyt hypertrophi ppm male femal hepatocyt cytoplasm vacuol ppm male greater control year nonneoplast lesion hepatodiaphragmat nodul hepatocyt cystic degener expos ation expos male basophil foci ppm male compar control genet toxicolog pentachlorophenol percnt pure test salmonella typhimurium strain ta ta ta ta dose up mug plate induc hamster signific revert coloni strain activ test cytogenet effect cultur chines hamster ovari cell pentachlorophenol weak sister chromatid exchang chromosom aberr sister chromatid exchang test weak mug absenc sister chromatid exchang note chromosom aberr test pentachlorophenol induc signific frequenc aberr cell presenc dose mug vitro result test chromosom aberr frequenc micronucl erythrocyt note bone marrow male mice administ pentachlorophenol intraperiton inject hour interv dose administ mice lethal condit year feed evid carcinogen activ pentachlorophenol male femal fed ppm evid carcinogen activ pentachlorophenol male feed ppm year control feed year stopexposur mesothelioma nasal squamous cell carcinoma evid carcinogen activ pentachlorophenol femal feed ppm year maintain control feed year stopexposur male femal recov transitori reduct bodi gain end year male surviv compar control
count miss metaboliteintens set measur analyt perform metabolom platform metabolom requir quantit individu entir sampl set unfortun miss intens sampl common miss profound influenc metabolom result extent miss metabolom set paramet measur analyt perform techniqu work report scope miss robust fill miss isotop label cil lcms metabolom platform unlik convent lcms cil lcms quantifi differ individu compar sampl mass spectral peak intens ratio peak pair mixtur differenti label sampl peakpair featur uniqu mean extract intens inform raw mass spectra approach peakpair peak algorithm isom lcms set generat csv file tabl id peak ratio inform ie metaboliteintens tabl zerofil program freeli avail mycompoundidorg automat miss csv file go back raw lcms peak pair calcul intens ratio enter ratio tabl miss low abund peak pair demonstr perform technic replic set human urin metabolom furthermor propos standard approach count miss replic set way gaug extent miss metabolom platform final illustr appli zerofil program conjunct dansyl cil lcms lead mark improv signific differenti patient control metabolom subject
synthesi fedaa new pet imag probe peripher benzodiazepin receptor express peripher benzodiazepin receptor pbr associ neuroinflamm daa fedaa promis radioligand positron emiss tomographi pet imag pbr design new radiolabel analog daa fedaa fedaa pet imag pbr express brain precursor nfluorophenoxyphenyl nfluoroethoxi hydroxybenzylacetamid synthes step moder yield precursor label chotf isol pressur liquid chromatographi hplc purif target radioligand nfluorophenoxyphenyl nfluoroethoxi methoxybenzylacetamid fedaa radiochem yield decay correct end bombard eob co specif activ radiotrac gbq micromol end synthesi eo
applic sigmoid sinus tunnelpack pushpack inferior petrous sinus microsurg manag jugular paraganglioma outcom microsurg jugular paraganglioma control bleed inferior petrous sinus retrospect patient review singl univers hospit fortythre patient jugular paraganglioma diagnos past year clinic surgic control intraop blood loss intraop manag facial nerv preoper postop central nerv twentysix patient underw microsurg eighteen six cde gross total resect achiev patient mean blood loss surgeri recurr rate over mean followup month new facial palsi cranial nerv deficit occur patient infratempor fossa approach type sigmoid sinus tunnelpack pushpack techniqu facilit control bleed inferior petrous sinus improv outcom microsurg jugular paraganglioma
exact statist test carcinogen effect anim bioassay ii ageadjust test statist discuss applic anim carcinogenesi bioassay test general null hypothesi frequenc independ level endpoint sex bioassay condit surviv propos earlier farrar crump fundam appl toxicol involv test statist standard statist hypothesi test signific random refin introduct exact incident test analog asymptot test hoel walburg natl inst take account differ rate result differ surviv independ addit consider test statist test propos sensit specif case where endpoint sex applic procedur result nation toxicolog program ntp bioassay concern decabromodiphenyl iodin glycerol illustr sensit test differ test statist distinct altern hypothes compar qualit ntp strength evid carcinogen effect bioassay result clarifi otherwis equivoc evid carcinogen difficulti discuss relev construct exact fatal incident test analog test peto et al iarc monogr suppl
birth cohort papillari thyroid unit state papillari thyroid report past decad reason unknown pattern papillari thyroid unit state compon birth cohort defin year birth period age trend diseas nation institut surveil epidemiolog end result program conduct univari ageperiodcohort model birth cohort pattern age period cohort effect trend over clear birth cohort pattern men women result ageperiodcohort model period effect appear impact trend birth cohort effect explain trend papillari thyroid carcinoma period women period effect like advanc diagnost techniqu medic detect thyroid nodul explain specul birth cohortrel chang environment exposur exposur diagnost xray polybromin diphenyl ether contribut papillari thyroid past decad
partial hepatectomi cirrhot right later total patient cirrhot solitari hepatocellular carcinoma hcc locat later right lobe underw surgeri techniqu clamp finger dissect oper mortal acut chronic failur total oper minut actual resect minut averag amount blood transfus procedur preoper serum bromsulphalein retent rate proportion reflect postop peak serum conjug bilirubin resect specimen less gm less enzym sgot sgpt lactat dehydrogenas cell postop promin patient hypotens hypotens less enzym level return preoper level fourteenth postop excretori capac cell measur serum bromsulphalein retent rate still abnorm less took month declin level still exceed preoper level less partial hepatectomi cirrhot clamp finger dissect simpl rapid techniqu serious effect
applic silver stain cytolog specimen neuroendocrin metastat cytolog specimen neuroendocrin metastat regard silver stain properti after applic argentaffin argyrophil stain techniqu masson grimelius seviermung content serotonin intestin carcinoid presenc demonstr cytolog argentaffin individu cell formalin fixat prerequisit stain melanin malign cell display argentaffin irrespect fixat air dri formalin bouin fluid acetonealcohol serotonin melanin distinguish cytolog sampl neuroendocrin masson argentaffin differ fixat nonargentaffinposit neuroendocrin weak stain unreact grimelius argyrophil techniqu seviermung argyrophil techniqu gave disturb nonspecif background stain difficult interpret cytolog sampl grimelius appear silver stain neuroendocrin cell cytolog materi irrespect hormon content argentaffinposit argentaffinneg sampl stain least degre
cell blot techniqu stain microscop cell blot nitrocellulos paper standard cytolog histolog stain procedur success appli nitrocellulos nc paper stain spectrum cell type blot stain procedur papanicolaou hematoxylin eosin immunoperoxidas techniqu type consist suspens monolay cultur well fresh prepar nontumor tissu suspend cell manual blot nc paper fix fixat propanol neutralbuff formalin carnoy solut bouin fluid fixat stain abov after stain nc paper dehydr absolut propanol transpar soak xylen mount perman mount medium permount glass slide microscop proteinblot capac nc paper schleicher schuell compar convent cell blot media millipor gelman cellulos acet bovin serum albumin dotblot nc cellulos acet filter stain protein amido black cytolog histolog stain amido blackstain filter dehydr absolut propanol transpar xylen mount permount densitometr trace indic nc paper bound amount protein feasibl cytolog histolog stain techniqu nc paper proteinblot capac allow situ stain microscop babi hamster kidney cell bind fibronectin blot nc paper signific techniqu cell biolog research discuss
cytolog diagnosi medullari carcinoma thyroid seviermung silver stain calcitonin immunocytochemistri medullari carcinoma thyroid preoper diagnos ultrason guid fine needl aspir biopsi after cytocentrifug cell display dens cytoplasm silver granul seviermung techniqu appli airdri acetoneethanolfix sampl obvious calcitonin immunoreact after fixat bouin fluid prove identif nonpalp metastas recurr medullari carcinoma thyroid cytolog type medullari thyroid carcinoma cell difficult routin stain
sort out mixup proven tissu section confirm pcr microsatellit standard identif system usual ensur biopsi materi correct associ patient sometim unexpect proven proof origin tissu sampl question tissu mislabel contamin tissu patient techniqu confirm tissu proven compar tissu gender abo blood weak confirmatori power dnabas polymeras chain pcr techniqu report pair formalinfix paraffinembed micron tissu section patient whom carcinoma biopsi section sequenti biopsi sequenti biopsi autopsi tissu result sampl code addit case fragment patient tissu block benign tissu patient fragment hematoxylinandeosinstain section separ scrape off glass slide tissu clinic case suspect mislabel suspect carryov malign tissu short tandem repeat sequenc str microsatellit pair repeat vari repeat individu variat polymorph pcr panel strs acpp int cyp chromosom isol sampl after xylen deparaffin proteinas digest amplifi radioact pcr primer give size amplifi electrophores denatur polyacrylamid gel dri autoradiograph segment success extract sampl fix bouin fluid compar allel size panel tissu pair bouin pair success match fragment correct assign clinic problem solv strs inform robust well suit pcr portion tissu section effect confirm proven benign malign biopsi autopsi materi
caveolin potenti highrisk biomark diagnost techniqu cannot effici distinguish latent lowrisk highrisk signific caveolin cav except play role cell tumorigenesi furthermor cav involv metastat cav express induc condit focus prognost aggress highgrad serum cav serum antioxid activityglutathion gsh diphenylpicrylhydrazyl dpph trolox equival antioxid capac teac ferricreduc antioxid power frap nndimethyldiaminobenzen dmpd free frk blue chromium peroxid cro serum sampl patient control insignific differ cav sera patient control vs ng control signific cav stage tnm compar stage signific associ histolog grade patient serum cav antioxid capac bodi indic cav interest tool predict diseas burden
cyclotron sc bench bedsid sc pet radionuclid promis decay characterist ebeta av kev nuclear imag attract altern shortliv ga min ebeta av kev optim sc acceler allow preclin clinic pet imag caco target prepar irradi proton mev beam Ã®a min sc separ target materi dga extract resin scx cation exchang resin radiolabel activ up mbq stabil test perform dotanoc differ scaveng gentis dynam pet arj tumorbear mous perform after inject scdotanoc optim separ yield up gbq sc radionuclid puriti presenc gentis radiolabel sc dotanoc achiev radiochem yield specif activ mbq nmol quantiti allow clinic applic dynam pet imag visual uptak scdotanoc arj excret radioact kidney mous concept frombenchtobedsid clear demonstr extend cyclotronproduc sc suffici activ sc excel radionuclid puriti obtain clinic applic irradi enrich calcium cyclotron work demonstr promis introduc sc clinic routin nuclear imag pet
good result after hartmann oper rectal risk patient purpos per postop complic low anterior resect hartmann oper ho rectal perform depart frequenc ho patient undergon low anterior resect la ho rectal depart surgeri gentoft hospit januari decembesr total patient oper la ho techniqu period la perform patient ho patient asascor patient underw ho signific differ complic rate mortal rate patient not differ ho la asa iii patient underw la die anastomot leakag asa iii patient oper ho die signific differ per postop complic materi ho la safer choic risk rectal patient asa term mortal rate compar nation index
percutan radiofrequ ablat osteoid osteoma techniqu result osteoid osteoma benign primari bone typic occur children young adult besid local pain wors night prompt relief medic acetylsalicyl ass characterist bone lesion longterm medic ass not altern strategi potenti sever effect differ minim invas imageguid techniqu osteoid osteoma context radiofrequ rf ablat becom clinic routin techniqu result imageguid rf ablat compar altern strategi techniqu needleshap rf applic percutan place imag guidanc highfrequ altern appli tip applic lead ionic motion tissu result local heat thermal destruct surround tissu publish primari secondari success rate techniqu surgic resect open curettag compar success rate associ complic rate addit imageguid rf ablat osteoid osteoma associ low cost imageguid rf ablat gold standard osteoid osteoma
effect oral acetylsalicyl onÃ¢ blood fluiditi infus speed inÃ¢ theÃ¢ patient picc influenc oral acetylsalicyl blood fluiditi infus speed patient peripher insert central cathet picc picc place prolong patient fibrin sheath consist cellular noncellular generat place insert grow down over cathet final cover vent cathet lead cathet dysfunct decreas infus speed addit viscos status patient lead acut embol add risk death random control trial research carri out april januari second hospit xiangya central south univers changsha china particip picc chosen random alloc control particip conduct rout picc maintain techniqu took acetylsalicyl Ã¢mg per after dinner control receiv rout picc maintain techniqu infus speed hemorheolog index test end nd th month instrument repeat measur varianc indic take acetylsalicyl oral signific main effect shear blood viscos red blood cell deform index pÃ¢Ã¢ signific main effect well effect plasma viscos pÃ¢Ã¢ signific main effect well interact effect oral acetylsalicyl low shear blood viscos red blood cell aggreg index pÃ¢Ã¢ repeat measur anova take acetylsalicyl oral signific main effect effect interact effect infus speed pÃ¢Ã¢ oral acetylsalicyl improv hemorheolog condit infus speed fibrin sheath patient
prevent pelvic radiat diseas pelvic frequent diagnos patient requir multidisciplinari approach frequent radiotherapi gastrointestin gi radiat induc complic transient longterm problem mild sever aris noncancer tissu result radiat pelvic origin actual call pelvic radiat diseas pelvic radiat diseas chang radiat techniqu length up type stage variabl notabl even radiat techniqu ie intensitymodul radiotherapi radiat induc gi effect still not neglig addit radiat induc gi effect even after decad improv patient life expect unavoid risk radiat induc complic onc manag pelvic radiat diseas challeng prevent radiat induc reason way avoid dramat drop qualiti life patient manuscript updat practic review best avail evid field prevent pelvic radiat diseas
diagnosi genotyp human papillomavirus physic status cervic precancer lesion ee ratiobas vs el ee ratiobas detect techniqu cervic lesion integr human papillomavirus hpv infect danger quick invas clinician hamper lack quick conveni precis techniqu detect integr mix infect genotyp hpvs cervix practic tool physic status differ hpvs clinic signific target popul compris women hpv infect histori ofÃ¢Ã¢six month abnorm cervic cytolog el ee ratio novel techniqu ratio ee ee ee ee ee ee viral genom imbalanc ratio indic integr diagnost predict perform compar ee ratio detect accuraci techniqu goldstandard techniqu detect integr papillomavirus sequenc dip realiz multigenotyp detect goal primer probe librari integr rate genotyp hpv correl tumorigen potenti women lesion grade carri viral load el ee ratio achiev sensit specif detect hpv integr ee ratio much sensit specif interfer episom copi techniqu lead falseneg result result el ee ratio miss dip stochast detect natur el ee ratio effici ee ratio dip predict precancer lesion predict predict result round biopsi el ee ratio sensit predict ee ratio triag test detect hpv integr effect narrow candid colposcop cervic biopsi therebi expens cervic prevent
detect map methyl materi nanopor methyl epigenet modif involv addit methyl heavili involv gene express regul therebi diseas work detect local methyl achiev nanopor sensor twodimension materi graphen molybdenum disulphid mos label methyl site methylcpg bind domain protein mbd molecular dynam simul electron transport calcul transloc methyl dnambd complex materi nanopor extern voltag bias passag mbdlabel methyl site pore dip blockad induc strand well peak transvers electron sheet across layer methyl site clear recogn dip record ionic blockad estim error final defin spatial resolut materi nanopor devic minim distanc methyl site singl measur pair ionic recognit low pair transvers electron conduct detect indic resolut latter techniqu approach open new rout precis effici profil methyl
partit protein cytokinesi human breast cell line human breast cell line htb mda htb index di analys togeth diploid mous embryon carcinoma cell line pcc tvvideo timelaps techniqu pedigre cytochem paramet protein individu cell rapid scan microspectrophotomet postmitot sister cell pair analys after feulgennaphtholyellow stain di cell line reflect wellknown clinic ploidi entiti differ malign potenti mitot disturb partit protein daughter cell mda closest triploid modal di durat mitosi consider longer near triploid line compar line mda line least sensit suboptim growth condit report call attent causal mitot error intraclon genotyp cell mass heterogen
fluorodeoxyglucos uptak human cell line hypoxia malign neoplasm common rate glucos util poor perfus area low autoradiograph excis fdg uptak viabl cell near necrot portion vitro cell fdg uptak hypoxia uptak hfdg human cell line htb htb ip ovarian carcinoma after exposur differ atmospher vari period glucos transport independ well estim level glut glucos transport membran protein fdg uptak ovarian carcinoma cell line over basal condit cell expos mild hypox environ hr hr exposur fdg uptak greater hr anoxia fdg uptak over basal condit ovarian carcinoma cell membran transport omethylglucos omg hypoxia ovarian carcinoma immunochem assay glut membran express glut transport cell expos hypoxia hypoxia cellular uptak fdg differ malign human cell line glucos transport membran express glut glucos transport contribut phenomenon fdg uptak visual pet imag reflect hypoxia
sustain deliveri system novel techniqu tissu cultur greatest advanc biomed research tissu cultur effect mode action organ compound myriad problem associ classic approach pharmaceut tissu cultur contamin logist problem inher intermitt dose nearleth dose requir achiev effect physiolog dose impetus search mean effect deliveri rout tissu cultur set specif object ceram deliveri system novel purpos sustain level anticanc inositol hexaphosph ip inositol tissu cultur set prolifer rate viabil htb intraductil breast ibc cell expos sustain level ip compar convent mean deliveri dissolv media morpholog chang associ steril asept techniqu employ entir hour incub tcpl deliveri system util tissu cultur set deliv ip sustain manner hour ip physiolog dose did not induc signific chang biochem mda morpholog cell sustain deliveri result cellular atrophi well fragment compar convent mean sham empti capsul regardless rout ip result decreas total protein content compar sham capsul control approach novel ceram deliveri system tissu cultur give breakthrough inform basic research limit elimin contamin logist problem associ intermitt dose tissu cultur
magnet reson imag hyperpolar agent applic past decad hyperpolar hp agent activ mri applic address twin challeng quantit imag hp helium he xenon xe gase reach stage where clinic research hp xe pois larger scale clinic research asthma chronic obstruct pulmonari diseas fibrot lung diseas advanc polar technolog uniqu capabl imag xe gas exchang lung tissu blood hp xe mri attract new attent parallel hp mri steadili advanc preclin research applic imag cardiac diseas hp pyruv mri techniqu undergon phase trial pois new trial institut cardiac applic review methodolog behind hp gase hp liquid state agent gas liquid phase hp agent share technolog achiev nonequilibrium polar outsid field mri scanner strategi imag acquisit translat challeng move preclin clinic research cover array applic review organ numer section brief introduct physic biolog properti common polar agent brief summari applic polar imag acquisit reconstruct specif improv acquisit effici hp mri main physic properti enabl uniqu measur physiolog pathway detail review literatur describ hp agent pathway cardiac diseas lung preclin clinic research conclud futur direct challeng summari
minim invas surgeri followup perform earli pattern recurr surviv patient undergo laparoscopicassist colectomi primari thirtynin patient avail minimum month postop followup techniqu expect surgic outcom patient undergo laparoscop assist colectomi slowli defin procedur becom common avail area greatest concern laparoscopicassist colectomi surgic patient primari anecdot report literatur describ port site recurr wound recurr patient undergo laparoscopicassist colectomi rais concern recurr common patient undergo laparoscop procedur surviv compromis wound recurr laparoscop port site recurr describ numer intraabdomin precis unknown author review patient earli pattern recurr surviv twohundr thirtyeight laparoscopicassist colectomi perform norfolk surgic june septembesr thirtynin patient underw resect june septembesr avail least year followup preoper physic carcinoembryon antigen chest xray comput tomographi scan endoscopi biopsi postop followup consist physic test cea chest xray comput tomographi scan abdomen endoscopi colon patient lost followup surviv rate pattern recurr compar nodeneg nodeposit patient compar convent after open surgeri men women age year mean followup month month patient recurr nine death recurr tumorrel death rate duke stage stage stage stage stage stage six patient duke stage diseas die metastat month surgeri patient anastomot recurr unusu pattern recurr diseas note wound port site recurr patient undergo laparoscopicassist colectomi primari malign advers pattern recurr decreas surviv note year followup compar standard open surgeri statist prospect random longterm followup requir defin potenti benefit advers effect laparoscop surgeri malign
systemat approach drugdna interact raman spectroscopi bind metalfre bleomycin calf thymus bleomycin activ compon antineoplast blenoxan target cell mode action involv ambigu exist way bleomycin bind raman spectroscopi calf thymus bleomycin complex temperatur curvefit techniqu appli spectra spectral region obscur overlap band associ nucleotid deriv inform frequenc bandwidth intens vibrat mode region allow identif band associ specif assign nucleotid residu bind bleomycin signific chang bandwidth intens frequenc uncomplex consist degre degre temperatur support least partial mode bleomycin temperatur depend pronounc physiolog relev temperatur degre c
perform liquid chromatographi system quantif hydroxyl format dihydroxi benzoic hypoxanthin xanthin oxidas enzym system known produc superoxid ion hydrogen peroxid hydroxyl hypoxanthin via xanthin uric chelat iron system superoxid iron iron ironchel react hydrogen peroxid reactiv hydroxyl limit colourimetr spectrophotometr techniqu date mechan hydroxyl format hypoxanthin xanthin oxidas system monitor perform liquid chromatographi util ionpair reagent tetrabutylammonium hydroxid salicyl probe quantif hydroxyl format set up hypoxanthin xanthin oxidas system hydroxyl attack salicyl dihydroxi benzoic dihydroxi benzoic approxim ratio hydroxyl involv hydroxyl salicyl system demonstr potenc dimethyl sulphoxid butanol ethanol scaveng phytic protect constitu against inhibit hydroxyl salicyl magnitud classic scaveng effect absenc edta appli free generat faec preliminari result indic faecal flora abl produc ros abund
cutan cryosurgeri cutan cryosurgeri local applic freez temperatur achiev destruct skin lesion broad benign premalign skin condit certain malign skin condit cure rate cellular destruct accomplish deliveri cryogen via dipstick probe spray techniqu primari care safeti effect low cost eas good cosmet result lack need anesthesia cryosurgeri effect altern case molluscum contagiosum dermatofibroma keloid plantar genit wart effect cure common wart salicyl cryosurgeri general choic actin keratosi contraind cryosurgeri cryofibrinogenemia cryoglobulinemia raynaud diseas agammaglobulinemia myeloma complic cryosurgeri hypopigment alopecia avoid limit freez less second referr dermatologist case diagnost uncertainti skin requir larger amount tissu destruct result complic rate
crosslink biodegrad cytocompat salicyl polyest local sustain deliveri salicyl vitro suppress chronic inflamm support cell prolifer continu surg polym intent deliv antiinflammatori molecul sustain manner abov backdrop report synthesi novel stabl crosslink polyest salicyl sa incorpor polymer backbon propos simpl synthesi rout melt condens assynthes polym hydrophob glass transit temperatur Ã¢c Ã¢c cure nmr ftir spectral techniqu ester linkag assynthes sabas polyest phdepend degrad rate rate salicyl assynthes sabas polym physiolog condit vitro polyest underw surfac eros exhibit linear degrad kinet chang degrad rate after mass loss record after month Ã¢c ph deliveri salicyl chang slope sustain rate month cytocompat polyest carri out cc murin myoblast cell techniqu like mtt assay flow cytometri result strong sabas polyest support cell prolifer cultur not cell death quantifi propidium iodid pi stain cell henc polyest implant materi local sustain deliveri salicyl applic adjuv chronic wound heal altern commerci avail polym like polylact polyglycol copolym
advanc solid nsaid correl quantit monitor circul cell positron emiss tomographycomput tomographi imag detect characteris tumorderiv circul epitheli cell cetc circul cell ctcs main focus basic oncolog research over year numer past decad ctcs promis tool estim risk metastat relaps describ result imag quantif ctcs patient advanc carcinoma anticanc ctc serial detect success estim positron emiss tomographycomput tomographi connect remiss decreas ctc count connect stabl diseas stabl ctc connect diseas pd ctc count case patient pd incomplet ctcs not solid region result conclud patient solid benefit serial quantif ctcs addit imag techniqu sensit result imag alon
tobacco occup coffe nutrient canadian populationbas casecontrol male femal casecontrol pair risk ever versus never cigarett male femal doserespons sex risk associ filter cigarett compar nonfilt cigarett after control cigarett usag signific risk note male pipe smoker male exsmok risk aftesr year smoke less onehalf male smoker risk worker rubber photograph petroleum medic food industri male worker occup expos dust fume sex risk male consum type coffe regular coffe instant coffe femal consum instant coffe doserespons risk male consum water nonpubl suppl not femal risk male femal consum nitratecontain food beverag coffe fiddlehead green hair dye usag femal phenacetin usag male femal carri risk diverg area aspirin associ not causal reevalu artifici sweeten confirm signific risk male doserespons cumul popul attribut risk male cigarett smoke industri exposur exposur nonpubl water suppli femal cigarett smoke industri exposur instant coffe consumpt
test new anticoagul free flap reconstruct head neck free flap reconstruct head neck defect despit improv surgic techniqu surgeon flap failur still occur thrombot occlus after vessel anastomosi flap loss result thrombot occlus anticoagul decid new protocol anticoagul effect flap surviv complic intervent patient head neck underw surgic defect reconstruct microvascular free flap postop period patient taken aspirin enoxaparin subcutan flap surviv complet necrosi loss flap free flap success rate much need reexplor occur patient patient need reexplor problem venous blood flow aspirinenoxaparin shortterm protocol good choic after free flap transfer reconstruct head neck surgic defect
review patent therapeut potenti deliveri hydrog sulfid hydrogen sulfid hs colorless gas characterist smell rotten egg onc thought gas evid now hs play role patholog physiolog activ role util diseas disord hypertens inflamm edema cardiovascular issu chronic pain challeng face hs involv achiev optimum therapeut synthes physiolog stabl donor clinic appropri deliveri system did extens literatur search therapeut potenti issu hs systemat flow pattern introduct patent accept file aspect hydrogen sulfid search unit state patent trademark offic databas http patftusptogov googl patent https patentsgooglecom search term hs therapeut effect pharmacolog action biochemistri measur deliveri incorpor own public discuss deliveri approach associ challeng research discov novel techniqu prepar noxious gas discov synthes hs donor control predict deliveri system donor util far deriv antiinflammatori like hs aspirin allium sativum extract inorgan salt phosphorodithio deriv thioaminoacid deriv control deliveri system hs maintain physiolog stabil optimum therapeut window patient complianc easier manufactur administ numer patent overcom challeng hs therapeut donor deliveri mechan review scientif knowledg gain last decad research move hs foul smell pungent gas status gasotransmitt potenti therapeut applic suitabl donor deliveri system donor precis sustain hs extend period need translat clinic practic
identif low oxygentoler bacteria secret patient discuss aetiolog signific microaerophyl organ propionibacterium acn consist associ pc link circumcis pc support anaerob involv circumcis anaerob colonis glan peni link anaerob pc opportunist necrot hypothesi helicobacterlik pc justifi pilot activ surveil patient enrol postprost massag urin sampl screen matrixassist laser desorpt ioniz timeofflight malditof techniqu bacteri identif after cultur anaerob aerob condit outÃ¢ patient oblig anaerob nÃ¢Ã¢ microaerophil nÃ¢Ã¢ whom anaerob organ none control sampl oblig anaerob mean psa low toler bacteria outlier result differ nonsignific proport pc patient organ grow low compar control degre signific smoke cigarett need translat research trial aspirin begun 
flavonoid not anymor veterinari client nutraceut adjuv varieti ailment pet evid client companion anim nutraceut supplement plan client say veterinarian approv trend not extend healthi pet receiv routin supplement unfortun few resourc safeti nutraceut exist evid dose humanformul supplement lipoic cat veterinarian need safe upper limit common nutraceut client give pet human formul articl focus primarili flavonoid epigallocathechinogal egcg flavanol 
affin specif quercetin potenti quercetin que member whole famili structur differ flavonoid serv antitumor agent recogn not fulli understood interact seri flavonoid far varieti techniqu specif que sophist densiti theori dft employ generat optim structur que complex adenin guanin thymin cytosin far prefer que concern structur energet well nmr shift argument clear indic lowest bind mode que dock quadruplex receptor structur duplex receptor structur singl point mutat quadruplex duplex residu conspicu stabil effect origin complex que receptor consequ fundament standpoint shed new light molecular mechan interact que discuss
simpl effici largescal prepar genkwanin daphn genkwa sieb et zucc normalphas flash chromatographi genkwanin flavonoid antioxid antitumor activ isol purifi flower daphn genkwa sieb et zucc largescal normalphas flash chromatographi npfc dri flower bud extract methanol room temperatur residu suspend water extract petroleum ether chloroform genkwanin chloroform insolubl fraction targetguid thin layer chromatographi tlc well solubl solvent system compos cyclohexaneaceton flow rate minth insolubl chloroform fraction separ yield genkwanin puriti hplc structur compound esim nmr result indic npfc larg preparativescal speedi simpl separ technolog feasibl appropri proport solvent system tlc condit
transnas peg tube placement patient head neck head neck hnca patient risk malnutrit dysphagia malign advers event patient requir gastrostomi percent hnca patient unabl undergo per oral percutan gastrostomi transnas endoscopi option gastrostomi placement patient clinic epidemiolog characterist outcom transnas peg tpeg placement retrospect tertiari care hospit univers texa md anderson center patient underw tpeg placement epidemiolog advers event outcom tpeg placement sixteen patient underw tpeg placement januari patient hnca metastasi indic transnas approach airway compromis malign oropharyng obstruct trismus procedur success gastrostomi tube push techniqu anesthesiologistguid propofol sedat nasotrach intub patient white men mean age year mean bodi mass index patient total advers event poor wound heal wound site infect patient leukopenia neutropenia lymphopenia mean white blood cell count absolut neutrophil count absolut count eleven patient aliv lost followup die review retrospect cohort patient bias tpeg placement viabl safe option hnca patient standard endoscop approach not feasibl
awak craniotomi resect surgic brain locat eloqu area anterior tempor frontal lobe languag memori area near motor cortex risk eloqu impair awak craniotomi display rule maximum resect minimum impair central nervous system case report discuss awak craniotomi brain surgeri alzahra hospit isfahan iran yearold woman leftsid bodi hypoesthesia last month yearold sever headach month durat oper craniotomi brain resect awak craniotomi plan allow maximum intraop test resect neurolog morbid avoid anesthesia offer suffici analgesia hemodynam stabil sedat respiratori awak cooper patient differ neurolog test airway manag anesthesia awak craniotomi surgeri awak craniotomi safe techniqu allow maxim resect lesion close eloqu cortex low risk neurolog deficit
nonintub thoracoscop surgeri region anesthesia vagal block target sedat thoracoscop surgeri endotrach intub novel techniqu diagnosi thorac diseas report nonintub thoracoscop surgeri tertiari medic center taiwan august august consecut patient lung pleural diseas nonintub thoracoscop surgeri region anesthesia achiev thorac epidur anesthesia intern intercost blockad target sedat perform propofol infus achiev bispectr index demograph clinic outcom retrospect chart review thorac epidur anesthesia patient intern intercost blockad patient final diagnosi primari lung patient metastat lung benign lung pneumothorax median anesthet minut thorac epidur anesthesia minut intern intercost blockad oper procedur lobectomi patient wedg resect segmentectomi sixteen patient requir convers tracheal intub signific mediastin movement patient persist hypoxemia patient dens pleural adhes patient ineffect epidur anesthesia patient bleed patient tachypnea patient patient convert thoracotomi bleed mortal note patient nonintub thoracoscop surgeri technic feasibl safe less invas altern diagnosi thorac diseas
anesthesia awak craniotomi case report intracrani procedur achiev patient awak challeng patient complianc homeostasi case intracrani surgeri remov left pariet lobe patient awak procedur after patient psycholog prepar propos excis left pariet lobe lesion wake state clarifi accept continu infus propofol remifentanil administ maintain ramsay score bilater scalp blockad perform ropivacain mayfield head fixat devic instal drape adjust maintain airway eye access map electr excis dura mater incis pad lidocain appli minut surgeri unev patient discharg seventh hospit complic mainten analgesia hemodynam stabil challeng patient awak targetcontrol infus propofol desir level conscious remifentanil titrat analgesia sedat accumul blockad ropivacain satisfactori analgesia conclud anesthet techniqu satisfactori patient
anaesthet analges neurocognit effect organ protect reoccurr updat avail general local anaesthet third generat inhal anaesthet propofol amid local anaesthet effect reassur safe associ low toxicolog adverseeffect debat anaesthet techniqu exhibit effect beyond primari effect fulli revers depress central nervous system dose depend anaesthesia anaesthet involv neurocognit effect elder after surgeri call postop cognit dysfunct hand anaesthet exhibit organ protect potenti ischemia reperfus injuri improv surviv after cardiac surgeri anaesthet anaesthet techniqu effect reoccurr risk metastasi paper updat around evid around anaesthesia potenti contribut effect occurr postop cognit adverseeffect organ protect properti influenc reoccurr metastasi
anesthet techniqu recurr oncolog surgeri unravel puzzl surgeri anesthet techniquestimul immunosuppress periop period cancerrel mortal anesthet techniqu outcom patient inconclus review discuss avail literatur anesthet techniqu appli oncolog surgeri longterm outcom anesthet techniqu surviv recurr search pubm databas up june conduct public term anesthet techniqu recurr region anesthesia recurr local anesthesia recurr anesthet techniqu immunosuppress anesthet techniqu oncolog surgeri surgeri anesthesiastimul activ hypothalamicpituitaryadren hpa axi sympathet nervous system sns immunosuppress solubl volatil anesthet opioid suppress cellmedi cmi promot prolifer cell angiogenesi propofol not suppress cmi inhibit angiogenesi region anesthesia ra protect cmi diminish surgic neuroendocrin block affer neural transmiss hpa axi sns decreas requir opioid volatil anesthet therebi decreas recurr preclin retrospect highlight potenti benefit anesthet techniqu cancerrel mortal recurr attenu immunosuppress surgic patient specif type wellplan prospect random control trial rcts underway definit result benefit anesthet techniqu surviv oncolog surgeri
periop anesthesia care narrat review discuss uptod focus avail best clinic practic periop anesthesia care bundl effect main object apprais literatur local anesthet region outcom opioid nonsteroid antiinflammatori nsaid abil decreas recurr patient undergo surgeri brief discuss addit topic periop relev anesthesiologist volatil intraven anesthet periop anxieti nutrit result publish systemat review look associ recurr region anesthesia yield inconclus insuffici evid definit benefit region anesthesia basic scienc anti effect induc local anesthet new refin anim model opioid safe periop pain manag preliminari evid nsaid essenti multimod analgesia volatil anesthet format preclin clinic propofol indic protect qualiti periop period patient uniqu environ where surgic mediat lead suppress region anesthesia techniqu indic multimod analgesia nsaid opioid local anesthet prevent pathophysiolog effect pain neuroendocrin view essenti balanc anesthesia
manual transtrach frequenc pressur ventil left main bronchus carin mass surgic resect child myofibroblast imt call pseudotumor rare condit account less primari lung common benign lung children case report object highlight role manual transtrach frequenc pressur ventil hfppv facilit surgic resect mainten adequ littl compromis ventil ayear boy weigh diagnos case imtof left main bronchus biopsi success surgic excis left thoracotomi hfppv improvis techniqu ventil surgeri total intraven anaesthesia propofol infus increment fentanyl hfppv after complet surgeri convent pressur ventil ppv continu endotrach tube ett check bronchial stump leak after surgeri patient wean extub oper room hospit cours unev patient discharg after hfppv manual improvis techniqu applic carin surgeri optim ventil uninterrupt surgic resect
jobexposur matrix parent occup childhood associ parent occup childhood case childhood age diagnos control random digit dial denver colorado usa jobexposur matrix assign parent exposur job titl emphas implic acut leukemia brain parent occup year prior birth child oddsratio oddsratio confid interv extend below null matern exposur benzen petroleum coke pitch tar soot total or total patern exposur hydrocarbon result individu hydrocarbon larger oddsratio anilin benzen petroleum coke pitch tar potenti exposur creosot strong associ brain expos case percent confid interv control potenti childhood risk did not alter result spite uncertainti error exposur classif result tend corrobor past research associ specif parent occup exposur childhood 
mutagen contamin soil review intent accident discharg pollut lithospher result soil contamin case eg wood preserv wast coaltar airborn combust byproduct contamin soil constitut genotox hazard work comprehens review publish inform soil mutagen total genotox activ work employ salmonella mutagen test strain ta ta addit employ varieti plant eg tradescantia clone vicia faba zea may allium cepa mutagen activ compil salmonella mutagen indic signific differ mean potenc revert per gram dri industri urban rural agricultur site addit analys signific empir sactiv ta mutagen soil polycycl hydrocarbon pah directact ta mutagen soil dinitropyren dnp plant assay reveal excel signific differ heavili contamin industri rural agricultur site anaphas aberr allium cepa direct soil contact waxi locus mutat assay zea may direct soil contact tradescantia assay appear less exposur aqueous soil leachat addit analys empir anaphas aberr allium mutat arabidopsi cs contamin soil micronuclei tradescantia soil metal eg sb cu cr pb cd ni zn review publish remedi exercis effect remov genotox petrochem wast year remedi refractori genotox materi eg explos creosot frequent mutagen hazard extend period despit contamin mutagen hazard risk advers effect eg mutat human terrestri biota difficult quantifi
separ procedur natur occur antioxid phytochem phytochem fruit veget spice tradit herbal medicin plant play protect role against human chronic diseas cardiovascular diseas cvd diseas associ excess free ros antioxid phytochem exert effect neutral reactiv ten thousand phytochem tradit medicin carotenoid stand out natur antioxid phytochem good antioxid role effect individu compound not well known hundr carotenoid thousand far plant singl plant complex profil compound sometim labil heat air light exist low plant make separ detect antioxid phytochem challeng task review focus antioxid activ type sampl sampl procedur separ chromatograph electrophoret techniqu detect quantif ultravioletvisiblediod array mass spectrometri discuss
mhcb haplotyp impact suscept resist rsva infect impact ofÃ¢ haplotyp histocompat complex mhc outcom infect synthet dam line sdl broiler strain rous sarcoma virusÃ¢ rsvÃ¢ genom mhcb haplotyp reveal total known standard haplotyp constitut twentyf differ genotyp new haplotyp bp size design bx inocul rsva sdl chick result regressiveÃ¢ phenotyp vari profil index tpiÃ¢ haplotyp bhad lowÃ¢ tpiÃ¢ score less mortal resist toÃ¢ rsvaÃ¢ haplotyp bÃ¢ bÃ¢ higherÃ¢ tpiÃ¢ score indic suscept rsva theÃ¢ genotyp bx bx mean tpi score closer resist haplotypeÃ¢ sequenc new haplotyp bx reveal haplotyp metastas chick compris mix fibrosarcoma myxosarcoma
dual tnf induc effect nrf mediat antioxid defenc astrocyterich cultur role protein kinas activ tnf pleiotrop molecul protect detriment effect neurodegener tempor effect tnf induc nrf system astrocyterich cultur glutathion gsh level gammaglutamylcystein ligas gammagcl activ protein level nrf keap catalyt modulatori subunit gammagcl gammagclc gammagclm astrocyterich cultur expos differ tnf acut exposur astrocyterich cultur ng tnf gsh gammagcl activ protein level gammagclm gammagclc nrf parallel decreas level keap antioxid element mediat transcript block inhibitor erk erk jnk akt inactiv gskbeta enhanc transcript tnf decreas compon nrf system parallel keap nrf system tbhq intact aftesr block after tnf downregul after correl activ mapk gskbeta inhibit signal pathway revers effect upregul nrf system tnf protect cell gammagcl activ downregul pronounc implic result situat where nrf decreas alzheim diseas effect tnf detriment
enrich isol barbigeron millettia pachycarpa benth highspe countercurr chromatographi prepar hplc enrich antitumor compound barbigeron rotenoid deriv millettia pachycarpa benth perform twostep highspe countercurr chromatographi hsccc separ step target fraction fra ethyl acet extract pachycarpa benth barbigeron via hsccc solvent system nhexaneethyl acetatemethanolwat normal phase head tail elut hsccc repeat elimin contamin fraction after separ min barbigeron puriti fra ternari solvent system nhexanemethanolwat normal phase elut final prepar hplc employ isol barbigeron rotenoid deriv structur confirm esim nmr nmr
econom consequ hiv aid india hiv aid press public health problem india avail inform indic rise trend infect impact hiv aid econom front young reproduct age estim cost loss lifetim attribut hivrel mortal india popul year hiv infect rate societ viewpoint adopt discount rate estim loss personyear hiv aid scenario popul hiv aid second popul hiv aid differ personyear live cohort popul personyear lost hiv aid calcul personyear live life tabl approach demograph census popul fiveyear cohort agespecif death rate assumpt hiv rate urban rural area differ age avail consensus expert estim cohort popul rural urban area extrapol popul differ age convert personyear lost monetari term minimum wage estim rs per annum total undiscount lifeyear lost hiv aid popul india million year million year urban million year rural area averag year lost per person lifeyear lost per case hiv year assum minimum wage rs year total econom loss rs billion loss per case rs us estim nation per capita incom rs total econom loss rs billion discount rate appli futur loss total potenti year life lost million million urban million rural area monetari term rs billion minimum wage assumpt billion nation per capita incom assum cost year hiv aid impos signific burden econom front loss like underestim cost hiv aid patient prevent programm labour cost not taken account decid hiv aid need prioriti int he indian context necessari estim diseas tuberculosi 
risk chronic ill oper medic case control result melbourn associ risk chronic ill oper medic case age sexmatch control deriv larg comprehens populationbas conduct melbourn australia statist signific deficit case hypertens heart diseas stroke chronic chest diseas chronic arthriti statist signific excess hemorrhoid case differ consist colon rectal male femal statist signific differ twice breast case control uterin case control statist signific deficit case aspirincontain medic supplement consist colon rectal male femal statist signific excess larg bowel polypectomi case model signific associ simultan logist regress equat indic hypertens heart diseas chronic arthriti aspirin independ effect consist colon rectal male femal effect independ risk describ melbourn relev risk etiolog discuss
racial differ prevent practic africanamerican hispan women compar prevent practic hispan africanamerican women age older crosssect survey inpati outpati unit teach hospit locat south central los angel conveni sampl women age older demograph lifestyl characterist prevent practic prevent practic report selfbreast mammographi papanicolaou pap smear digit rectal stool occult blood sigmoidoscopi chemoprophylaxi inform facetofac interview africanamerican women like pap smear ever aspirin prophylaxi hispan women differ prevent servic ethnic except pap smear aspirin screen rate low africanamerican hispan women
prospect sugar intak risk type diabet women prospect intak total type sugar associ risk type diabet contribut sugar intak pathogenesi type diabet not settl context primari prevent limit prospect women health random control trial aspirin prevent cardiovascular diseas valid semiquantit food frequenc questionnair complet women age year older main outcom type diabet predictor sugar intak sucros glucos fructos lactos cox proport hazard model multivari rrs type diabet quintil sugar intak compar lowest quintil estim compar lowest quintil sugar intak rrs cis quintil sucros fructos glucos lactos after adjust known risk type diabet associ subgroup analys stratifi bmi intak sugar not appear play deleteri role primari prevent type diabet prospect support american diabet associ guidelin moder amount sugar incorpor healthi 
quantit illustr public health potenti aspirin aspirin show potenti risk diseas public health cardiovascular diseas alzheim diseas paper fiction scenario year old individu encourag take aspirin crude assumpt simpl calcul kaplanmei surviv curv aspirin user main exercis longterm low dose aspirin doubl chanc individu live healthi life research need
role today helicobact pylori peptic ulcer helicobact pylori pylori nonsteroid antiinflammatori aspirin nsaid today main etiolog duoden du gastric gu ulcer countri area preval pylori infect decreas probabl consumpt nsaid proport ulcer not associ pylori nevertheless proport helicobact pylorineg nsaidneg ulcer low less furthermor proport probabl overestim search infect nsaid not perform proper characterist idiopath gu after exclud miss helicobact pylorineg nsaidneg du associ third quarter case comorbid sever cirrhosi respiratori renal cardiac failur malign numer digest diseas give du crohn diseas probabl frequent gastric hypersecret pyloriposit du pathogen idiopath du duoden load outcom idiopath ulcer littl reliabl concern risk complic proton pump inhibitor dosag allow prolong heal
associ nonsteroid antiinflammatori lung iowa women health aspirin nonsteroid antiinflammatori nsaid associ risk lung inconsist limit effect aspirin separ nsaid iowa women health prospect cohort iowa women age year old baselin nsaid ovesr year followup case lung associ lung aspirin nonaspirin nsaid after adjust lung risk hazard ratio hr estim multivari cox proport hazard regress women analyt cohort after control age educ alcohol intak packyear smoke status bodi mass index total fruit intak rr women take six aspirin confid interv hr women take six nonaspirin nsaid confid interv statist signific trend frequenc aspirin ptrend nonaspirin nsaid ptrend analys histolog type smoke status yield null result inform dosag durat not avail not aspirin nsaid risk lung cohort postmenopaus women
quantit immunochem fecal occult blood test neoplasia guaiacbas fecal occult blood test fobt screen not specif human hemoglobin low sensit automateddevelop immunochem fobt qualitycontrol specif human hemoglobin not requir restrict measur sensit specif quantit immunochem fecal hemoglobin measur detect advanc adenoma patient undergo colonoscopi fecal hemoglobin threshold give posttest probabl neoplasia immunochem fobt need prospect crosssect ambulatori endoscopi servic main health medic organ tel aviv israel consecut ambulatori patientssom asymptomat risk neoplasia symptomaticwho undergo elect colonoscopi volunt prepar immunochem fobt hemoglobin content bowel movement measur compar colonoscopi sensit specif predict likelihood ratio cis fecal hemoglobin measur clinic signific neoplasia amount fecal hemoglobin measur immunochem fobt perform colonoscopi clinic signific neoplasia patient patient advanc adenoma patient immunochem fobt hemoglobin threshold ng buffer sensit specif ci ci ci ci clinic signific neoplasia fecal sampl standard sampl size depend fecal consist patient test discontinu aspirin anticoagul patient risk result not appli averagerisk popul quantit immunochem fobt good sensit specif detect clinic signific neoplasia test perform screen averagerisk popul not known
clinic impact drugdrug interact aspirin prednisolon center advers gastrointestin gi event complic aspirin prednisolon cotherapi preval advers gi event expect cotherapi overlap dearth literatur interact clinic advers gi event retrospect preval advers gi event associ coadministr aspirin prednisolon gastroprotect agent medic record patient prescrib aspirin prednisolon januari june durat aspirinprednisolon overlap preval advers gi event detail concurr medic patient male mean sd age year total patient gastroprotect common proton pump inhibitor preval advers gi event patient patient gi symptom abdomin pain diarrhea dysphagia vomit patient sign gi injuri duoden ulcer iron defici anemia malloryweiss tear naranjo algorithm classifi patient experienc advers adr probabl adr preval advers gi event low manag weak associ occurr event coadministr aspirin prednisolon togeth concurr prescript gastroprotect clinic impact aspirin prednisolon ddi minim
intern clinic practic guidelin prophylaxi venous thromboembol patient Ã¢guidelin address manag venous thromboembol vte patient heterogen implement suboptim common intern consensus address practic clinic relev question set intern consensus work expert set up guidelin evidencebas medicin approach grade system vte lowmolecularweight heparin lmwh recommend fondaparinux unfraction heparin ufh thrombolysi casebycas best clinic practic guidanc vena cava filter vcf contraind anticoagul pulmonari embol recurr optim anticoagul period reassess contraind anticoagul recommend anticoagul resum safe vcf not recommend primari vte prophylaxi patient guidanc earli mainten month longterm beyond month vte lmwh minimum month prefer over antagonist vka idraparinux not recommend after month lmwh vka continu individu benefitrisk ratio toler patient prefer activ guidanc vte recurr patient anticoagul option switch vka lmwh vka lmwh dose lmwh vcf insert guidanc prophylaxi postop vte surgic patient lmwh od low dose ufh tid recommend pharmacolog prophylaxi start preoper continu least allow type lmwh superior evid support fondaparinux altern lmwh prophylact dose lmwh recommend extend prophylaxi after laparotomi indic patient risk vte low risk bleed lmwh vte prevent patient undergo laparoscop surgeri recommend laparotomi guidanc mechan not recommend monotherapi except pharmacolog contraind prophylaxi vte hospit medic patient mobil recommend prophylaxi lmwh ufh fondaparinux children adult acut leukemia lasparaginas depend local polici patient characterist prophylaxi patient guidanc patient receiv prophylaxi not recommend routin primari pharmacolog prophylaxi vte indic patient local advanc metastat pancreat lung low risk bleed patient thalidomid lenalidomid steroid vte prophylaxi recommend set vka low therapeut dose lmwh prophylact dose lowdos aspirin effect efficaci regimen special situat brain sever renal failur crcl min thrombocytopenia pregnanc guidanc context dissemin implement good clinic practic manag vte second death patient public health prioriti
improv surviv outcom incident betablock patient nonsmallcel lung definit radiat preclin norepinephrin direct cell migrat effect mediat betaadrenerg receptor retrospect review patient nonsmallcel lung nsclc receiv definit radiotherapi rt cox proport hazard model util associ betablock intak locoregion progressionfre surviv lrpfs distant metastasisfre surviv dmfs diseasefre surviv dfs surviv os univari patient take betablock improv dmfs dfs os not lrpfs compar patient not take betablock multivari betablock intak associ dmfs hazard ratio hr dfs hr os hr adjust age karnofski perform score stage histolog type concurr radiat dose gross volum hypertens chronic obstruct pulmonari diseas aspirin associ betablock lrpfs hr betablock associ improv dmfs dfs os larg cohort nsclc patient futur prospect trial valid retrospect length betablock influenc surviv outcom
thyroid risk not diabet patient thyroid risk regard diabet status diabet durat antidiabet sulfonylurea metformin insulin acarbos pioglitazon rosiglitazon populationbas reimburs databas taiwan random sampl subject cover nation health insur recruit after exclud patient type diabet subject men women recruit analys logist regress estim oddsratio oddsratio confid interv ci independ variabl age sex diabet status durat antidiabet medic comorbid live region occup potenti lead diagnosi thyroid model diabet patient probabl receiv potenti detect vs after multivariableadjust ci diabet status diabet durat year year year year vs nondiabet antidiabet agent sulfonylurea associ thyroid ci ci insulin metformin acarbos pioglitazon rosiglitazon furthermor patient benign thyroid diseas live kaop eastern region receiv potenti detect risk male sex hypertens dyslipidemia chronic obstruct pulmonari diseas vascular complic statin aspirin nonsteroid antiinflammatori associ risk lack associ diabet thyroid patient diabet durat year risk sulfonylurea risk thyroid 
unclassifi pleomorph spindl cell pulmonari neoplasm brain metastas after prasugrel excess new solid neoplasm vs death vs after prasugrel triton trial improv therapeut outcom optim platelet inhibit usual occur after month prasugrel women risk hypothesi offer prasugrel not aspirin clopidogrel indirect modul growth enhanc metastat dissemin instabl platelettumor cell aggreg via inabl keep local platelet thrombi excess chronic platelet inhibit year old femal diabet patient underw drugelut stent implant patient receiv load dose prasugrel prasugrel daili well aspirin daili after month dual antiplatelet she expector blood cough lung xray ct scan reveal numer lung nodul later diagnos unclassifi pleomorph spindl cell malign solid neoplasm patient die brain metastasi femal gender durat prasugrel exposur rare unclassifi neoplasm patholog type metastat aggress natur index patient regard caution effect novel antiplatelet agent onset test futur megatri
associ bullous pemphigoid uk casecontrol associ bullous pemphigoid bp unit kingdom casecontrol compar histori consecut patient bp control subject tertiari care center immunobul diseas skin clinic oxford univers hospit eightysix consecut bp patient consecut control region age sex dermatolog diagnos crude adjust oddsratio confid interv bp loop diuret frequent bp patient crude oddsratio ci adjust oddsratio signific differ diuret aspirin antidepress antiepilept antihypertens central nervous system agent eg antipsychot patient bp calcium supplement antibiot antihistamin prednisolon multivari demonstr loop diuret patient bp bp mechan behind associ clear warrant 
nonintub uniport video assist thorac surgeri vat lobectomi new procedur depart vat video assist thorac surgeri lobectomi center call nonintub vat lobectomi nit nonintub thorac surgeri gain author endotrach intub muscl relax patient not carri out surgeri perform patient breath spontan deal gain uniport nit vat lobectomi patient femal male lung underw nit vat uniport lobectomi mean age year year mean fev mean bmi prior surgeri patient receiv benzodiazepin premed local anesthet lidocain incis bupivacain intercost vagus nerv blockag besid routin monitor bispector index bis guid targetcontrol infus tci propofol sedat carri out help laryng mask anesthesia skin soft tissu incis perform fifth intercost space axillari line singl incis sight need introduct camera togeth instrument need dissect resect lobe placement chest tube complet atelectasi lobe remov right upper lobe midlob right lobe right lobe right upper lobe wedg resect left lobe after resect extend mediastin sampl block dissect perform periop mortal convers endotrach intub need non case mean oper minut min mean drainag period prolong air leak postop fever occur patient subcutan emphysema case pneumonia recurr pneumothorax redrainag necessari case patholog resect lobe endobronchi hamartochondroma complet atelectasi lobe chronic pneumonia adenocarcinoma squamous cell carcinoma carcinosarcoma typic carcinoid stage malign case ia ib iia iib iiia averag remov mediastin lymph node nonintub nit vat lobectomi safe procedur satisfi aspect oncolog guidelin postop drainag period shorter complet atelectasi surgeri
intraop dexmedetomidin promot postop sleep recoveri mastectomi general anesthesia postop sleep disturb fatigu mastectomi risk prolong convalesc patient breast design effect intraop dexmedetomidin postop sleep fatigu recoveri mastectomi general anesthesia fortyseven patient random maintain propofol remifentanil ringer solut control propofol remifentanil dexmedetomidin dex surgeri general anesthesia night surgeri patient receiv dexmedetomin spent sleep compar control oper compar control patient dex score global item recoveri questionnair oper question fatigu sever score oper intraop dexmedetomidin suffici improv postop sleep disord promot postop recoveri advers effect dexmedetomidin sleep disturb contribut recoverypromot effect
case left frontal highgrad glioma diagnos pregnanc pregnanc acceler glioma growth therapeut abort recommend prior resect addit extent glioma resect close correl patient surviv cm yearold righthand primigravida institut gestat obtain second opinion gestat patient newonset general convuls seizur gcss poor control anticonvuls polytherapi earli second trimest cm lesion locat her left frontal supplementari motor area sma suspect grade iii glioma classifi world health organ guidelin limit evid adjuv pregnanc neurolog symptom seizur stabil matern condit enabl safe birth case pregnant patient awak craniotomi intraop magnet reson imag imri advantag achiev gross total resect reduct direct cortic induc seizur fetal exposur anesthet asleepawakeasleep techniqu perform gestat propofol pregnant patient prohibit general anesthesia maintain sevofluran remifentanil until scan imri re induc dexmedetomidin remov accomplish supraglott airway sga until patient cranium open complic procedur postop period gestat patient deliv healthi babi patholog patient reveal anaplast astrocytoma radiotherapi began month postdeliveri evid recurr patient child did not medic development concern point month followup evid adjuv pregnanc limit extens resect monitor recommend brain presum malign awak craniotomi advantag pregnant patient subject movement preserv patient motor fetal exposur anesthet multidisciplinari discuss take place decisionmak well care periop prepar awak craniotomi even case pregnant patient
retrospect cohort mortal nest casecontrol worker expos creosot woodtreat plant unit state object malign nonmalign mortal risk worker expos creosot background literatur review retrospect cohort consist employe plant unit state where wood primarili railroad tie util pole creosotebas preserv period cover mortal cohort term causespecif standard mortal ratio smrs confid interv cis expect death us nation gender race year agespecif mortal rate addit cohort nest casecontrol lung myeloma conduct inform tobacco consumpt detail employ job titl case match control job classifi categori potenti exposur creosot oddsratio or cis calcul job categori length exposur mortal entir cohort expect death vs expect smr ci close employe hour whose potenti exposur general much salari employe hour employe except myeloma none specif site signific furthermor detail length employ did not reveal signific mortal excess upward trend six death myeloma death expect smr ci length employ did not upward trend myeloma signific mortal report nonmalign diseas length employ did not reveal upward trend casecontrol risk lung associ tobacco consumpt not job exposur categori exampl lung oddsratio routin exposur creosotebas wood preserv ci casecontrol analys myeloma did not reveal associ employ plant exposur creosotebas wood preserv creosotetr evid employ woodtreat plant exposur creosotebas wood preserv associ signific mortal sitespecif nonmalign diseas result interpret caution 
preval mummichog delawar estuari watersh mummichog fundulus heteroclitus six locat delawar estuari watersh histopatholog object compar preval skin fish locat sediment polynuclear hydrocarbon pah avail fish locat industri christina river subwatersh hershey run newport marsh upriv downriv locat motiva enterpris refineri discharg canal delawar river locat st jone river locat blackbird creek adult mummichog fish per locat sein held necropsi neoplast skin lesion diagnos fish diagnos st jone motiva newport marsh upriv newport marsh downriv blackbird creek mummichog foci hepatocellular alter putat preneoplast lesion hepatocellular carcinoma signific differ hepatocellular carcinoma preval hershey run mummichog fish fish compar locat pool fish hershey run contamin creosot adjac superfund site where sediment frequent report total pah greater total pah maximum locat report total pah neoplasia associ exposur sediment pah deriv creosot preval biomark eg adduct pah bile sediment tissu chemistri recommend evid specif 
timeresolv fluoroimmunoassay plasma urin odesmethylangolensin phytoestrogen odesmethylangolensin odma plasma serum urin odma daidzein occur soybean afford protect against breast interest timeresolv fluoroimmunoassay trfia europium chelat label after synthesi ocarboxymethylodma compound coupl bovin serum albumin antigen rabbit tracer europium chelat synthes oderiv alphamethyldeoxybenzoin after enzymat hydrolysi ether extract immunoassay carri out resolv fluoroimmunoassay trfia crossreact test angolensin dihydrogenistein dihydrodaidzein equol ohangolensin transohequol ohodma cisohequol ohequol antiserum crossreact angolensin crossreact not influenc result specif plasma sampl hydrolyz extract urin sampl direct after hydrolysi extract correl coeffici plasma trfia result gcms result correl coeffici urin trfia result gcms result over entir nmol low nmol ie intraassay coeffici variat cvs plasma odma urin odma differ vari interassay cvs vari work plasma urin odma assay nmol l
vitro incub human fece daidzein antibiot interindividu differ bacteria equol daidzein equol dihydrodaidzein dhd odesmethylangolensin odma intestin bacteria third half individu produc equol evid exist support potenti cancerprotect effect equol vitro daidzein fecal bacteria effect antibiot fresh frozen fece equol produc nonproduc incub daidzein antibiot degre except frozen sampl fecal inocul equol produc convert daidzein equol convers occur anaerob not aerob condit fecal inocul equol nonproduc did not produc equol produc odma dhd betweensubject differ effect antibiot daidzein appar antibiot inhibit equol effect dhd result bacteria involv daidzein differ subject simpl vitro system facilit influenc equol minim need anim model human intervent furthermor analys conduct fecal sampl frozen store
mammograph densiti daidzeinmetabol phenotyp overweight postmenopaus women circul hormon associ mammograph densiti intermedi breast risk differ circul hormon estron testosteron premenopaus women capac daidzein predomin soybean equol odesmethylangolensin odma intestin bacteri daidzein interindividu variabl capac produc daidzein individu equol produc nonproduc odma produc nonproduc test hypothesi daidzeinmetabol phenotyp associ mammograph densiti particip recruit sedentari postmenopaus women age year particip year physic activ intervent preintervent mammograph densiti computerassist grayscal threshold techniqu fiftyf women consum supplement soy protein daidzein firstvoid urin sampl fourth daidzeinmetabol phenotyp equol odma measur gas chromatographymass spectrometri associ daidzeinmetabol phenotyp percent mammograph densiti adjust age maximum adult gravid famili histori breast serum folliclestimul hormon free testosteron mammograph densiti equol produc compar nonproduc odma produc mammograph densiti greater nonproduc result intestin bacteri profil associ postmenopaus mammograph densiti associ not entir explain differ reproduct anthropometr characterist circul hormon
preval daidzeinmetabol phenotyp differ caucasian korean american women girl interindividu differ soy daidzein equol odesmethylangolensin odma human gut bacteria associ alter risk chronic diseas differ report preval equolproduc phenotyp popul preval soyconsum asian popul western popul date preval daidzeinmetabol phenotyp asian compar caucasian not context standard phenotyp preval equol odmaproduc phenotyp korean american ka women girl live seattl washington area compar preval caucasian american ca women girl compar habit firstvoid morn urin after soy challeng equol odmaproduc phenotyp microg preval equolproduc phenotyp vs odmaproduc phenotyp vs ka ca women girl kas consum approxim soy food cas signific associ consumpt soy food equolproduc phenotyp support report compar western popul asian popul equolproduc preval addit preval odmaproduc phenotyp kas daidzeinmetabol pattern general differ kas cas
phytoestrogen exposur polymorph comt cyp esr shbg gene associ risk prospect phytoestrogen exposur biomark estim intak british men recruit norfolk arm european prospect nutrit men result compar healthi men match age date recruit level phytoestrogen daidzein glycitein odesmethylangolensin equol enterodiol enterolacton measur spot urin serum sampl singlenucleotid polymorph comt cyp esr shbg gene genotyp urinari level phytoestrogen correl strong serum level correl coeffici glycitein daidzein urinari serum level correl intak food diari not foodfrequ questionnair oddsratio phytoestrogen exposur not associ risk men cc genotyp esri pvuii polymorph risk compar men tt genotyp adjust oddsratio result util prospect exposur evid phytoestrogen alter risk british men allel pvuii polymorph associ risk
variat plasma phytoestrogen european adult phytoestrogen play role chronic diseas occurr variabl plasma european popul geograph region european countri denmark franc germani greec itali spain sweden netherland uk th region oxford uk where particip recruit vegan vegetarian subject particip european prospect nutrit epic plasma daidzein glycitein daidzein odesmethylangolensin odma equol mammalian lignan enterodiol enterolacton measur particip comput geometr mean region multivari regress influenc region adjust gender age bmi alcohol intak smoke status laboratori batch subject below detect limit microg nmol glycitein odma equol exclud subject oxford uk subject netherland cambridg uk microg nmol lignan denmark microg nmol vari lignan vari vegetarian vegan cohort oxford nonvegetarian region region plasma phytoestrogen despit fact plasma phytoestrogen europ low compar asian popul vari subject differ region
daidzeinmetabol phenotyp mammograph breast densiti premenopaus women unit state mammograph breast densiti breast risk hormon sensit daidzein equol odesmethylangolensin odma associ hormon hormon mediat few capac produc breast densiti equol odmaproduc phenotyp breast densiti premenopaus women unit state hundr women attend clinic visit urin sampl soy challeng sampl gcms daidzeinmetabol phenotyp percent densiti ng urin unadjust adjust analys differ breast densiti produc nonproduc equol odma popul lowsoy consum premenopaus women associ daidzeinmetabol phenotyp breast densiti phenotyp per se not influenc premenopaus breast densiti
lack prospect associ plasma urinari phytoestrogen risk european prospect cancernorfolk phytoestrogen risk result epidemiolog not yield consist support propos effect inadequ databas phytoestrogen level food biomark phytoestrogen intak clearer insight phytoestrogen exposur risk risk european prospect cancernorfolk cohort age serum urin sampl phytoestrogen daidzein enterodiol enterolacton glycitein odesmethylangolensin odma equol case control case control summari variabl total lignan enterodiol enterolacton total daidzein odma equol glycitein creat conjunct individu phytoestrogen logist regress analys reveal signific associ risk total serum oddsratio oddsratio confid interv ci total serum lignan ci risk total serum ci total serum lignan ci null associ individu serum phytoestrogen urinari phytoestrogen biomark evid support invers associ phytoestrogen exposur risk
urin accur reflect circul ascertain complianc soy intervent ifl protect against chronic diseas ifl exposur tradit measur plasma pl reliabl urin uncertain ifl excret overnight urin ou spot urin su reliabl reflect ifl pl matric soy intak complianc random doubleblind placebocontrol soy intervent trial postmenopaus women ifl daidzein glycitein equol odesmethylangolensin dihydrodaidzein dihydrogenistein liquid chromatographi mass spectrometri ou su pl baselin everi month ovesr year betweensubject intraclass correl matric median betweensubject pearson correl median roupl median rsupl median rousu allow equat predict ifl matric equat random avail valid correl residu equationgener measur ifl median roupl median rsupl median rousu median absolut ifl differ oupl supl ousu nmol nmol nmol matric signific ifl differ placebo soy intervent end signific correl ifl count soy dose intervent ou su ifl excret reflect circul pl ifl level healthi postmenopaus women accur noninvasivelycollect urin reliabl system ifl exposur soy intak complianc
profil phytoestrogen human urin asian countri intak rich phytoestrogen associ decreas risk hormonedepend human biomonitor phytoestrogen human urin intak phytoestrogen report phytoestrogen level urin specimen unit state japan littl known human intak phytoestrogen asian countri phytoestrogen name enterolacton enterodiol daidzein equol odesmethylangolensin odma coumestrol human urin sampl asian countri vietnam hanoi ho chi minh cambodia phnom penh india chennai kolkata simpl sensit reliabl liquid chromatographi lc tandem mass spectrometri ms ms residu level phytoestrogen urin sampl asian countri compar urin sampl japan ehim urin sampl unit state albani phytoestrogen daidzein predomin urin sampl vietnam sampl cambodia india enterolacton urinari sampl hanoi vietnam notabl sampl cambodia india unit state sampl japan lowest daidzein enterolacton urin sampl india equol odma microbi daidzein produc gut microflora notabl urin sampl hanoi vietnam ratio equol odma daidzein sampl hanoi japan indic biotransform effici daidzein popul hanoi equol addit urin link breast risk vietnames popul potenti protect effect against breast intak profil phytoestrogen vari consider even asian countri
correl urinari phytoestrogen excret lifestyl intak middleag elder chines women lignan phytoestrogen postul health benefit antiestrogen anticanc procardiovascular health amelior menopaus symptom urinari excret daidzein glycitein odesmethylangolensin odma dihydrodaidzein dihydrogenistein equol lignan enterodiol enterolacton biomark phytoestrogen exposur epidemiolog urinari excret phytoestrogen correl lifestyl women particip shanghai women health swhs populationbas prospect cohort urban chines women age year enrol median nmol creatinin daidzein glycitein odma dihydrodaidzein dihydrogenistein equol enterodiol enterolacton level enterodiol odma level us women age except enterolacton level popul urinari excret older women women engag regular exercis associ soy food intak invers fruit intak urinari excret dihydrodaidzein dihydrogenistein equol enterodiol enterolacton invers associ bodi mass index bmi urinari excret correl soy food intak healthi lifestyl invers associ fruit intak middleag elder chines women add inform rapid grow bodi research potenti health benefit phytoestrogen
urinari enterolacton associ obes alter men us nation health nutrit survey phytooestrogen famili plantderiv xenooestrogen prevent phytooestrogen intak obes status popul still crosssect associ urinari phytooestrogen obes paramet children adult children age year adult age Ã¢Ã¢ year particip us nation health nutrit survey analys multivari logist regress appli associ bmi waist circumfer serum total cholesterol hdlcholesterol ldlcholesterol tag fast glucos fast insulin syndrom urinari phytooestrogen level stratifi age sex stronger associ ci year survey associ urinari daidzein odesmethylangolensin equol enterodiol popul enterolacton level invers associ tag level fast glucos level fast insulin level syndrom male age year associ hdlcholesterol level result epidemiolog evid urinari enterolacton invers associ obes adult male
urinari risk type diabet prospect us women associ urinari excret risk type diabet td conduct nest casecontrol td pair nurs health nhs nhsii free diabet cvd urin sampl urinari excret daidzein well odesmethylangolensin odma dihydrogenistein dhge dihydrodaidzein dhde assay liquid chromatographi ms selfreport td case confirm valid questionnair urinari excret daidzein associ risk td cohort compar extrem tertil urinari td ci daidzein ci test linear trend not signific trendÃ¢ dma dhde dhge nonsignific associ td risk invers associ daidzein td risk stronger postmenopaus women did not hormon replac interactionÃ¢ ci compar extrem tertil women urinari excret associ td risk us women postmenopaus women did not hormon research warrant replic western popul low intak
compar effect puerarin granulocyt colonystimul acut myocardi infarct compar effect puerarin granulocyt colonystimul gcsf acut myocardi infarct ami size infarct area cytokin seventynin patient anterior ami random convent western medic puerarin pg gcsf gcg puerarin gcsf addit infarct size plasma gcsf matrix metalloproteinas mmp serum interleukin il tnf detect after infarct size correl level gcsf mmp il tnf puerarin gcsf effect decreas infarct size effect cytokin differ entir
rapid hplc phytoestrogen legum human urin grow evid phytoestrogen protect against against breast measur exposur popul compound level food human tissu bodi fluid protect properti agent simpl fast procedur extract simultan hydrolyz phytoestrogen conjug food item fast highperform liquid chromatographi hplc precis common phytoestrogen biochanina daidzein formononetin coumestrol flavon intern standard hplc appli measur phytoestrogen abund equol odesmethylangolensin human urin propos methodolog loss thermal degrad extract hydrolysi sampl handl entir workup solid phase extract inter intraassay variabl level common pea bean western eastern compar coumestrol level raw can cook food futur epidemiolog human urinari level methodolog compar after soybean intak
vitro sun protect stabil commerci sunscreen mass spectrometri sunlight exposur type injuri human skin common harm effect ultraviolet uv exposur erythema pigment lesion lead longterm effect minim sunscreen cosmet uv filter main compon formul molecul absorb reflect diffus uv ray alon broaden protect differ wavelength regulatori agenc defin ingredi quantiti countri enforc compani conduct test confirm sun protect spf uva ultraviolet standard spf test conduct vivo human subject industri mindset apart econom ethic reason introduct vitro interest altern risk associ uv exposur test well assert analyt result work describ novel methodolog spf direct sunscreen formul describ cosmetom platform mass spectrometri analyt choic
genet variant risk gastric pathway genomewid associ discov candid singl nucleotid polymorph snps hypothes signific biolog pathway gastric gc perform candid causal snps pathway icsnpathway gc genomewid associ gwas dataset snps gc case control asian ethnic integr linkag disequilibrium snp annot pathwaybas candid snps gene pathway icsnpathway produc hypothet mechan gc rs rsÃ¢Ã¢Ã¢efnaÃ¢Ã¢Ã¢ephrin receptor bind rsÃ¢Ã¢Ã¢umpsÃ¢Ã¢Ã¢drug pyrimidin rsÃ¢Ã¢Ã¢gbaÃ¢Ã¢Ã¢cyanoamino rs rs rsÃ¢Ã¢Ã¢plceÃ¢Ã¢Ã¢lipid biosynthet regul cell growth cation homeostasi pathway gwas dataset hypothet biolog mechan contribut gc suscept
short leukocyt telomer length alon smoke contribut risk gastric esophag squamous cell carcinoma human telomer shorten divis somat cell shorten telomer length result genom instabl associ malign differ popul conflict associ telomer length peripher blood leukocyt risk gastric gc esophag squamous cell carcinoma escc chines han popul total gc case escc case age sexmatch healthi control oddsratio or confid interv cis calcul logist regress gc escc patient shorter telomer length rtl median sd gc escc control fourfold gc risk ci escc risk ci subject shortest quartil telomer length compar quartil cumul effect short rtl smoke intensifi risk gc escc moreov cumul effect rtl smoke drink risk gc ptrend escc ptrend interest rtlrelat rs rs genet variant associ gc risk result indic short rtl involv suscept gc escc alon geneenviron interact manner short telomer length potenti molecular lifestyl risk highrisk individu
liquiritigenin ultra perform liquid chromatographi coupl tripl quadrupol mass spectrometri applic linear pharmacokinet liquiritigenin plasma simpl sensit rapid ultra perform liquid chromatographi tandem mass spectrometri uhplcm ms valid quantif liquiritigenin promis antitumor agent liquiritigenin intern standard separ agil extend column elut gradient mobil phase system acetonitril water perform ioniz electrospray mass spectromet via monitor mrm transit liquiritigenin monitor onestep protein precipit acetonitril remov impur extract analyt plasma chromatograph run min good linear ng precis rsd intraday interday accuraci intraday interday recoveri stabil accept limit valid appli linear pharmacokinet liquiritigenin plasma 
effect emodin baicalein sever acut pancreat therapeut effect emodin baicalein sever acut pancreat sap mechan sap total sap induc retrograd inject sodium taurochol biliarypancreat duct random assign untreat emodin emodin baicalein sandostatin meanwhil anothesr sham oper timepoint surviv rate ascit volum patholog lesion score pancrea tissu serum amylas tnf il level index therapeut effect surviv rate untreat ascit volum remark less sandostatin emodin differ sandostatin serum amylas level timepoint untreat differ serum tnf untreat point tnf level sandostatin emodin differ sandostantin serum il sandostatin untreat untreat sandostatin emodin differ sandostatin timepoint patholog score pancrea point untreat score sandostatin emodin differ sandostatin emodin baicalein signific therapeut effect sap 
new vitro skin sensit assay epiderm sensit assay episensa reconstruct human epidermi chang regulatori requir social view anim test acceler reliabl altern test predict skin sensit potenti new vitro skin sensit assay reconstruct human epidermi rhe model expect broader applic domain exist vitro assay microarray reveal express gene atf dnajb gclm hspa hsph cellular upregul rhe model after skin sensit fluorodinitrobenzen oxazolon not nonsensit benzalkonium chlorid predict perform gene eight skin sensit eg cinnam aldehyd nonsensit eg sodium lauryl sulfat pre prohapten eg pphenylenediamin isoeugenol criteria set obtain accuraci anim test llna atf dnajb gclm exhibit predict accuraci test pre prohapten correct predict atf dnajb result rhebas assay term epiderm sensit assay episensa skin sensit assay broad applic domain pre prohapten
parthenolid accumul express gene parthenolid biosynthesi exogen applic methyl jasmon salicyl tanacetum parthenium upregul germacren synthas downregul parthenolid hydroxylas gene play key role parthenolid accumul feverfew plant methyl jasmon salicyl parthenolid sesquiterpen lacton antimigrain anticanc properti parthenolid amount quantifi highperform liquid chromatographi after foliar applic methyl jasmon Ã¢m salicyl feverfew leav cours result indic exogen applic methyl jasmon salicyl activ parthenolid biosynthesi parthenolid content reach amount after methyl jasmon salicyl control plant parthenolid transient methyl jasmon salicyl until did not signific differ compar control plant point transcript level earli pathway upstream gene terpen biosynthesi hydroxymethylglutarylcoenzym reductas deoxydxylulosephosph reductoisomeras hydroxymethyl butenyl diphosph reductas biosynthet gene parthenolid germacren synthas germacren oxidas costunolid synthas parthenolid synthas methyl jasmon salicyl differ intens transcript level gene methyl jasmonatetr plant salicyl acidtr plant parthenolid content measur express pattern aforement gene parthenolid hydroxylas branch gene parthenolid express pattern earli pathway gene not direct consist parthenolid accumul pattern henc parthenolid accumul probabl modul express biosynthet gene germacren synthas branch gene parthenolid hydroxylas
serum protein profil miniatur solidphas extract matrixassist laser desorpt ioniz mass spectrometri serum profil matrixassist laser desorpt ioniz mass spectrometri maldim hold promis clinic tool earli diagnosi human diseas sampl prepar key achiev reproduc wellresolv signal maldim prerequisit translat maldim diagnost clinic applic maldi matric miniatur solidphas extract spe serum protein desalt generat reproduc highqual protein profil maldim simpl protocol serum profil matrix mixtur dihydroxybenzo alphacyanohydroxycinnam miniatur spe maldim membran disc hydrophob ionexchang chelat properti allow reproduc maldi mass spectra serum proofofprincipl applic spe chelat materi maldim protein peak serum report distinguish person diagnos breast control preliminari result indic simpl spe maldim serum profil versatil scalabl platform clinic proteom
uniform dihydroxybenzo layer matrix maldifticr msbase lipidom uniform dihydroxybenzo dhb layer construct matrix matrixassist laser desorpt ioniz fourier ion cyclotron reson mass spectrometri maldifticr ms quick chang lipid biolog system lipid extract biolog sampl dissolv chloroform deposit onto dhb layer benefit insolubl dhb chloroform uniform matrix crystal still maintain lipid analyt distribut homogen layer reproduc maldifticr ms take advantag benefit resolut fticr ms fragment ion ms ms lot lipid chang lipid drugresist cell compar pair drugsensit cell princip compon pca partial leastsquar discrimin plsda employ discoveri chang lipid simplic speedi demonstr new promis approach lipidom 
popul versus hospit control intak casecontrol china intak popul hospit outpati control risk estim hospit outpati control differ popul control parallel casecontrol leukemia breast china conduct popul hospit outpati control separ match case ratio valid food frequenc questionnair administ facetofac interview condit logist regress estim oddsratio or confid interv cis control close distribut intak risk estim breast adjust or ci daidzein glycitein total hospit outpati popul control hospit outpati control compar popul control measur intak chines hospit set
